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Stem cells have two unique qualities. First, they are capable of self-renewal, ensuring a lifetime 
supply of ancestors for replacement or repair. Second, they may differentiate into intermedi-
ate and downstream types of cells specific to the organ or tissue, including progenitor cells 
(which can multiply but not renew) and terminally differentiated cells1. As such, their poten-
tial in cell replacement therapy and regenerative medicine has been widely acknowledged. 
There are two general types of stem cells, referred to as adult stem cells (ASCs) and embryonic 
stem cells (ESCs).
ASCs appear sequentially during fetal development, and are limited in their developmental 
potential. As a result, stem cells isolated from a fully developed animal or human are already 
programmed to become brain, blood, bone or other cells of the resident tissue or organ2. For 
example, the blood system has self-renewing long- and short-term hematopoietic stem cells, 
which give rise to a number of multipotent progenitors and nine fully differentiated cells of 
the myeloid and lymphoid lineages. Generally, adult stem cells are few in number, hard to 
isolate, and with the exception of some neural types, difficult to culture and expand.
In contrast, ESCs are generally derived by culturing a few dozen cells removed from the 
interior of a blastocyst (Figure 1). In mammals, this collection of cells, called the inner cell 
mass, eventually develops into the epiblast and hypoblast, and subsequent gastrulation 
forms the germ layers of the animal proper. Approximately 10% of the time, a self-renewing, 
pluripotent cell line will result, with potential to differentiate into all of the cell and tissue 
types of the adult animal, including downstream stem and progenitor cells3. When cul-
tured on a supporting feeder layer of mouse embryonic fibroblast, ESCs can be expanded 
indefinitely in vitro, while maintaining a stable karyotype. When engrafted unmodified into 
immunocompromised mice, both mouse (m) and human (h)ESCs form teratomas comprised 
of tissue types from endoderm, ectoderm and mesoderm lineages.
The pluripotent and self-renewing nature of ESC makes them an ideal source from which 
to generate multiple tissues for regenerative therapies. The first hESC lines were generated 
by Thompson et al. in 19984. Since then, successful in vitro differentiation of many cell types 
has been reported, including cardiomyocytes, neurons, pancreatic beta cells, hepatocytes, 
oligodendrocytes and erythrocytes5. Not surprisingly, this area of research is generating 
unprecedented interest from the general public not only because of the expectation of a 
new horizon in clinical medicine, but also through the intense debate over the ethical and 
safety issues, and practical hurdles to therapy. With respect to the latter, one of the most 
important obstacles facing in vivo engraftment and function of transplanted hESCs is the 
potential immunologic barrier. That is, since ESC-derived therapeutic cells will not be “self 
derived”, they would be predicted to face an aggressive recipient immune system and be the 
focus of rejection6. At the same time, hESCs theoretically represent an immune-privileged cell 
population, as embryos consisting of 50% foreign paternal material are usually not rejected 
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by the maternal host. Futhermore, some types of adult stem cells (for example mesenchymal 
and amnion) have been reported to avoid immune rejection though production of immu-
nosuppressive molecules, facilitating their survival following intra- and even interspecies 
transplantation7
The subject of ESC immunogenicity has been the topic of much debate8. The aim of the 
work presented in this dissertation is to clarify and characterize the immunobiology of ESC 
Figure 1
Figure 1. Derivation, culture, and differentiation of embryonic stem cells. Undifferentiated embryonic stem cells are isolated from the inner 
cell mass of an embryo at the blastocyst stage. The cells can be propagated indefinitely in vitro and differentiated towards different adult cell 






transplantation and to provide a clear answer as to whether rejection of ESC is something 
that could potentially hamper successful implementation into clinical therapy.
IMMuNObIOlOgy Of TRaNSPlaNTaTION
Tissues, organs or cells transplanted between genetically non-identical (allogeneic) individu-
als will inevitably lead to rejection secondary to activation of the innate and adaptive immune 
systems. In general, the greater the number of genetic differences between the donor and re-
cipient, the more rapid the rejection response. The major system characterized as responsible 
for tissue incompatibility is the Major Histocompatibility Complex (MHC) The MHC encodes 
a series of highly polymorphic groups of genes9. The MHC locus produces two classes of cell 
surface glycoproteins, referred to as class I and class II MHC molecules. In humans, the MHC 
is called human leukocyte antigen (HLA). HLA class I and class II molecules play a central role 
in allogeneic (allo)antigen recognition by T lymphocytes. They are essentially cell-surface re-
ceptors embedded in the plasma membrane which display antigen, in the form of a peptide 
inserted into the peptide binding groove of each molecule, for presentation to T cells. Most 
human cells express HLA class I molecules but the expression of HLA class II molecules is 
restricted to antigen-presenting cells (APCs), such as dendritic cells10.
Alloantigens can be recognized by the immune system by two distinct pathways known 
as the direct and indirect pathways of allorecognition. For direct recognition of donor al-
loantigens, donor cells act as the antigen-presenting cells and present the mismatched MHC 
molecules as intact molecules to the recipient immune system for recognition by recipient 
T cells. For indirect recognition of donor alloantigens the donor molecules are processed 
into small peptides and presented by recipient-derived APCs to recipient T cells following 
migration to the regional lymph nodes11.
T lymphocytes, or T cells, possess surface-bound receptors for antigen called the T cell 
receptor (TcR). CD4+ T cells in general recognize exogenous antigen on the surface of an APC 
in conjunction with MHC class II molecules. The other major T cell subset, CD8+ T cells, in 
general recognizes endogenous antigens displayed by a transformed or infected host cell 
in complex with MHC class I molecules10. Upon activation, T cells will undergo clonal prolif-
eration. Furthermore, activated T-cells can provide a co-stimulatory signal to B-cells. Upon 
activation, B cells terminally differentiate into plasma cells, which produce a secreted form 
of the B-cell receptor (BcR) called antibody. Massive attack of the transplanted graft by both 
activated T-cells and B-cell derived antibody ultimately leads to rejection10.
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IMMuNObIOlOgy Of EMbRyONIC STEM CEll TRaNSPlaNTaTION
It has been shown that, in their undifferentiated state, hESCs express low levels of MHC-I12, 13. 
MHC-I expression increased two to four-fold when the cells were induced to spontaneously 
differentiate to EBs, and an eight to ten-fold when induced to differentiate into teratomas 
12. Futhermore, MHC-I expression was strongly upregulated after treatment of the cells with 
interferon-γ, a potent MHC expression inducing cytokine known to be released during the 
course of an immune response. MHC-II antigens were not expressed on hESCs or hESC deriva-
tives 12.
Although the presence of MHC-antigens on ESC suggest susceptibility of the cells to 
immune attack, recent reports have shown that both mESCs and hESCs seem to have the 
capability to evade immune recognition in allogeneic as well as in xenogeneic hosts. mESCs 
have been shown to survive in immunocompetent mice 14, as well as in rats 15 and sheep 16 for 
many weeks after transplantation. In addition, not only have hESCs been reported to inhibit 
allogeneic T-cell proliferation in vitro, but also to evade immune recognition in xenogeneic 
immunocompetent mice 17. In contrast, a recent report found that one month after transplan-
tation, hESC were totally eliminated in a similar model 18.
IN VIVO VISualIzaTION Of TRaNSPlaNTEd STEM CEll faTE: ThE ROlE Of 
MOlECulaR IMagINg
Specific studies evaluating immunogenicity of hESCs in vivo are few and have yielded mixed 
conclusions regarding hESC’s potential to induce immune response and/or survive in al-
logeneic and/or xenogeneic hosts17-19. In these studies, results were based on histological 
techniques to evaluate hESC survival. These techniques provide only a “snapshot” representa-
tion rather than a comprehensive picture of cell survival over time. To allow non-invasive cell 
tracking, our group has developed and validated reporter gene-based molecular imaging 
techniques.
Molecular imaging can be defined as the characterization, visual representation, and quantifi-
cation of biologic processes at the cellular and molecular level within intact living organisms. 
All molecular imaging techniques have two requisites: 1) a molecular probe that provides 
a quantifiable signal based on the presence of a gene, RNA, biochemical process, receptor, 
or cell; and 2) a method to monitor the molecular probe20. The earliest molecular imaging 
approaches relied on radiolabeled tracers as probes that could be repeatedly monitored 
for short periods of time, clinically known as nuclear imaging. A recent advance in the field 
of molecular imaging has come in the form of reporter gene imaging. The concept behind 






In particular, firefly luciferase (Fluc) reporter gene-based optical bioluminescence imaging 
(BLI) has proven to be a reliable technique for assessing engraftment and survival of stem 
cells following transplantation21. In BLI, the reporter gene produces a Fluc enzyme, which 
oxidizes the reporter probe (D-luciferin) to produce light as a signal. Ultrasensitive charged 
coupled device (CCD) cameras can then sense the photons as they pass from within the stem 
cell, though tissue and out of the subject. An important advantage in using BLI is that the 
expression of the Fluc reporter gene, is expressed only by living cells, making it a highly ac-
curate tool for following transplant rejection of organs or cells in the living subject22.
ChaRaTERIzaTION Of EMbRyONIC STEM CEll TRaNSPlaNTaTION 
IMMuNObIOlOgy uSINg MOlECulaR IMagINg: SCOPE Of ThE ThESIS
The scope of the current thesis is to gain insight into immunological aspects of transplan-
tation of embryonic stem cells or their differentiated progeny by using molecular imaging 
techniques to follow cell fate.
The first part of this thesis describes in vivo bioluminescent imaging (BLI) as a novel tool to 
visualize and quantify survival and rejection of transplanted cells and/or organs. chapter 2 
describes a ‘proof of concept’ study of the use of non-invasive BLI to visualize cardiac allograft 
rejection following transplantation. By performing heterotopic transplantation of Fluc/eGPF 
transgenic L2G mouse donor hearts into allogeneic wild-type recipients, cardiac allograft 
Figure 2
Figure 2. Concept of reporter gene imaging. The DNA promoter construct contains a promoter region that drives the reporter gene. The 
construct is deliverd into the cell nucleus via a viral or nonviral vector. The reporter gene is then transcribed to mRNA and subsequently 
translated to reporter gene protein within the cell. The molecular probe diffuses into the cytosol to interact with the reporter protein resulting in 
the generation of a signal (thick arrow), registered by the detector. (Reproduced with permission from Sheik et al.20)
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rejection can be quantified non-invasively and longitudinally. In addition, by using a trans-
genic mouse line in which a CD5 promoter drives the expression of luciferase gene as cardiac 
donors, new insights are gained concerning the pace and distribution of CD5+ passenger 
leukocytes leaving the donor heart and traveling throughout the recipient body. In chapter 
3, non-invasive BLI is utilized to track mononuclear bone marrow cells (BMCs) isolated from 
L2G mice following injection into the infarcted myocardium of syngeneic FVB recipients. In 
this study, the viability and effects of transplanted BMCs on cardiac function in the acute and 
sub-acute inflammatory phases of MI is investigated. In addition, the phenotype of BMCs 
transplanted into acute inflammatory myocardium is analyzed.
The second part of the thesis focused on immunological aspects of ESC transplantation. 
In the first two chapters, a comprehensive introduction into the potentials and pitfalls of 
hESC transplantation is given. chapter 4 describes the potential of hESC to differentiate into 
multiple somatic cell types that can potentially cure patients in the future. Furthermore, it 
introduces molecular imaging techniques and explains its value for non-invasive tracking 
of hESCs following transplantation. chapter 5 focuses specifically on a promising derivative 
of ESC: the ESC-derived cardiomyocyte. It describes progress in hESC-to-cardiomyocyte dif-
ferentiation and potential role in cardiac regenerative therapy and summarizes the hurdles 
that still need to be overcome before ESC-derived cardiomyocyte transplantation can be 
translated into the clinics. Finally, it lays out how molecular imaging can contribute to prog-
ress in this field.
chapter 6 describes the first study ever to address immunological aspects of embryonic 
stem cell transplantation in vivo. It shows that allogeneic mESCs are eventually rejected when 
transplanted into infarcted mouse myocardium. In vivo differentiated mESCs elicit an ac-
celerated immune response as compared to undifferentiated mESCs. In order to visualize 
and quantify ESC immunogenicity, molecular imaging of transplanted ESC was introduced 
in chapter 7, a manuscript that was kindly previewed by Fedak23. In this study, in vivo BLI is 
used to non-invasively track the fate of transplanted mESCs stably transduced with a double 
fusion reporter gene consisting of firefly luciferase (Fluc) and enhanced green fluorescent 
protein (eGFP). Following syngeneic intramuscular transplantation, the mESCs survive and 
differentiate into teratomas. In contrast, allogeneic mESC transplants are infiltrated by a 
variety of inflammatory cells, leading to rejection within 28 days. Acceleration of rejection 
is observed when mESCs are allotransplanted following prior sensitization of the host. Fi-
nally, the study demonstrates that mESC-derivatives are more rapidly rejected as compared 
to undifferentiated mESCs. These data show that mESCs do not retain immune-privileged 
properties in vivo and are subject to immunological rejection as assessed by novel molecular 
imaging approaches.
In chapter 8, a manuscript that was previewed by Chidgey et al in Cell Stem Cell6, the step 
towards hESCs is made and the immunogenicity of human ESC is addressed in a xenogeneic 






survival is significantly limited in immunocompetent as opposed to immunodeficient mice. 
Repeated transplantation of hESCs into immunocompetent hosts results in accelerated 
hESC death, suggesting an adaptive donor-specific immune response. The specific role of 
T-lymphocyte subsets in mediation of the murine anti-hES cell immune response is further 
delineated. In addition, the efficacy of various combinations of clinically available immuno-
suppressive regimens for enhancing survival of transplanted hES cells in vivo is compared.
Finally, chapter 9 includes a summary of this thesis as well as a discussion on future pros-
pects of ESC transplantation and ways to overcome the immunological challenges. chapter 
10 provides a summary in Dutch.
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In vivo Visualization of Cardiac 
allograft rejection and Trafficking 
passenger Leukocytes Using 
Bioluminescence Imaging
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Anthony D. Caffarelli, Jorg L. de Bruin, Cristopher H. Contag, and Robert C. Robbins
In vivo visualization of acute cardiac transplant rejection
Circulation 2005; 112[suppl I]: I-105-110
Chapter 224
abSTRaCT
Background: We investigated the feasibility of bioluminescence imaging (BLI) for the in vivo 
assessment of cardiac allograft viability and visualization of passenger leukocytes during the 
course of acute rejection.
Methods and results: Hearts of FVB (H-2q) luciferase-GFP transgenic mice (β-actin promoter) 
or FVB luciferase transgenic mice (CD5 promoter) were heterotopically transplanted into 
either BALB/c (H-2d) or FVB recipients. Light intensity emitting from the recipient animals 
was measured daily by in vivo BLI until 12 days post-transplant. Graft beating score (0 to 4) 
was assessed by daily abdominal palpation until 12 days post-transplant. Inflammatory cell 
infiltration (CD45 stain) and structural changes of GFP+ cardiomyocytes were followed by im-
munohistochemistry. All cardiac allografts were acutely rejected by 12 days post-transplant. 
The intensity of emitting light from cardiac allografts declined 4 days post-transplant and 
correlated with graft beating scores (R2 = 0.91, p = 0.02). Immunohistochemistry confirmed 
these results by showing an increase of CD45+ inflammatory cell infiltration and destruction 
of GFP+ cardiomyocytes in the cardiac allografts during acute rejection. In vivo BLI visualized 
migration and proliferation of CD5+ passenger leukocytes in both syngeneic and allogeneic 
recipients. In the allograft recipients, light signal from CD5+ passenger leukocytes peaked at 6 
hours and diminished by 12 hours; whereas in the syngeneic recipients, the signal remained 
high until 10 days post-transplant.
conclusion: BLI is a useful modality for the quantitative assessment of in vivo cardiac graft 
viability and tracking of passenger leukocytes in vivo during the course of acute rejection.







Allogeneic heart transplantation has become a commonly used therapy for end-stage heart 
disease. Early graft loss due to acute rejection, even though reduced by current immuno-
suppressive strategies, remains a significant problem in clinical heart transplantation.1 In 
addition, many cardiac allograft recipients experience episodes of acute rejection, and these 
episodes are a critical risk factor for the subsequent development of graft coronary artery 
disease which predisposes to late graft loss.2 Acute rejection is an immune response medi-
ated by the coordinated infiltration and effector functions of host alloantigen-specific T cells 
in the allograft.3 In addition, donor-derived passenger leukocyte migration contributes to 
acute rejection.4
Cell migration is a crucial element during the development of the immune system and 
mediates the immune response during acute cardiac rejection. There is extensive and con-
tinual redistribution of cells to different anatomic sites throughout the body. These trafficking 
patterns control immune function and host responses to transplanted heart. The ability to 
monitor the fate and function of migrating cells, therefore, is imperative to both understand-
ing the role of lymphocytes in acute cardiac rejection and to devising rational therapeutic 
strategies. Determining the fate of immune cells and understanding the functional changes 
associated with migration and proliferation requires effective means of obtaining in vivo 
measurements in the context of intact organ systems.
We have developed in vivo bioluminescence imaging (BLI) based on the observations that 
light passes through mammalian tissues, and that luciferase can serve as internal biological 
sources of light in the living body.5 This method is a rapid and noninvasive functional imag-
ing method that employs light-emitting reporters and external photon detection to follow 
biological processes in living animals in real time. Using this approach we have elucidated 
the spatiotemporal trafficking patterns of malignant cells, lymphocytes, and other mature 
immune cells within living animal models of human biology and disease.5-8 In addition, to 
enable the in vivo study of biological processes that involve movement of cells within the 
three-dimensional organism, e.g., developmental cell migration, immune cell trafficking, 
engraftment of bone marrow and other tissues, we have previously generated a transgenic 
donor mouse line in which a CMV-β-actin promoter drives the expression of two reporters, 
luciferase and green fluorescent protein (GFP). Furthermore, we have also developed a trans-
genic mouse line in which a CD5 promoter drives the expression of luciferase gene.
Using these transgenic mice and in vivo BLI technology, we tested the hypothesis that in 
vivo BLI can be used for the in vivo assessment of allograft viability and in vivo visualization of 




Previously, we made a transgenic mouse line (FVB-L2G85) by pronuclear injection of a gene 
construct expressing two reporters, firefly luciferase and GFP, under the control of the widely 
expressed β-actin promoter (Y.-A.C., unpublished data). The overexpression of luciferase and 
GFP in heart was confirmed by bioluminescent and fluorescent microscopy (Figure 1A and B). 
Figure 1
Figure 1. Bioluminescent and fluorescent microscopic analysis of heart sections from luciferase and green fluorescent protein (GFP) 
double transgenic mouse and in vivo 3-D bioluminescent imaging of the luciferase-GFP transgenic heart recipient mouse. Ex vivo 
bioluminescent imaging of donor heart section from luciferase-GFP transgenic mouse (A). Fluorescent microscopic analysis of section of 
the heart from luciferase-GFP transgenic mouse (B). In vivo 3-D bioluminescent imaging of the recipient mouse in which luciferase-GFP 
transgenic donor heart was heterotopically transplanted (C). 






We have also developed a transgenic mouse line in which a CD5 promoter drives the expres-
sion of luciferase gene.9 Female BALB/c and FVB mice (4 to 6 weeks old) were obtained from 
The Jackson Laboratory and used as recipient. All procedures were approved by the Animal 
Care and Use Committee of Stanford University.
Mouse heterotopic heart transplantation.
Hearts of transgenic FVB-L2G85 mice (H-2q) were heterotopically transplanted into wild-type 
BALB/c (H-2d) or syngeneic FVB recipient abdomen as an acute rejection model. Heterotopic 
cardiac transplantation was performed according to the method of Corry et al10 with some 
modifications. Anesthesia was induced with 3% inhaled isoflurane (Halocarbon Laboratories, 
River Edge, NJ). During surgery, the animals were maintained on 2.5% inhaled isoflurane. The 
total ischemic time of cardiac allograft was 40 minutes.
Graft survival and Allograft functional Analyses.
Graft viability was assessed by direct abdominal palpation of the heterotopically trans-
planted heart as previously described.11 Cardiac graft function was expressed as the beating 
score, assessed by the Stanford cardiac surgery lab graft scoring system (0: no contraction, 1: 
contraction barely palpable, 2: obvious decrease in contraction strength, but still contracting 
in a coordinated manner; rhythm disturbance, 3: strong, coordinated beat but noticeable 
decrease in strength or rate; distention/stiffness, 4: strong contraction of both ventricles, 
regular rate, no enlargement or stiffness).
In vivo bioluminescent imaging.
Mice were anesthetized with 2% inhaled isoflurane and luciferin was administered at a dose 
of 150 mg/kg i.p. At the time of imaging, animals were placed in a light-tight chamber and 
using an in vivo imaging system employing a cooled charge couple device (CCD) camera (IVIS 
100, Xenogen Corp., Alameda, CA), photons transmitted through the tissue emitted from 
intracellular luciferase were collected for 10 seconds to 10 minutes (as indicated in the figure 
legends) depending on the intensity of the bioluminescence emissions.
Because bioluminescence is dependent upon tissue penetration, the intensity from the 
cardiac grafts may vary depending upon the location of the grafts in the abdomen (i.e. 
cardiac grafts can change position and bowel may cover the grafts); therefore, we chose the 
3D imaging system, which allowed us to obtain signal intensity from 8 different directions 
(Figure 1C). Thus allowing us to calculate the summation of light intensities obtained from 8 
different direction scans, which then was used to represent cardiac allograft viability.
Using applications in LivingImage software (Xenogen Corp) an overlay on Igor image 
analysis software (Wavemetrics, OR), gray scale reference images were collected under low 
light, and the intensity of the bioluminescent signals from the animal was measured in com-
plete darkness (blue least intense and red most). The 2 images were then superimposed and 
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annotated using Canvas (Deneba, Miami, FL). To quantify allograft viability, the light emitting 
from the allograft was outlined as the region of interest (ROI) and ROI photon intensity was 
measured using LivingImage software. In vivo photon intensity measures were correlated to 
ex vivo tissue sections by dissecting the tissues, incubating fresh tissues in D-luciferin, and 
imaging these tissues without the overlying tissues.
tissue collection and immunofluorescent histology.
To evaluate inflammatory cell infiltration, cardiomyocyte destruction and proliferation of 
donor derived fibroblasts, cardiac grafts were perfused with saline and rapidly excised at 
different days after transplantation. They were fixed in 2% paraformaldehyde for 2 hours 
and cryoprotected in 30% sucrose overnight. Then, tissue was frozen in optimal cutting 
temperature compound (OCT Compound, Sakura Finetek USA, Inc. Torrance, CA) and sec-
tioned at 5 µm on a cryostat. Sections were blocked and incubated with either rat anti-CD45, 
rat anti-CD5 or mouse anti-Vimentin (all BD Pharmingen) primary antibodies for 1 hour at 
room temperature. After washing in PBS, sections were incubated with either goat anti-rat 
Alexa Fluor 594 (red), goat anti-rat Alexa Fluor 488 (green) or goat anti-mouse Texas Red (all 
Molecular probes, Eugene, OR) secondary antibodies for 30 minutes at room temperature. 
Sections were then washed in PBS, counterstained with 4,6-diamidino-2-phenylindole (DAPI, 
Molecular probes) and examined with a Leica DMRB fluorescent microscope (Leica Microsys-
tems, Frankfurt, Germany).
statistics.
Values are expressed as mean ± SE. Differences in cardiac graft beating score and light in-
tensity of cardiac grafts were analyzed by a 2-way repeated-measures ANOVA. Correlation 
between cardiac graft beating score and light intensity emitted from cardiac grafts were 
analyzed by regression analysis (StatView 5.0; SAS Institute, Cary, NC). Significance was ac-
cepted at p < 0.05.
RESulTS
In vivo visualization of acute cardiac rejection and quantitative analyses of cardiac 
allograft viability using bioluminescence imaging.
Bioluminescent and fluorescent microscopic analysis of the heart from luciferase-GFP trans-
genic mice confirmed expression of both luciferase and GFP (Figure 1A and B). There was no 
bioluminescent signal from the non-transgenic littermates (Data not shown). Using the heart 
of luciferase-GFP transgenic mice as donor organ, we investigated the feasibility of BLI for 
quantitative assessment of cardiac allograft viability in the course of acute rejection. As the 
luciferase-GFP transgenic mice have FVB background, we used BALB/c mice as recipients to 







Figure 2. In vivo visualization of acute cardiac rejection and quantitative analyses of cardiac allograft viability using bioluminescence 
imaging. Cardiac graft beating score of the study group (A). Light intensity of the study group (B). In vivo 3-D bioluminescent imaging of the 
study group (C). Representative sections of immunohistochmically stained cardiac grafts of the study group. Red = inflammatory cells (CD45 
stain), green = cardiomyocyte (GFP), blue = nuclei (DAPI stain) (magnification x400). Note that the light intensity of the luciferase-green 
fluorescent protein (GFP) transgenic donor heart recipient mice correlates with cardiac graft function and histology in the course of acute cardiac 
rejection. Allo = allogeneic = FVB luciferase-GFP transgenic donor heart were heterotopically transplanted into BALB/c recipient (n = 5). Syn = 
syngeneic = FVB luciferase-GFP transgenic donor heart were heterotopically transplanted into FVB recipient (n = 5).
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induce acute rejection. In the course of acute rejection, we measured cardiac graft viability in 
vivo using 3D BLI as described earlier.
All FVB cardiac allografts transplanted into BALB/c recipients were acutely rejected by 12 
days following transplantation. In contrast, all FVB cardiac isografts transplanted into FVB 
recipients survived until 12 days after transplantation. Cardiac allograft beating score as-
sessed by daily abdominal palpation showed significant difference between isografts and 
allograft (p < 0.001, Figure 2A). The intensity of emitting light from cardiac allografts declined 
4 days post-transplant and correlated with graft beating scores (R2 = 0.91, p = 0.02, Figure 
2B and C). To confirm correlation between cardiac graft viability and light intensity, cardiac 
allo- and isografts were procured at day 2, 4, 6, 8, 10, and 12 days after transplantation and 
stained with an antibody against CD45, a marker expressed on all inflammatory cells. Im-
munohistochemistry showed an increase of inflammatory cell infiltration and destruction of 
GFP+ cardiomyocytes in the cardiac allografts in the course of acute rejection (Figure 2D). In 
contrast, only mild inflammatory cell infiltration as well as preserved GFP+ cardiomyocyte 
structure were observed in cardiac isografts by 12 days after transplantation (Figure 2D). 
Taken together, changes of photon signal intensity of cardiac graft correlate with cardiac 
graft viability and histological findings in the course of acute cardiac rejection. Therefore, our 
data suggest that in vivo BLI may be a useful tool for the quantitative assessment of cardiac 
graft viability in vivo.Figure 3
Figure 4
Figure 3. Donor-derived CD5+ passenger leukocytes in CD5 promoter luciferase transgenic donor heart. Representative sections of CD5 
promoter luciferase transgenic donor heart stained with anti-mouse CD5 recognized by FITC conjugated secondary antibody (green). Sections 
were counterstained with 4,6-diamidino-2-phenylindole (DAPI, blue). Arrowheads show representative CD5+ donor-derived passenger 
leukocytes in donor heart (X400).






In vivo visualization of donor-derived passenger cD5+ cell response in the cardiac 
allograft recipients in the course of acute rejection.
Solid organ grafts contain bone marrow-derived hematopoietic cells, passenger leukocytes, 
of donor origin. These donor-derived hematopoietic cells are transferred to the recipient at 
the time of transplantation.4 We next investigated the possibility of BLI to visualize passenger 
leukocytes and track their destination in vivo using CD5 promoter luciferase transgenic mice 
as a donor of syngeneic and allogeneic cardiac transplantation. As shown in figure 3, the 
presence of CD5+ donor-derived passenger leukocytes in donor heart was confirmed by im-
munohistochemistry. However, In vivo BLI of donor heart did not show emitting light from 
CD5+ donor-derived passenger leukocytes probably because of the small number of CD5+ 
donor-derived passenger leukocytes in donor hearts. Interestingly, in vivo BLI successfully 
visualized migration and proliferation of CD5+ donor-derived passenger leukocytes shortly 
after transplantation (30 minutes) in both syngeneic and allogeneic recipients, indicating 
these cells proliferated immediately (Figure 4). In the cardiac allograft recipients, biolumi-
Figure 3
Figure 4
Figure 4. In vivo visualized donor-derived CD5+ passenger leukocytes showed donor-derived CD5+ passenger leukocytes proliferate 
immediately after transplantation and diminished at 24 hours after transplantation in the course of acute rejection. In vivo 
bioluminescent imaging of the recipient mice in which CD5 promoter luciferase transgenic donor hearts were heterotopically transplanted. 
Note that the light intensity of allograft recipient increased 30 minutes after transplantation, and peaked at 6 hours, and decreased at 12 hours, 
and diminished at 1 day after transplantation. In contrast, the light intensity of isografts recipient increased at 30 minutes after transplantation 
and peaked at 1 and 2 days, stayed by 10 days after transplantation. Allo = allogeneic = FVB CD5 promoter luciferase transgenic donor heart 
were heterotopically transplanted into BALB/c recipient (n = 5). Syn = syngeneic = FVB CD5 promoter luciferase transgenic donor heart were 
heterotopically transplanted into FVB recipient (n = 3).
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nescence signal from CD5+ donor-derived passenger leukocytes increased with time. The 
signal peaked at 6 and 8 hours after transplantation, rapidly decreased at 12 hours, and had 
diminished at 1 day after transplantation (Figure 4). In contrast, in vivo BLI of the syngeneic 
recipients showed that signal intensity from CD5+ donor-derived passenger leukocytes in-
creased at 30 minutes after transplantation, peaked at 1 and 2 days and was measurable until 
10 days after transplantation (Figure 4). CD5+ donor-derived passenger leukocytes migrated 
from the cardiac allograft in the abdomen through the recipient body and were observed at 
anatomic sites corresponding to the location of regional abdominal lymph nodes (1 hour) 
liver (2 hours) thoracic lymph nodes (4 hours) and inguinal lymph nodes (6 hours). In com-
parison, in the syngeneic recipients, CD5+ donor-derived passenger leukocytes were found 
in the neck (30 minutes), chest and liver (2 hours). Confirmation of tissue origin was obtained 
by ex vivo imaging of dissected tissue incubated with D-luciferin (Data not shown). Since all 
FVB cardiac allografts transplanted into BALB/c recipients were acutely rejected at 12 days 
following transplantation, our data suggest that the contribution of the donor-derived CD5+ 
passenger leukocytes to acute rejection is limited to the early phase of acute rejection.
dISCuSSION
This study was designed to show the feasibility of using in vivo BLI to visualize the changes of 
cardiac allograft viability and donor-derived passenger CD5+ cells in response to cardiac al-
lografting during the course of acute rejection. Using in vivo BLI, we have successfully shown 
that light intensity emitted from cardiac allografts decreases after 4 days in the course of acute 
rejection. In addition, the light intensity emitted from donor-derived passenger CD5+ cells 
diminished within 1 day after allo-transplantation. In vivo BLI of different promoter luciferase 
transgenic donor heart recipients allowed us to quantify the kinetics of the viability of the 
cardiac allografts and the location of the donor-derived passenger CD5+ cells longitudinally.
Graft beating score is non-quantitative as well as a subjective classification system. It is use-
ful to determine cardiac graft survival as used elsewhere, however, it is not suitable to assess 
cardiac graft viability because this method assess only whether the cardiac allograft is beat-
ing or not. In vivo BLI of the cardiac graft provides detailed information of cardiac allograft 
viability in the course of acute rejection by calculating emitting light from each cardiac cells 
within the cardiac graft with 3D imaging. Therefore, this modality may be useful tool to assess 
cardiac graft viability in the clinical heart transplantation.
We observed a temporal increase of light intensity 3 to 5 days after transplantation. We 
attempted to prove donor-derived cells proliferation including passenger leukocytes and 
fibroblast by staining with anti-CD45 antibody and anti-vimentin antibody. However, we did 
not see any GFP and CD45 double positive cells at day 3 to 5, and we did not see an increase 
of GFP or vimentin positive cells from day 0 to day 6. This temporal increase of light intensity 






may be due to increase of luciferase gene expression by ischemia-reperfused injured myo-
cardium. We have observed a similar phenomenon in other animal models of BLI exposed to 
stress (unpublished data).
By using this in vivo imaging approach, we found that donor-derived passenger CD5+ cells 
in cardiac allograft proliferated immediately after transplantation and diminish by 24 hours 
after transplantation in the course of acute rejection. In addition, these cells migrated to liver 
and thoracic lymph nodes, but not migrate to spleen. In contrast, donor-derived passenger 
CD5+ cells in syngeneic graft stay by around 10 days after transplantation and diminished 
maybe because of their life-time (around 7 days). This study is the first study to visualize 
donor-derived passenger leukocytes in the recipient. Traditionally, the evaluation of donor-
derived passenger leukocyte migration from the transplanted organ to the other organs 
and destruction of cardiomyocyte structure by acute rejection have been performed post 
mortem on histological specimens or other biological experiments. Therefore, it has always 
been controversial what is the in vivo sequence of these events. BLI is useful modality for 
immune cell trafficking in vivo and reducing the number of animals per experiment since 
changes in a given population can be studied over time.
We observed CD5+ donor-derived passenger leukocytes also proliferated immediately 
after transplantation in syngenic recipients. This data suggests that alloantigen-dependent 
response is not necessary to drive CD5+ donor-derived passenger leukocytes’ proliferation. 
One can suggest that alloantigen-independent response, such as ischemia-reperfusion of 
CD5+ donor-derived passenger leukocytes might cause their proliferation in recipient after 
transplantation.
Donor-derived passenger leukocytes that are transplanted with the graft have the capacity 
to present donor alloantigens as intact molecules to the responding T cells by means of the 
so-called direct pathway of allorecognition.12 CD5 is expressed at relatively high levels on all T 
lineage cells, at low levels on B-1a cells, and is below detectable levels on B-2 cells.9 Therefore, 
the light signal we observed in this CD5 promoter luciferase mice donor study is emitted 
from donor-derived passenger T cells. In the present study, we demonstrated donor-derived 
passenger T cells diminished within 24 hours post-transplant in cardiac allograft recipient. 
Further studies using luciferase gene driven by other cell surface markers such as CD4 (T 
helper cell), CD8 (cytotoxic T cell), CD11c (dendritic cell), CD11b (macrophage), and B220 (B 
cell) for the in vivo visualization of immune response will increase our basic understanding of 
not only the passenger leukocyte function and destination in allograft recipient, but also the 
mechanisms of immune response in solid organ and cellular transplantation.
We have assessed CD5+ cell location in the cardiac transplant recipient mice in the course 
of acute rejection using BLI. We did not assess functional and immunological change of these 
cells. Nevertheless, this is the first study to visualize CD5+ cells in vivo in the course of acute 
rejection.
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The results of this study provide the foundation for refinement of bioluminescence imag-
ing in a non-human primate study. Clinically this novel method of noninvasive diagnosis of 
cardiac allograft rejection could potentially eliminate the need for routine surveillance en-
domyocardial biopsy. Application of in vivo BLI to the study of cardiovascular disease as well 
as transplant immunobiology will greatly accelerate and refine preclinical analyses, and lead 
to the development of tools with clinical utility. A number of advances have already been 
described and suggest that there is considerable growth yet to be realized in the nascent 
field of molecular imaging.
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Timing of Bone Marrow Cell 
Delivery has Minimal Effects on 
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Background: Despite ongoing clinical trials, the optimal time for delivery of bone marrow 
mononuclear cells (BMCs) following myocardial infarction (MI) is unclear. We compared the 
viability and effects of transplanted BMCs on cardiac function in the acute and sub-acute 
inflammatory phases of MI.
Methods and results: The time-course of acute inflammatory cell infiltration was quantified 
by FACS analysis of enzymatically digested hearts of FVB mice (n=12) following LAD ligation. 
Mac-1+Gr-1high neutrophil infiltration peaked at day 4. BMCs were harvested from transgenic 
FVB mice expressing firefly luciferase (Fluc) and green fluorescent protein (GFP). Afterwards, 
2.5x106 BMCs were injected into the left ventricle of wild-type FVB mice either immediately 
(Acute BMC) or 7 days (Sub-acute BMC) after MI, or after a sham procedure (n=8 per group). 
In vivo bioluminescence imaging (BLI) showed an early signal increase in the Acute BMC 
group at day 7, followed by a trend towards improved BMC survival in the Sub-acute BMC 
group that persisted until the BLI signal reached background levels after 42 days. Compared 
to controls (MI + saline injection), echocardiography showed a significant preservation of 
fractional shortening at 4 weeks (Acute BMC vs saline; P<0.01) and 6 weeks (both BMC groups 
vs saline; P<0.05), but no significant differences between the two BMC groups. FACS analysis 
of BMC injected hearts at day 7 revealed that GFP+ BMCs expressed hematopoietic (CD45, 
Mac-1, Gr-1) markers, minimal progenitor (Sca-1, c-kit), and no endothelial (CD133, Flk-1) or 
cardiac (Trop-T) cell markers.
conclusion: Timing of BMC delivery has minimal effects on intramyocardial retention and 
preservation of cardiac function. In general, there is poor long-term engraftment and BMCs 
tend to adopt inflammatory cell phenotypes.







Ischemic heart disease is the principal cause of heart failure and its prevalence continues to 
increase1. Due to the low regenerative capacity of the human heart, myocardial infarction 
(MI) leads to an irreversible loss of cardiomyocytes and ventricular remodeling. In recent 
years, treatment with autologous bone marrow-derived stem cells has been suggested to 
reduce myocardial damage in patients with MI2. Although different bone marrow cell sub-
populations have been proposed to aid to cardiac repair, unfractionated autologous bone 
marrow mononuclear cells (BMCs) were used as donor cells in the majority of clinical trials, 
mainly because of the ability to safely and quickly isolate these cells. The mononuclear part 
of the bone marrow includes a heterogeneous mixture of cells with varying percentages of 
hematopoietic stem cells, endothelial progenitor cells, mesenchymal stem cells, and side 
population cells, as well as adult myeloid and lymphoid cells3.
The potential mechanism(s) by which transplanted BMCs can improve cardiac function re-
mains a subject of debate. Beyond these mechanical considerations, several basic technical 
issues remain to be clarified, such as the optimal cell type, route of delivery, and timing of cell 
transplantation. Following acute MI, a robust inflammatory response occurs that is necessary 
for healing and scar formation and contributes to cardiac remodeling4. The benefits of BMC 
transplantation in the acute phase after MI may thus be jeopardized by the local inflammation 
that renders the myocardium a hostile environment for the injected cells. On the other hand, 
experimental studies have demonstrated that BMC transplantation can lead to a reduction 
of cardiomyocyte apoptosis5, suggesting that early timing of cell delivery might be the most 
efficient. Clearly, the optimal time point for cell delivery after myocardial infarction remains 
unknown.
To date, very few studies have addressed the timing of BMC transplantation, and those 
studies have relied on post-mortem analysis such as real-time PCR6 and immunohistochem-
istry7. These methods are highly dependent on the chosen time points of animal sacrifice 
and provide only a limited “snapshot” representation rather than a complete picture of cell 
survival over time. To overcome these issues, our group has been developing and validating 
imaging techniques for tracking transplanted stem cells in vivo8. In this study, we investigated 
the viability and effects of transplanted BMCs on cardiac function in the acute and sub-acute 
inflammatory phases of MI using molecular imaging techniques. In addition, we analyzed the 
phenotype of BMCs transplanted into acute inflammatory myocardium.
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MaTERIalS aNd METhOdS
transgenic L2G animals expressing fluc-GfP.
The donor group consisted of male L2G85 mice (8 weeks old), which were bred on FVB 
background and ubiquitously expressed green fluorescent protein (GFP) and firefly luciferase 
(Fluc) reporter genes driven by a β-actin promoter as previously described9. Recipient animals 
consisted of syngeneic, female FVB/NJ mice (8 weeks old, Jackson Laboratories, Bar Harbor, 
ME, USA). Animal care was provided in accordance with the Stanford University School of 
Medicine guidelines and policies for the use of laboratory animals.
Preparation of bone marrow mononuclear cells (BMcs).
BMCs were harvested from the long bones of male L2G85 transgenic mice and isolated by 
centrifugation in a density cell separation medium (Ficoll-Hypaque; GE Healthcare, Piscat-
away, NJ) prior to intramyocardial injection.
BMc proliferation assay.
Proliferation was determined by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. 5x105 BMCs were plated in 100 μl IMDM (10% FBS) into a 96-well 
plate in triplicates and were incubated under normoxic (95%O2/5%CO2) and hypoxic 
(1%O2/5%CO2/94%N2) conditions for 32 hours. 20 μl of MTT was added to each well, followed 
by incubation for an additional 4 hours. Absorbance was determined with a multi-well ab-
sorbance reader (Genios, Tecan Systems Inc., San Jose, CA) at 490 nm using Magellon v6.2 
software.
surgical model for acute and subacute myocardial infarction.
Female FVB mice (8 weeks old) were intubated with a 20-gauge angiocath (Ethicon 
Endo-Surgery, Inc. Cincinnati, OH) and placed under general anesthesia with isoflurane (2%). 
Myocardial infarction (MI) was created by ligation of the mid-left anterior descending (LAD) 
artery with 8-0 ethilon suture through a left anterolateral thoracotomy as described10. In the 
acute MI model, both the infarct and peri-infarct regions were injected with 25 μL containing 
2.5x106 cells or saline immediately following MI using a Hamilton syringe with a 30-gauge 
needle. In the subacute model, BMCs were injected after re-thoracotomy on day 7 following 
MI. All surgical procedures were performed in a blinded fashion by one micro-surgeon (G.H.) 
with many years of experience on this model.
flow cytometric analysis of cell and/or myocardial tissue.
Freshly isolated BMCs were washed and incubated with conjugated primary antibody for 45 
min at 4˚C. For tissue analysis, hearts were surgically explanted, minced and digested for 2 
hours in Collagenase D (2 mg/mL; Worthington Biochemical) at room temperature in RPMI 






1640 media (Sigma Chemical Co.) with 10% fetal calf serum (FCS; Life Technologies). Myo-
cardial cell suspensions were run through a 70-m cell strainer, washed in FACS buffer (PBS 
2% FCS) and incubated with conjugated primary antibody for 45 min at 4˚C. For Troponin T 
staining, a 30-min incubation in cell permeabilization buffer was performed prior to antibody 
incubation. Finally, cells were washed, incubated with 7-amino-actinomycin D (7-AAD) cell 
viability solution (eBiosciences), and analyzed on a FACSCalibur system (BD Biosciences). The 
following antibodies were used in this study: APC-conjugated CD45 (clone: 30-F11), Gr-1 
(RB6-8C5) and C-kit (2B8); Phycoerythin (PE)-conjugated Mac-1 (M1/70), Flk-1 (Avas 12α1) 
(BD Biosciences), Sca-1 (D7) and CD133 (13A4) (eBioscience); purified goat-anti Troponin 
T-C (C-19) (Santa Cruz Biotechnology) followed by Alexa Fluor 647 Chicken Anti-Goat IgG 
(Molecular probes)
In vivo optical bioluminescence imaging (BLi).
BLI was performed using the IVIS 200 (Xenogen, Alameda, CA, USA) system. Recipient mice 
were anesthetized with isoflurane and placed in the imaging chamber. After acquisition of 
a baseline image, mice were intraperitoneally injected with D-Luciferin (400 mg/kg body 
weight). Mice were imaged on days 2, 4, 7, and weekly until sacrifice at week 6. BLI signal 
was quantified in units of maximum photons per second per centimeter square per steridian 
(photons/s/cm2/sr) and presented as Log[photons/s/cm2/sr].
echocardiography to assess left ventricular fractional shortening (LVfs).
Echocardiography was performed using the General Electric Vivid 7 Dimension imaging 
system equipped with a 13-MHz linear probe (General Electric, Milwaukee). Animals were 
induced with isoflurane, received continuous inhaled anesthetic (1.5%–2%) for the duration 
of the imaging session, and were imaged in the supine position. Echocardiography was per-
formed by an independent operator (J.A.G.) blinded to the study conditions. M-mode short 
axis views of the left ventricle were obtained and archived. Analysis of the M-mode images 
was performed using GE built-in analysis software. Left ventricular end diastolic diameter 
(EDD) and end-systolic diameter (ESD) were measured and used to calculate fractional short-
ening (FS) by the following formula: FS = (EDD – ESD)/EDD.
Ex vivo taqMan Pcr.
In our protocol, the transplanted cells were derived from male mice and were transplanted 
into female recipients, which facilitates quantification of male cells in the explanted female 
hearts by tracking the Sry locus found on the Y chromosome. Animals were sacrificed and 
hearts (n=3 per group) were explanted, minced, and homogenized in 2 mL DNAzol (Invitro-
gen, Carlsbad, CA, USA). The DNA was isolated according to the manufacturer’s protocol. The 
DNA was quantified on a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, 
DE, USA) and 500 ng DNA was processed for TaqMan PCR using primers specific for the Sry 
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locus. RT-PCR reactions were conducted in iCylcer IQ Real-Time Detection Systems (Bio-Rad, 
Hercules, CA, USA). Detection levels were compared to a standard curve to assess the number 
of viable cells per sample. All samples were conducted in triplets.
tissue collection, immunofluorescent, and histological analysis.
Explanted hearts were fixed in 2% paraformaldehyde for 2 hours at room temperature and 
cryoprotected in 30% sucrose overnight at 4°C. Tissue was frozen in optimum cutting tem-
perature compound (OCT compound, Sakura Finetek) and sectioned at 5 μm on a cryostat. 
Serial sections were blocked and incubated with rat anti-CD45 (clone 30-F11) (BD Biosciences) 
for 1 hour at room temperature, followed by goat anti-rat Alexa 594 (Molecular Probes) for 
30 min. Sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes) and analyzed with a Leica DMRB fluorescent microscope (Leica Microsystems, Frank-
furt, Germany). Hematoxylin and Eosin (H&E) staining (Sigma) was performed according to 
established protocols.
statistical analysis.
Data are presented as mean ± SEM. Comparisons between groups were done by independent 
sample t-tests or analysis of variance (ANOVA) with LSD post hoc tests, where appropriate. 
Differences were considered significant for P-values <0.05. Statistical analysis was performed 
using SPSS statistical software for Windows (SPSS)
RESulTS
Quantification of acute myocardial inflammation following myocardial infarction in 
mice.
Acute MI triggers an acute inflammatory phase, dominated by infiltrating neutrophils that 
produce reactive oxygen species and proteases that cause cardiomyocyte injury. This is 
followed by a proliferative phase, in which infiltrating macrophages produce cytokines and 
growth factors that stimulate fibroblast proliferation and neovascularization11. After inducing 
MI in our mice, conventional histology showed a robust and progressive infiltration of inflam-
matory cells into the infarcted area over time, followed by scar formation and subsequent 
remodeling of the left ventricle (Fig 1A). To determine the transition of the inflammatory 
into proliferative phase, we performed a quantitative analysis of intra-myocardial infiltrating 
cell subsets using flow cytometry of enzymatically digested hearts. MI was created by LAD 
ligation in FVB mice (n=12), which were sacrificed on days 2, 4, 7, and 14 following MI (n=3 
per group). Progressive infiltration of CD45+ infiltrating leukocytes was found to peak on day 
4 and day 7 following MI (Fig 1B and D). More specifically, early infiltration of Mac-1+Gr-1high 
neutrophils was found to peak on day 4 (Fig 1C and E), whereas Mac-1+Gr-1low macrophages 






infiltrated the heart most predominantly on day 7 (Fig 1C and F). These findings demonstrate 
that in our murine model, transition of the aforementioned phases occurs between days 4 
and 7 following MI.
characterization of fluc+GfP+ BMc.
We have previously validated in vivo BLI as a reliable tool to monitor BMC engraftment into 
ischemic myocardium12. BLI measurements correlate highly with post-mortem methods of 
donor cell detection12, 13. BMC harvested from transgeneic L2G85 mice (FVB background) 
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Figure 1. Quantification of myocardial inflammation following LAD ligation in FVB mice. (a) H&E staining performed on sections of the 
left ventricle at different time-points following LAD ligation shows increasing infiltration of mononuclear cells over time leading to ventricular 
remodeling. (b) Corresponding panels of flow cytometric analysis show that intramyocardial infiltration of CD45+ leukocytes reaches a 
maximum at 4 to 7 days following LAD ligation. (c) More specifically, infiltration of Mac-1+Gr-1high neutrophils (N) peaks on day 4, whereas Mac-
1+Gr-1low macrophages (M) peak on day 7 following LAD ligation. (d) Graphical representation of infiltration of inflammatory cell subsets.
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exhibit a robust correlation between Fluc expression and BMC number (Fig 2A), as well as a 
strong expression of GFP (Fig 2B). FACS analysis confirmed the presence of stem/progenitor 
cells as well as adult hematopoietic cells within the BMC population (Fig 2C). The prolifera-
tion capacity of BMC was tested in vitro. Under hypoxic conditions, the cells showed robust 
proliferation when compared to BMCs kept under normoxic conditions (Fig 2D).
Effects of timing of BMC delivery following MI on cell viability.
To determine whether the survival of transplanted BMCs depends on the timing of delivery, 
FVB mice (n=24) were randomized into the following groups: (1) LAD ligation + immediate 
BMC injection (Acute BMC); (2) LAD ligation + BMC injection at 7 days post-MI (Sub-acute 
BMC); and (3) Sham surgery + BMC injection (BMC control). In vivo BLI showed an early signal 
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Figure 2. Characterization of firefly luciferase (Fluc) and green fluorescent protein (GFP)-positive BMCs. (a) Ex vivo BLI shows a robust 
correlation between cell number and reporter gene activity. (b) There is robust expression of GFP by BMCs. (c) Further characterization of the 
BMC subsets shows low numbers of stem/progenitor cells (Sca-1, c-kit, CD133) and high numbers of adult hematopoietic cells (CD45, Mac-1, 
Gr-1). (d) Viability and proliferation capacity of transgenic BMCs were confirmed in vitro. After 36 hours under hypoxic conditions, BMCs 
proliferated significantly more compared to BMCs that were maintained under normoxic conditions (*P<0.01).






increase in the Acute BMC group on day 7 (Acute BMC: 4.50±0.05 vs Sub-acute BMC: 4.34±0.05 
Log[photons/s/cm2/sr]; P<0.05), similar to validated findings in our previous study12. This suggests a 
significantly higher proliferation of donor BMCs delivered into acute MI milieu as compared to 
BMCs delivered in a sub-acute MI milieu. BLI further showed a trend (though not statistically 
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Figure 3. Longitudinal in vivo tracking of transplanted BMCs. (a) Representative BLI images of BMC transplanted animals either acutely 
(Acute BMC, upper panels) or 7 days after MI (Sub-acute BMC, lower panels) show proliferation of the cells early after transplantation. 
Thereafter, in both groups the BLI signal decreases gradually over time to reach background levels at day 42. Color scale bar values are in 
photons/s/cm2/sr. (b) Graphical representation of longitudinal BLI shows a significantly increased signal intensity in the Acute BMC group at 
day 7 (*P<0.05), followed by a trend towards improved BMC survival in the Sub-acute BMC that persisted until BLI signal reached background 
levels at day 42 day. (c) Ex vivo quantitative TaqMan PCR found no significant differences when comparing negative control (Neg) and 
6-week BMC-injected hearts. Significantly more male BMCs were found in the 2 hour positive control (Pos) hearts (n=3 per group, n.s. = not 
significant, *P<0.001). 
Chapter 346
significant) towards improved BMC survival in the Sub-acute BMC group that persisted until 
the BLI signal reached background levels in both groups at 42 days. No significant difference 
was in BLI signal was found between Sub-acute BMC and control BMC animals (not shown). 
These results suggest that, independent of timing of delivery, intramyocardial retention of 
BMC is limited to 6 weeks following transplant.
Ex vivo quantification of BMc survival.
To confirm BLI findings and to rule out the possibility that BMC death might have been caused 
by recipient immune response towards the reporter gene, we performed LAD ligation on an 
additional set of female FVB mice, which were randomized to receive 2.5x106 non-labeled 
(wild-type) BMCs from male FVB donors (n=6) or saline (Negative control, n=3). BMC-injected 
animals were sacrificed at 2 hours (Positive control) and 6 weeks (n=3 per group). Their hearts 
were processed for quantitative TaqMan PCR analysis. Consistent with BLI data, there were 
no significant differences between 6-week BMC-injected hearts and saline-injected hearts, 
demonstrating that no male donor BMCs could be detected intramyocardially at the 6 week 
time-point. In comparison, significantly higher BMC numbers were found in 2 hour BMC 
hearts (Fig 3C).
effects of timing of BMc delivery on preservation of cardiac function.
Preservation of cardiac performance was analyzed by echocardiography performed pre-op-
eratively (base-line) and every 2 weeks following MI in the Acute and Subacute BMC animals, 
and compared to a control group receiving LAD ligation + saline injection (FVB, n=8). A rep-
resentative M-mode tracing used for analysis is shown in Figure 4A. A significant preservation 
of fractional shortening was seen in BMC groups at 4 weeks (Acute BMC: 33.2±1.7% vs saline: 























Figure 4. Echocardiographic assessment of cardiac function.  (a) Representative M-mode echocardiogram at the level of the papillary 
muscle from which left ventricular diameters were measured. (b) Echocardiography revealed a significant preservation of left ventricular 
fractional shortening at 4 weeks in the Acute BMC group and 6 weeks in both BMC groups compared to saline control animals. No significant 
difference in cardiac performance was found between Acute and Sub-acute BMC animals. (*P<0.05, **P<0.01)






29.0±1.6%; P<0.01) and 6 weeks (Acute BMC: 33.7±1.2%; Sub-acute BMC: 33.4±2.2% vs saline: 
27.6±1.7%; P<0.05 for both BMC groups vs. saline) following MI. However, no significant dif-
ferences in cardiac contractility were found between both BMC groups during the 6-week 
study period (Fig 4B).
BMcs delivered into acute inflammatory environment adopt adult hematopoietic 
phenotypes.
In the first week following injection, BLI imaging showed a significantly higher proliferation 
rate of donor BMCs that were delivered into acute inflammatory myocardium, as compared 
to BMCs delivered into sub-acute inflammation (Fig 3A and B). Since BMCs represent a het-
erogeneous cell population, we aimed to investigate the phenotype of transplanted BMC 
at 7 days following injection into acute myocardial inflammation. LAD ligation + acute BMC 
(n=4) or saline (n=3) injection was performed in an additional set of FVB mice, which were 
sacrificed for heart procurement at 7 days post-transplant. Conventional H&E staining of 
sections of the left ventricle showed robust mononuclear cell infiltration and early signs of 
scar formation consistent with MI (Fig 5A). Immunofluorescent staining on a corresponding 
section revealed the presence of intramyocardial mononuclear cells, which appeared to be 
mostly of GFP+ donor origin (Fig 5B). Interestingly, staining with the pan-leukocyte marker 






Figure 5. Immunohistochemical analysis of BMC transplanted hearts. (a) H&E staining of the left ventricular wall shows mononuclear 
cell infiltrates and scar formation consistent with myocardial infarction. (b) Immunofluorescent staining on a corresponding section reveals an 
abundant presence of GFP+ BMCs (green) within the infarcted myocardium, which is rich in CD45+ inflammatory cells (red). Counterstaining was 
performed with 4,6-diamidino-2-phenylindole (DAPI, blue). (c) High power views of the selected area (Fig 2B white square) reveal that the vast 
majority of donor BMCs express CD45 and retain round shapes with large nuclei, representing an inflammatory phenotype.
Chapter 348
CD45 revealed that the vast majority of GFP+ donor cells co-expressed CD45 (Fig 5B and C). 
Next, we performed a systematic flow cytometric analysis on explanted hearts following 
enzymatic digestion (n=3 per group). Figure 6A shows representative flow cytometry panels 
confirming that GFP+ donor BMCs (right panel, arrow) co-expressed CD45, compared to 
saline-injected control hearts (left panel). Serial analysis showed that donor BMCs expressed 
CD45, Mac-1 and Gr-1, and minimal numbers of Sca-1 and c-kit, and remained negative for 
CD133, Flk-1 and/or Troponin (Trop)-T (Fig 6B). These results suggest that at 7 days following 
acute delivery, donor BMCs were mostly of adult hematopoietic phenotypes, and showed no 
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Figure 6
Figure 6. Ex vivo phenotyping of donor BMCs confirms inflammatory phenotype. (a) Representative flow cytometry panels of saline 
(left) and BMC (right) injected hearts at 7 days after acute BMC delivery. At this time-point GFP+ BMCs (arrow) co-express CD45, confirming 
their inflammatory phenotype. (b) Serial flow cytometric analysis reveals that GFP+ BMCs predominantly express inflammatory cell markers 
(CD45, Mac-1, Gr-1), rather then stem cell (Sca-1, c-kit), endothelial progenitor cell (CD133, Flk-1) or cardiomyocyte (TropT) markers. Data are 
presented as percentage of GFP/marker+ cells reduced by background staining.
dISCuSSION
Despite ongoing clinical trials, the optimal time-point of BMC delivery following acute MI 
remains a point of debate. A review of current literature reveals few studies that have system-
atically addressed the issue of timing of BMC transplantation14. This study was designed to 
determine the effects of timing of BMC delivery following acute MI in a standardized mouse 
LAD ligation model. Specifically, we have demonstrated that: (1) BMC transplantation in either 
acute or sub-acute myocardial infarction has a mildly positive effect on cardiac preservation, 
confirming earlier findings in animals models15 and clinical trials2; (2) retention of BMC engraft-
ment and preservation of cardiac function are not critically dependent on the timing of delivery; 
and (3) injection of BMCs into the acute inflammatory environment of myocardial infarction 
leads to early proliferation of donor cells that adopt adult hematopoietic phenotypes.






Earlier studies from our laboratory using in vivo BLI of transplanted BMCs revealed that the 
cells can effectively home in on and engraft into infarcted myocardium12, 13. Although the 
present study confirms the therapeutic effect of BMC transplantation in the setting of acute 
MI, it also clearly shows that delivery of the cells in the time-window following the hostile 
acute inflammatory phase–7 days after MI–does not result in extended long-term survival of 
donor BMCs. In addition, no significant differences were found in the preservation of cardiac 
function between BMCs injected groups during a 6-week period of observation.
To our knowledge, timing of BMC delivery has thus far not been investigated in experimen-
tal models. However, other cell populations, such as BM-derived mesenchymal stem cells7 
and fetal cardiomyocytes16, showed therapeutic improvements in rat models when delivered 
in a the time-window of 1 to 2 weeks following MI. Most likely, the different observations 
made in our study are the results of the different cell populations used for transplantation. To 
represent the present clinical situation, we specifically used unfractioned BMCs. In addition 
to survival data, we show that the portion of BMCs responsible for cardiac preservation seem 
to be adult hematopoietic cells, rather than BM-derived endothelial, endothelial progeni-
tor, or cardiac cells, at least following acute delivery at the time-point tested. These findings 
strengthen the hypothesis that preservation of cardiac performance by BMC transplantation 
might be attributable to modulation of the natural process of myocardial inflammation and 
infarct healing17.
Investigations aimed to reveal the mechanism(s) by which stem cells might preserve car-
diac function have been plenty. Early reports pointed toward the myocardial regeneration by 
repopulation of BM-derived endothelial cells and/or cardiomyocytes18; however, subsequent 
studies failed to support those observations19. Other proposed mechanisms include donor-
host cell fusion and neovascularization by either vasculogenesis and/or secretion of para-
crine factors leading to angiogenesis and arteriogenesis20. Recently, studies have focused on 
additional mechanisms of action of transplanted BMCs, which could be by a direct paracrine 
effect on the inflammatory cascade. Burchfield et al. recently reported evidence that BMCs 
mediate cardiac protection by release of the immunomodulatory cytokine IL-10, leading to 
decreased intramyocardial accumulation of T-lymphocytes, which translated into reduced LV 
remodeling21. Similarly, Ciulla et al. found transplanted BMCs to reduce serum levels of pro-
inflammatory cytokines, which are known to contribute to myocardial apoptosis, necrosis, 
and scar formation22. These findings, combined with the results presented in the present 
study, suggest that BM progenitors could ameliorate LV remodeling following MI by continu-
ing to differentiate along the hematopoietic lineage.
The clinical relevance of this study is significant. A recent meta-analysis of randomized 
clinical trials of BMC transplantation in patients suffering from acute MI found no significant 
difference in global LV function when the cells were delivered in either the <5-day or 5- to 
–30-day time windows2. The present study provides the experimental proof for these clini-
cal findings. Specifically, we show that long-term survival and modest therapeutic efficacy 
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of BMCs seem to be relatively independent of timing of cell delivery. Clinically significant 
improvements of cardiac function in patients suffering from acute MI may thus be achieved 
by repeated cellular transplants, both in the acute and sub-acute phases of myocardial inflam-
mation.
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abSTRaCT
Human embryonic stem cells (hESCs) are capable of differentiation into every cell type of 
the human being. They are under extensive investigation for their regenerative potential in 
a variety of debilitating diseases. However, the field of hESC research is still in its infancy, as 
there are several critical issues that need to be resolved before clinical translation. Two major 
concerns are the ability of undifferentiated hESCs to form teratomas and the possibility of 
a provoked immune reaction after transplantation of hESCs into a new host. Therefore, it is 
imperative to develop non-invasive imaging modalities that allow for longitudinal, repetitive, 
and quantitative assessment of transplanted cell survival, proliferation, and migration in vivo. 
Reporter gene-based molecular imaging offers these characteristics and has great potential 
in the field of stem cell therapy. Moreover, it has recently been shown that reporter gene 
imaging can be combined with therapeutic strategies. Here, we provide an outline of the cur-
rent status of hESC research and discuss the concerns of tumorigenicity and immunogenicity. 
Furthermore, we describe how molecular imaging can be utilized to follow and resolve these 
issues.







Adult stem cells have great promise as potential treatments for a variety of intractable dis-
eases. However, these cells are generally limited in their plasticity. Therefore, it would be ideal 
to obtain or create a cell line that is truly able to differentiate into every cell of the body. The 
first such cell line was derived in the 1960’s and originated from teratomas that developed 
spontaneously in male mice of the 129 strain. These “embryonal carcinoma” (EC) cells were ca-
pable of teratoma formation after transplantation of single cells into a new host,1 confirming 
their ability to differentiate into progeny of all three germ layers (ectoderm, mesoderm and 
endoderm)--a phenomenon known as ‘pluripotency’.2 Further research led to the first isola-
tion of murine embryonic stem cells (mESCs) in 1981 from the epiblast of blastocyst-stage 
mouse embryos,3, 4 followed by the establishment of the first human embryonic stem cell 
(hESC)-line in 1998.2 To date, there are more than 300 hESC lines, but only 22 hESC lines are 
commercially available and registered in the “NIH Human Embryonic Stem Cell Registry”.5
Although most studies using hESCs in disease models show auspicious results, there are 
several concerns about hESC transplantation. First, the pluripotent character of hESCs is 
somewhat a double-edged sword. They are an attractive candidate for cell based therapies, 
but their pluripotency can also lead to risk of teratoma formation after transplantation. 
Second, since it is presently impossible to transplant hESCs syngeneically, the possibility 
that hESCs might provoke an immune reaction following allogeneic transplantation must be 
considered. This review will discuss these issues and how molecular imaging can help resolve 
them.
dERIVaTION, MaINTENaNCE, aNd dIffERENTIaTION
Traditionally, hESCs are isolated from the inner cell mass of the human blastocyst, or as recently 
shown, can be derived from single blastomeres.6 The isolated cells can be expanded in vitro, 
with an average doubling time of 30-35 h.7 However, strict homeostatic culture conditions and 
the addition of inhibiting compounds are necessary to keep the hESCs in an undifferentiated 
state, a condition required for maintaining a normal karyotype and an unlimited capacity for 
self-renewal. This is possible by growing hESCs on a cellular feeder layer. Inactivated murine 
embryonic fibroblasts prove to be an effective feeder layer for the undifferentiated growth of 
hESCs because they secrete differentiation-inhibiting factors.8 Due to the risk of cross-species 
retroviral infection, however, this is an unattractive option in the long term. Recently, several 
reports have described the culture of hESCs in animal-free conditions, using human feeder 
cells consisting of foreskin,9 pure human fibroblast populations,10 or uterine endometrial cells 
and serum-free medium.11 Generally, these undifferentiated hESCs express transcription fac-
Chapter 458
tors OCT-3/4, Sox-2, and NANOG; surface markers CD9, CD133, and SSEA-3/4; proteoglycans 
TRA-1-60/81 and TRA-2-54; and enzyme alkaline phosphatases and telomerase.12, 13
Following withdrawal of inhibitory factors, hESCs will aggregate into three-dimensional 
clusters of cells in an early stage of differentiation, thereby losing pluripotency. These clusters, 
named Embryoid Bodies (EBs),14 form the first step of further differentiation into any type of 
progeny. Within the EBs, a microenvironment exists in which various signals will promote 
differentiation into all three germ layers. Although differentiation generally occurs spon-
taneously, much effort currently focuses on stimulating directed differentiation to achieve 
sufficiently large populations for clinical use. The generation of pure, differentiated cultures is 
indispensable for developing cell based therapies, and will help us better understand cellular 
developmental processes and test pharmacological strategies.
Differentiation into Mesoderm Lineages
While reports have been published of hESCs differentiating into various mesodermal lineages, 
including kidney, muscle, bone and blood cells,15 it is cardiomyogenesis that has received 
the most attention. Cardiomyogenesis typically manifests as a beating area within the EBs 
around 5 days after EB-formation, the surface of which increases gradually with time.16 Kehat 
and colleagues were the first to show that hESC-derived cardiomyocytes within these beating 
EBs actually resemble the structural and functional properties of early stage human cardio-
myocytes.16 Since then, several other methods have been tested to improve the efficiency of 
in vitro differentiation of hESCs into cardiomyocytes with moderate success.17-19
Differentiation into Ectoderm Lineages
Using different growth factors and stimulating environments, hESCs can also be driven to 
differentiate into brain, skin, and adrenal derivates.15 The potential of hESC-derived cultures 
for the treatment of neurodegenerative disorders is under intensive investigation. While 
many groups have described neuronal differentiation within the EB,20-22 factor-induced 
neuronal differentiation seems to be limited to the addition of retinoic acid (RA) and nerve 
growth factor (betaNGF),21 or the use of serum-free, conditioned medium.23 The coculture of 
hESCs with murine skull bone marrow-derived stromal cells also seems to induce neuronal 
differentiation.24
Differentiation into endoderm Lineages
From the beginning, hESCs were shown to be capable of differentiating in vitro into liver 
and pancreatic cells when exposed to a variety of growth factors.15 The creation of insulin-
secreting pancreatic cell populations has generated much interest, as this might ultimately 
provide a cell-based therapy for patients with type I diabetes.25 However, the identification 
of insulin-producing cells has proven to be difficult and susceptible to artifacts.26 Thus, the 
in vitro pancreatic differentiation from hESCs remains a challenging multi-step culturing 
procedure at present.27






In summary, although much is being done to improve the efficacy of in vitro differentiation 
systems, little is known about the cellular interactions that occur during natural differen-
tiation. Most of the in vitro differentiation methods are to some extent dependent on EB 
formation. The process of in vitro EB formation mimics the natural transcriptional pathways 
occurring in the developing embryo, leading not only to the differentiation into the desired 
cell type, but also to the production of undesired cells. The most dangerous example of the 
latter is undifferentiated hESCs that retain the ability to form teratomas. Until we understand 
the precise pathways of pluripotent differentiation, the acquisition of desired, transplantable 
cell types can only rely on stimulating known pathways and the pre-transplantation selection 
of the desired cell type.
teratoma formation
At present no selection method exists that can yield a 100% pure population, which is a ma-
jor obstacle for clinical translation. When transplanted in immunodeficient mice, hESCs form 
teratomas consisting of human tissues from all germ layers.2, 28 The formation and composi-
tion of teratomas seem to be influenced by several factors, including graft site,29 transplanted 
cell number, and developmental phase of the host,24 as described next.
One factor influencing hESC-based teratoma formation is the site of transplantation, which 
affects both growth and composition of the tumor. As recently shown by Cooke and col-
leagues, teratomas rising from hESCs will grow faster and contain more undifferentiated cells 
when transplanted in the liver of nude mice, as compared to subcutaneous transplantation.29 
It is of major interest why hESCs differentiate at the subcutaneous site but remain undif-
ferentiated in the liver. The authors hypothesize that this was due to the well vascularized, 
growth factor-rich, immune-privileged porous structure in the liver.29 These findings are not 
only a stimulant for further research on graft site and teratoma formation, but also indicate 
the importance of in vivo experiments, as there may be factors present in the liver that could 
help maintain hESCs in an undifferentiated state in vitro.
Another factor influencing teratoma formation is the number of undifferentiated hESCs that 
are viable after transplantation. As discussed earlier, transplantation of pure undifferentiated 
hESC inevitably leads to teratoma formation.2, 28 Interestingly, transplantation of selected 
hESC-derived cells in a more developed phase will not automatically lead to teratomas, even 
when this population is not 100% pure.30 However, there are no extant studies that assess 
the minimal cell number needed for teratoma formation, or stated otherwise, the maximum 
percentage of contamination with undifferentiated hESC. Our laboratory is actively investi-
gating these issues.
Recently, Muotri and colleagues have studied undifferentiated hESC after in utero trans-
plantation into the lateral brain ventricle of day-14 mouse embryos.24 The results showed 
that hESCs integrated into the brain, giving rise to neuronal and glial lineages, but not to 
teratomas. These findings suggest that hESCs are susceptible to environmental cues that can 
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modulate its differentiation and tumorigenic potential, as was suggested in earlier studies 
with hESCs in chick embryos.31
Taken together, these observations and questions are not only a stimulant for further 
research on teratoma biology, but also indicate the importance of developing novel imaging 
techniques to track their growth in vivo longitudinally, repetitively, and quantitatively.
immunogenicity
Another hurdle facing clinical transplantation of hESCs is the potential immunologic bar-
rier. The immune response generated after transplantation is directed towards alloantigens, 
which are antigens presented on the cell surface that are considered non-self by the recipient 
immune system.32 The major system of alloantigens responsible for cell incompatibility is the 
major histocompatibility complex (MHC). In humans, MHC-I molecules are expressed on the 
surface of virtually all nucleated cells and present antigens to CD8+ cytotoxic T cells, while 
MHC-II molecules are normally more restricted to antigen presenting cells such as dendritic 
cells and macrophages, and are selectively recognized by CD4+ helper T cells.33
It has been shown that hESCs express low levels of MHC-I in their undifferentiated state.34, 
35 In one study, the MHC-I expression increased two to four-fold when the cells were induced 
to spontaneously differentiate to EB, and an eight to ten-fold when induced to differentiate 
into teratomas.34 In contrast, a different group observed MHC-I downregulation after differ-
entiation induced with retinoic acid or on Matrigel or in extended cultures.35 In both studies, 
MHC-I expression was strongly upregulated after treatment of the cells with interferon-γ, a 
potent MHC expression-inducing cytokine known to be released during the course of an 
immune response. MHC-II antigens were not expressed on hESCs or hESC derivatives.34 The 
latter finding confirms that, in contrast to tissue allografts, hESC transplants are devoid of 
highly immunogenic mature dendritic cells, or any other type of specialized antigen present-
ing cells. Thus, the transplanted cells may not express MHC-II molecules required for effective 
priming of alloreactive CD4+ T cells through direct recognition.
Previously, our group tested allogeneic undifferentiated mESCs for their ability to trigger al-
loimmune response in a murine model of myocardial infarction.36 We found progressive intra-
graft infiltration of inflammatory cells mediating both adaptive (T cells, B cells, and dendritic 
cells) and innate (macrophages and granulocytes) immunity. Cellular infiltration progressed 
from mild infiltration at two weeks to vigorous infiltration at four weeks, leading to rejection 
of the mESC allograft. Moreover, we found an accelerated immune response against mESCs 
that had differentiated in vivo for 2 weeks, suggesting that mESC immunogenicity increases 
upon their differentiation.36
Although it was previously reported that hESCs failed to elicit immune responses during 
the first 48 hours after intramuscular injection of immunocompetent mice,37 a recent report 
using a similar model found hESCs to be completely eliminated at 1 month post-transplan-
tation.38 Thus, questions regarding the exact character and intensity of immune responses 






towards allogeneic hESCs and their derivatives remain. Solutions that reduce or eliminate 
the potential immunological response to transplanted allogeneic hESCs are urgently needed. 
Possible strategies to minimize rejection of hESC transplants have been extensively reviewed 
elsewhere.39, 40 Examples of these strategies include: (1) forming HLA isotyped hESC-line 
banks; (2) creating a universal donor cell by genetic modification; (3) inducing tolerance by 
hematopoietic chimerism; or (4) generating isogeneic hESC lines by somatic nuclear transfer. 
To optimize these techniques in the future, it is crucial to develop sensitive and reliable imag-
ing methods for monitoring the viability of transplanted cells in vivo.
Molecular imaging
To date, most studies on stem cell therapy have relied on conventional reporter genes such as 
GFP41 and β-galactosidase (lacZ) to monitor cell survival and differentiation. However, these 
reporter genes cannot be used to reliably track in vivo characteristics of transplanted cells 
due to poor tissue penetration and the need for extrinsic excitation light, which produces an 
Figure 1
Figure 1: Schematic overview of molecular imaging. Outline of a vector containing a DNA reporter construct with the reporter gene(s) driven 
by a promoter of choice.  Transcription and translation lead to production of mRNA and reporter protein, respectively. After administration of 
a reporter probe systemically, the reporter probe will be catalyzed by specific cells that have the reporter proteins. This amplification process 
can be detected by a sensitive imaging device. Examples of reporter genes and their specific reporter probes are listed per imaging modality. 
Abbreviations: Fluc, Firefly luciferase; PET, positron emission tomography; HSV-ttk, herpes simplex virus truncated thymidine kinase; [18F]-
FHBG, 9-(4-[18F]-fluoro-3hydroxymethylbutyl) guanine; SPECT, single photon emission computed tomography; hNIS, human sodium/iodide 
symporter; MRI, magnetic resonance imaging; CCD, charged coupled device; BLI, bioluminescence imaging. 
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unacceptable amount of background signal. Instead, GFP-labeled cells are typically identified 
histologically, which provides only a single snapshot representation rather than a complete 
picture of cell survival over time. To solve these shortcomings, our group has been develop-
ing reporter gene-based molecular imaging techniques.42
Molecular imaging can be broadly defined as the in vivo characterization of cellular and 
molecular processes.43 The backbone of reporter gene-based molecular imaging technique 
is the design of a suitable reporter construct. This construct carries a reporter gene linked to 
a promoter/enhancer, which can be inducible, constitutive, or tissue specific. The construct 
can be introduced into the target tissue by molecular biology techniques using either viral or 
non-viral techniques. Transcription of DNA and translation of mRNA lead to the production 
of reporter protein. After administration of a reporter probe, the reporter protein reacts with 
the reporter probe, giving rise to signals that are detectable by a charged-coupled device 
(CCD) camera, positron emission tomography (PET), single photon emission computed 
tomography (SPECT), or magnetic resonance imaging (MRI) (figure 1). For thorough review, 
please refer to other relevant articles.43, 44
imaging esc transplantation, tumorigenicity, and immunogenicity
A major advantage of reporter gene imaging is the incorporation of the reporter construct 
into the cellular DNA. This ensures that the reporter gene will only be expressed by living cells 
and will be passed on equally to the cell’s progeny. Thus, this imaging modality can provide 
significant insight into cell viability and proliferation. As discussed earlier, monitoring cell 
viability is a critical requirement to assess immunogenicity, as a provoked immune reaction 
can kill transplanted cells. Monitoring cell proliferation is another important feature, consid-
ering the tumorigenic potential of undifferentiated hESCs. Moreover, the ability to image the 
whole-body will allow us to track cell migration in other organs. This is a major advantage 
when compared to tissue biopsies using GFP-labeled cells.
In addition, multiple reporter genes can also be introduced into the same cell for multimo-
dality imaging. Recently, our group has tested the efficacy of mESC with a self-inactivating 
lentiviral vector carrying triple-fusion (TF) construct containing firefly luciferase (Fluc), mono-
meric red fluorescent protein (mRFP), and herpes simplex virus truncated thymidine kinase 
(HSV-ttk).45 The mRFP in the construct facilitates the imaging of single cells by fluorescence 
microscopy and allows for the isolation of a stable clone population by fluorescence activated 
cell sorter (FACS). The Fluc can be used to perform high throughput bioluminescence imag-
ing (BLI) for assessment of cell survival, proliferation and migration at relatively low costs. 
Finally, the HSV-ttk allows for deep-tissue PET imaging of gene expression in small animals45, 
46 as well as in patients.47, 48 After transplantation into the hearts of athymic nude rats, mESCs 
could be successfully followed for 4 weeks using BLI and PET imaging. Between week 2 and 4, 
both BLI and PET reporter gene signals increased rapidly, indicating teratoma formation. This 
was confirmed by histological analysis.45






Because of the risk of teratoma formation, it would be ideal to have an in vivo imaging 
modality in combination with a fail-safe suicide-gene mechanism. Using the antiviral drug 
ganciclovir, which is toxic against cells expressing HSV-ttk, Cao and colleagues were able to 
ablate teratoma formation and follow this progress non-invasively.49 This study reveals the 
excellent potential of reporter gene imaging for future use with hESC transplantation. In fact, 
preliminary studies in our lab suggest that as low as 100 undifferentiated hESCs (H9 line) 
can cause teratoma formation after subcutaneous injection (figure 2). Whether lower cell 
numbers (e.g. 1, 10, 50), other graft sites (e.g. intramuscular, intravenous), or different cell 
lines (e.g., federally and non-federally approved) have similar kinetics of teratoma formation 
will need to be determined carefully in the future.
Finally, a very critical question with regard to reporter genes is whether they will affect ESC 
differentiation and hamper efforts for clinical applications. A previous study from our lab has 
shown that the TF reporter genes affect <2% of total genes of mESC using transcriptional 
Figure 2
Figure 2: In vivo bioluminescence imaging of teratoma formation after transplantation of 100 hESCs. (A) Bioluminescence image showing 
longitudinal follow up after transplantation of 100 hESCs stably expressing a double fusion reporter gene (Fluc-GFP).  Faint imaging signals 
were seen as early as 2 hrs after transplant, which became progressively stronger over 2 weeks.  Histology at 8 weeks confirmed teratoma 
formation.  Note one of the hESC transplanted sites did not successfully engraft (arrow) as there were no detectable signals by 2 weeks. (B) 
Histology from a representative explanted teratoma showing hESCs that have differentiated into Histology from a representative explanted 
teratoma showing hESCs that have differentiated into derivates from different germ layers. (I) squamous cell differentiation with keratin 
pearl; (II) respiratory epithelium with ciliated columnar and mucin producing goblet cells; (III) osteoid (non-mineralized bone) formation; (IV) 
cartilage formation; (V) gland cells; and (VI) rosette consistent with neuroectodermal differentiation (400x magnification).
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profiling analysis.50 A more recent follow up study using proteomic analysis show that there 
were no significant differences between control mESCs versus mESCs with reporter genes.51 
Importantly, reporter probes such as D-Luciferin (for Fluc) and [18F]-FHBG (for HSV-ttk) had no 
adverse effects on mESC viability and proliferation as well.45 Ongoing studies are evaluating 
the effects of reporter gene expression and reporter probes on various hESC cell lines.
CONCluSION
Clearly, the capacity of hESCs to differentiate into almost all human cell types highlights 
their promising role in regenerative therapies for the treatment of heart disease, Parkinson’s 
disease, leukemia, diabetes, and other degenerative disorders. But the pluripotency of 
hESCs may also pose major risks such as teratoma formation. Likewise, hESCs might not 
be immunoprivileged and could trigger host immune responses, leading to decreased cell 
survival or acute rejection. These are issues that can become significant barriers to future 
clinical application of hESC-based therapies. To meet these challenges, researchers must gain 
a better understanding of the in vivo behavior of transplanted hESCs. This review outlines the 
burgeoning application of molecular imaging to track transplanted hESCs in vivo. Continuing 
research merging molecular imaging and hESC biology will likely lead to significant advances 
in the future, both scientifically and medically.
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abSTRaCT
Over the past few years, human embryonic stem cells (hESCs) have gained popularity as a 
potentially ideal cell candidate for tissue regeneration. In particular, hESCs are capable of 
cardiac lineage-specific differentiation and confer improvement of cardiac function follow-
ing transplantation into animal models. Although such data are encouraging, there remain 
significant hurdles before safe and successful translation of hESC-based treatment into clini-
cal therapy, including the inability to assess cells following transplant. To this end, molecular 
imaging has proven a reliable methodology for tracking the long-term fate of transplanted 
cells. Imaging reporter genes introduced into the cells prior to transplantation enable non-
invasive and longitudinal studies of cell viability, location, and behavior in vivo. Therefore, 
molecular imaging is expected to play an increasing role in characterizing the biology and 
physiology of hESC-derived cardiac cells in living subjects.







Coronary artery disease remains the leading cause of death in the Western world 1. As the 
human heart is not capable of regenerating the great numbers of cardiac cells that are lost 
after myocardial infarction, impaired cardiac function is the inevitable result of ischemic 
disease. Recently, three randomized clinical trails reported either clinically marginal 2, 3 or no 
4 significant benefit following adult bone marrow cell transplantation for patients suffering 
from acute and/or chronic ischemic heart disease. These reports add to a growing body of 
evidence that adult-derived stem cells have limited capacity to aid renewal and regenera-
tion of damaged organs and structures. By contrast, hESCs show greater promise, as they 
are capable of self-renewal and differentiation. hESCs were first isolated by Thompson and 
colleagues in 1998 5. They are derived from the inner cell mass of the human blastocyst 
and can be kept in an undifferentiated, self-renewing state when cultured in the presence 
of inhibitory compounds, such as mouse embryonic fibroblast feeder layer cells. Compared 
to adult stem cells harvested from the bone marrow, hESCs have the advantage of being 
pluripotent, which provides them with the ability to differentiate into virtually all cells of the 
human body. For cardiac applications, hESCs have the ability to differentiate into cardiac cell 
lineages 6, 7. These hESC-derived cardiac cells have structural and functional properties of hu-
man cardiomyocytes and can integrate with host myocardium after transplantation into rats 
8 and pigs 9. However, in order to critically evaluate and optimize hESC-based therapy for the 
heart, new methodologies for assessing the viability, location, and behavior of transplanted 
cells are needed. This article aims to provide a concise overview of the major hurdles that 
need to be addressed before hESC-derived cardiac cell transplantation can become a clinical 
reality. This is followed by an outline of potential of molecular imaging tools that may help to 
overcome these challenges in the future.
huRdlES fOR ClINICal TRaNSlaTION
Although substantial progress has been made in recent years towards improving culture 
conditions, differentiation strategies, and potential hESC-based cardiac regeneration, several 
unresolved issues exist between the laboratory and bedside that still need to be bridged 
(figure 1). This article will cover some of the major areas of concern regarding hESC-derived 
cardiac cell transplantation, including: (1) optimization of in vitro differentiation into cardiac 
cells; (2) purification of cardiac cells to minimize post-transplant cellular misbehavior such 
as teratoma formation; (3) in vivo integration and function with host myocardium; and (4) 
evaluation of post-transplant immune rejection and cell death.
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in vitro differentiation to cardiomyocytes.
Following removal of the inhibitory feeder layer cells, hESCs can aggregate into clusters of cells 
known as embryoid bodies (EBs). Within these EBs, various signals are activated to promote 
differentiation of cells into all three germ layers, including mesoderm-derived cardiac cells 
(figure 2). Formation of cardiomyocytes usually starts 5 days after EB-formation, presenting 
as a beating area within the EB. Moreover, the hESC-derived cardiac cells within these beat-
ing areas actually resemble the structural and functional properties of early stage human 
cardiomyocytes 6. Unfortunately, the rate of spontaneous differentiation of hESCs into cardiac 
cells is low. Typically ∼8% of the EBs grown in suspension undergo differentiation into beating 
clusters, and ∼30% of the cells contained in these clusters are actual cardiomyocytes 6
Mouse ESCs (mESCs) were originally isolated in 1981 10, and subsequent studies have 
focused on different strategies to induce cardiac-specific differentiation of mESCs in vitro. 
Retinoic acid was one of the first agents described that significantly increase the percentage 
of cardiomyocytes arising from ESCs 11. Similar effects have been described for oxytocin 12, 
dynorphin B 13, nitric oxide 14, and ascorbic acid 15. However, the efficacy of these compounds 
can be dose-dependent and bound to a specific time period in embryonic development 11. 
Other groups have focused on the role of growth factors in mESC-derived cardiac cell dif-
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Figure 1. Human embryonic stem cells: from laboratory to bedside. Areas of concern in derivation, culture, differentiation, purification, delivery, 
integration, and survival are outlined. 






bone-morphogenetic protein-2 17. Interestingly, findings from mESC studies do not appear 
to translate to hESC research. Thus far, only 5-aza-2’-deoxycytidine 7, combination of activin 
A and BMP-4 18, and co-culture with murine END-2 visceral endoderm-like cells 19 have been 
shown to enhance cardiomyogenesis in hESC cultures.
Purification of hesc-derived cardiac cells.
Once ESCs are successfully induced to adopt cardiac fate, it becomes yet another challenge to 
isolate and further purify such subpopulations while avoiding contamination by undifferenti-
ated, pluripotent ESCs. Following transplantation, undifferentiated ESCs could cause teratoma 
formation, which are complex tumors comprised of cellular or oganoid components reminiscent 
of normal derivatives from the three germ layers 20. This indicates the need to achieve a highly, 
if not completely, pure population of cardiomyocytes prior to transplantation. Currently, selec-
tion methods for ESC-derived cardiac cells include Percoll density gradient-based isolation, 
which can enrich up to ∼70% pure cardiac cell population for hESC 7 and ∼90% for mESC 21. An 
alternative strategy for cardiac cell purification combines genetic engineering and molecular 
biology techniques. Klug et al. utilized a fusion gene consisting of an alpha-cardiac myosin 
heavy chain (α-MHC) promoter that drives expression of aminoglycoside phosphotransferase, 
which is an enzyme that confers resistance to the antibiotic geneticin (G418). Once the trans-




Figure 2. Undifferentiated hESCs (H9 cell line) grow indefinitely in culture on mouse embryonic fibroblast feeder layer cells (upper left panel). 
Following withdrawal of inhibitory feeder cells, hESCs can aggregate into EBs (upper right panel). Formation of cardiac cells usually starts 5 
days after differentiation, initially presenting as a beating cluster within the EB. After isolation of EBs and further enrichment by Percoll gradient 
separation, these hESC-derived cardiac cells (lower panels) express cardiac lineage specific makers as shown by immunofluorescent staining 
of GFP-labeled cells with skeletal muscle alpha actin (α-Actin), connexin-43 (Cx-43), cardiac troponin T (cTnT), and Myosin Enhancer Factor 2c 
(MEF2c) (all in red; counterstaining with DAPI, blue).
Chapter 574
leads to expression of aminoglycoside phosphotransferase and allows these cells to survive 
against treatment with G418. The resultant surviving cells represent 99% pure cardiomyocyte 
population 22. Similarly, Muller et al. reported transfection of mESCs with a fusion gene of of 
myosin light chain-2v (MLC-2v) linked to enhanced green fluorescent protein (eGFP). In this 
case, mESC-derived cardiac cells expressed eGFP that enabled fluorescent-activated cell sort-
ing (FACS) and collection of cardiomyocyte population (97% pure) 23.
in vivo integration and function of esc-derived cardiac cells.
Data from rodent models evaluating the fate of mESC transplantation into the heart have 
demonstrated mixed results. Early reports by Min et al. evaluating transplantation of mESC-
derived beating cells into immunocompetent rat myocardium showed long-term (up to 32 
weeks) cell survival, improvement of cardiac function, and improved angiogenesis in the in-
farct zone 24, 25. Most notably, no adverse sequelae such as graft rejection, arrythmogenesis, or 
teratoma formation were observed. By contrast, two more recent studies demonstrated that 
mESCs transplanted into hearts of both immunocompetent mice 20 and athymic nude rats 
26 formed teratomas by as early as 3 to 4 weeks following transplantation. At present, there 
are few published studies testing the efficacy of hESC-derived cardiac cell transplantation 
for cardiac repair. Kehat et al. showed promising results by injecting hESC-derived cardiac 
cells into swine heart with complete atrioventricular block 9. They demonstrated electrome-
chanical and structural coupling of the transplanted cells with the host myocardium. Xue 
et al. also showed functional integration and active pacing of hESC-derived cardiac cells 
following transfer into healthy myocardium of guinea pigs 27. Furthermore, Laflamme et al. 
demonstrated that hESC-derived cardiac cells transplanted into athymic rat hearts success-
fully engrafted, proliferated, and expressed several cardiomyocyte markers 8. Notably, none 
of these studies reported cellular misbehavior or teratoma formation. It is also not clear what 
percentage of these transplanted cells actually survived after transplantation.
immune rejection of allogeneic hesc transplantation.
Several factors threaten hESC-derived cardiac cell survival following delivery into a new 
host, which, if properly modulated, might prevent the drastic post-transplant death of donor 
cells presently observed. One such major factor is cellular rejection based on immunological 
incompatibility. Theoretically, hESCs represent an immune-privileged cell population, since 
embryos consisting of 50% foreign material derived from the father are not rejected by the 
maternal host 28. However, the understanding the immunogenicity of hESCs and their deriva-
tives remains a challenge.
It has been shown that mESCs do not express major histocompatibility complex (MHC) an-
tigens, the major system of alloantigens responsible for cell incompatibility 29. Furthermore, 
mESCs can inhibit T-lymphocyte proliferation in vitro and establish multi-lineage mixed chi-
merism in vivo 30. However, when allogeneic undifferentiated mESCs were transplanted into 






a murine model of myocardial infarction, our group found progressive intra-graft infiltration 
of inflammatory cells mediating both adaptive (T cells, B cells, and dendritic cells) and innate 
(macrophages and granulocytes) immunity, leading to rejection of the mESC allograft 20. In 
contrast to mESCs, hESCs express low levels of MHC-I antigens 31, 32. Drukker et al. observed 
that MHC-I expression increased two to four-fold when cells were induced to spontane-
ously differentiate to EBs 31, and eight to ten-fold when cells differentiated into teratomas. 
In contrast, Draper et al. reported MHC-I downregulation upon hESC differentiation towards 
EB 32. Thus, questions regarding the character and intensity of immune responses towards 
allogeneic hESC-derived cardiac cells still remain. Solutions that reduce or eliminate the po-
tential immunological response are needed, including: (1) forming MHC isotyped hESC-line 
banks; (2) creating a universal donor cell by genetic modification; (3) inducing tolerance by 
hematopoietic chimerism; (4) generating isogeneic hESC lines by somatic nuclear transfer; (5) 
and/or using immunosuppressive medication. Details of these strategies to minimize rejec-
tion of hESC-derived transplants have been extensively reviewed by others 33, 34.
IMagINg hESC-dERIVEd CaRdIaC CEllS
Non-invasive cell tracking.
As outlined earlier, hESC-derived cardiac cell transplantation is potentially feasible, but there 
are several aspects that require improvement. For clinical translation to occur, it is essential 
that tools be developed for longitudinal tracking and evaluation of transplanted cell viabil-
ity and behavior. Traditionally, cell therapy studies have relied upon conventional reporter 
genes such as GFP and β-galactosidase (LacZ) to monitor cell survival and differentiation. 
However, visualizing GFP and LacZ cells requires postmortem tissue analysis, which provides 
only a single snapshot representation of cell fate, not a complete picture over time. Moreover, 
sampling error inherent in ex vivo analysis requires large numbers of animals be sacrificed to 
develop a realistic picture of longitudinal survival kinetics.
Another technique for measuring the efficacy of cell therapy is to assess secondary endpoints. 
Cardiac contractility can be monitored by conventional methodologies such as echocardiog-
raphy or magnetic resonance imaging (MRI). Cardiac perfusion can be assessed using positron 
emission tomography (PET) or single-photon emission computed tomography (SPECT). How-
ever, these data cannot be correlated to the biological state of the cells, as the cells themselves 
can neither be visualized nor assayed in the living subject. Aiming to provide insight into the 
location and survival of transplanted cells, recent studies have reported labeling mESCs with 
magnetic iron particles and following them by MRI 35. Although these iron particles are robust 
and facilitate repeated imaging over time, they do not reliably provide insight into cell prolifera-
tion and viability, due to the disparate passing of the particles from parent to daughter cells and 
the ability of non-specific immune cells (e.g., macrophages) to engulf particles, respectively.
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Molecular imaging: direct vs. indirect approach.
Ideally, a non-invasive method for in vivo tracking of hESC-derived cardiac cells should be ca-
pable of providing insight into the following processes: (1) localization and migration of the 
cells, (2) cell survival and proliferation kinetics, and (3) cell differentiation or de-differentiation 
patterns. Molecular imaging of reporter genes offers potential promise in meeting these 
goals. Molecular imaging can be broadly defined as the visualization of molecular and cellu-
lar processes in the living subject. For in vivo molecular imaging to work, two basic elements 
are required: a molecular probe that detects a quantifiable signal based on the presence of 
gene, RNA, or protein, and a method to monitor these probes in vivo 36. In general, molecular 
imaging can be divided into two categories: (a) direct imaging of probe-target interaction or 
(b) indirect imaging based on reporter gene and reporter probe.
The most commonly used direct cardiac imaging modality utilizes 18F-fluorodeoxyglucose 
([18F]-FDG), a glucose analog which can cross intact membranes into living cells and is 
phosphorylated by the endogenous enzyme, hexokinase, trapping the probe inside the cell. 
The phosphorylated [18F] will undergo positron annihilation to give off two 511 keV photon 
signals that can be detected by PET, providing a measurement of cell or tissue viability 37. 
This approach has recently been shown feasible for imaging clinical cardiac cell therapy. 
Hofmann et al. labeled autologous bone marrow cells with [18F]-FDG from nine patients 
suffering from acute myocardial infarction 38. The [18F]-FDG labeled cells were injected into 
either the infarct-related coronary artery or the antecubital vein five to ten days following 
coronary stenting. PET imaging was performed 50 to 75 minutes after the procedure and 
successfully detected the transplanted cell population in all patients, with higher signals in 
the intra-coronary group. Although PET is a valuable tool to monitor the location of cells 
shortly after transplant, the short half-life of the [18F]-FDG radiotracer (∼110 minutes) does 
not permit long-term follow-up of cell survival and/or migration. Furthermore, [18F]-FDG is 
not passed on to daughter cells during cell division and therefore does not provide insight 
into cell proliferation.
The concept behind indirect molecular imaging is an expansion upon basic reporter gene 
technology whereby a promoter or enhancer region of interest is linked to the imaging 
reporter gene. The nature of the promoter can be inducible, constitutive, or tissue specific. 
The construct can be introduced into the target cell using either viral or non-viral techniques. 
Once incorporated, the reporter gene produces the reporter protein which then interacts 
with the introduced reporter probe, producing an analytic signal that can be detected by 
the detector system. Depending on the reporter gene used, available imaging modalities 
include PET, SPECT, MRI or a charged-coupled device (CCD) camera 39. The two most widely 
used reporter gene imaging systems are firefly luciferase (Fluc)-based optical biolumines-
cence imaging and herpes simplex virus thymidine kinase (HSV-tk)-based PET imaging. For 
bioluminescence imaging, the Fluc reporter protein catalyzes the D-Luciferin reporter probe 
to produce low-energy photons (2-3 eV) that can be captured by an ultra-sensitive CCD 






camera. The reporter probe can be administered before every imaging session, allowing 
for multiple imaging acquisitions over time. For PET imaging, the HSV-tk reporter protein 
phosphorylates radiolabeled thymidine analogue 9-(4-[18F]fluoro-3-(hydroxymethylbutyl)
guanine ([18F]-FHBG) reporter probe, which emits high-energy photons (511 keV) that can be 
detected by PET. The reporter gene technique has been used to assay survival and localiza-
tion of transplanted rat embryonic cardiomyoblasts 40 and more recently of mESCs 26.
reporter gene imaging of escs and esc-derived cardiac cells.
Regarding transplantation of hESC-derived cardiac cell transplantation, reporter gene 
imaging can be used to monitor critical events. First, since the reporter gene can be inte-
grated into the DNA of transplanted cells, its expression is limited to only living cells, and 
thus facilitates assessment of cell survival. Second, the reporter gene can be passed onto 
daughter cells, thus providing insight into cell proliferation. This is an important feature given 
the tumorigenic potential of undifferentiated ESCs discussed earlier. Third, it is possible to 
introduce several reporter genes into the same cell, facilitating a multi-modality imaging 
approach. Recently, Cao et al. tested the efficacy of mESC with a self-inactivating lentiviral 
vector carrying the triple-fusion (TF) construct that consists of firefly luciferase (Fluc), red 
fluorescence protein (mRFP), and herpes simplex virus truncated thymidine kinase (HSV-ttk) 
26. The mRFP facilitates imaging of single cells by fluorescence microscopy and allows for the 
isolation of a stable clone population by FACS. The Fluc allows for bioluminescence imag-
ing for assessment of cell survival, proliferation, and migration in small animals. Finally, the 
HSV-ttk affords the ability to use PET imaging in small and large animals, as well as humans. 
Following transplantation into the hearts of athymic nude rats, mESC survival, migration, and 
proliferation was monitored for 4 weeks by bioluminescence and PET imaging. PET imaging, 
both with [18F]-FHBG to image cells and [18F]-FDG to image myocardial viability, proved to 
be a very sensitive tool to assess the tomographic location of mESC engraftment (figure 3). 
However, reporter gene signals increased rapidly within 4 weeks due to teratoma formation. 
Histologic samples obtained from both intra- and extra-cardiac sites revealed spontaneous 
differentiation of the mESC into all three germ layers. In a subsequent study, our group also 
demonstrated the ability of an anti-viral drug to selectively target teratomas expressing the 
HSV-ttk reporter gene 41. Thus, in addition to its use for monitoring cell fate, the reporter 
gene also serves as an inducible suicide gene that facilitates selective cellular ablation. This 
could be an important tool in controlling cellular misbehavior and/or teratoma formation of 
transplanted hESC-derived cells.
Recently, our group has successfully transduced hESCs (H9 line) with a lentiviral vector 
containing a double fusion (DF) reporter gene that consists of Fluc and eGFP. Cardiac cells de-
rived from hESCs using EB formation and Percoll gradient enrichment constitutively express 
Fluc and eGFP. Following transplantation into ischemic myocardium of severe combined 
immunodeficient (SCID) mice, these cells can be monitored by bioluminescence imaging for 
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>3 months (Cao et al., unpublished data). By contrast, injection of undifferentiated hESCs 
caused teratoma formation during the same period (figure 4). Taken together, these results 
highlight the valuable role of molecular imaging for following the developmental fate of 
transplanted hESCs and their derivates.
Finally, a critical question with regard to reporter genes is whether the might influence the 
biology and physiology of the stem cells. In the study by Cao et al., the TF construct had no 
influence on mESC morphology, viability, proliferation, and differentiation capacity in vitro 26. 
Likewise, both the bioluminescence (D-luciferin) and PET ([18F]-FHBG) reporter probes had no 
adverse effects on mESC behavior. In two recent studies, the TF reporter genes affected <2% 
of the total mESC genome using transcriptional profiling analysis 42 and caused no significant 
differences in protein expression quantified by proteomic analysis 43. Ongoing studies are 
also evaluating the effects of reporter gene and reporter probe on hESCs as well.
CONCluSION
The last several years have produced revolutionary advancemences in exploring the capabili-












Figure 3. Positron emission tomography imaging of transplanted mESCs in the myocardium. Two weeks after mESC transplantation, nude rats 
underwent [18F]-FHBG reporter probe imaging (top row) followed by [18F]-FDG myocardial viability imaging (middle row). Fusion of [18F]-FHBG 
and [18F]-FDG images (bottom row) shows the exact anatomic location of transplanted mESC (arrow) at the anterolateral wall in horizontal, 
coronal, and sagittal views. (Reproduced with permission from Cao et al.26) 






involving hESC-derived cardiac cells appear promising for improving cardiac function after 
ischemic injury. Nonetheless, we are still years away from safely translating these initial 
observations into therapy for humans. There are several issues within the field that require 
improvement, especially those related to in vitro differentiation and purification, as well as 
in vivo integration and survival of the transplanted cells. As the field of hESC-derived cell 
transplantation emerges, there will be an urgent need for reliable methodologies to track 
and assess behavior of the cells following transfer into the injured heart. Molecular imaging 
serves these needs and will likely play a prominent role in future hESC research.
aCkNOwlEdgEMENTS
This work is supported by the National Heart, Lung, and Blood Institute (JCW) and the Euro-








Day 2 Day 4 Day 7 Day 14 Day 21
1
Figure 4
Figure 4. Comparison of undifferentiated hESCs versus hESC-derived cardiac cell survival and behavior in vivo. Both hESC (top row) and 
hESC-derived cardiac cells (bottom row) were transplantated into ischemic myocardium of SCID mice. Bioluminescence imaging during the 
first three weeks following transplantation reveals acute donor cell death followed by stable survival of hESC-derived cardiac cells. In contrast, 
undifferentiated hESCs proliferate uncontrollably in the heart as well as other seeded organs (arrows) to cause teratoma formation. 
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abSTRaCT
Background: We investigated whether differentiation of embryonic stem cells (ESCs) in 
ischemic myocardium enhances their immunogenicity, thereby increasing their chance for 
rejection.
Methods: In one series, 129/SvJ-derived mouse ESCs (ES-D3 line) were transplanted by 
direct myocardial injection (1x106 cells) into murine hearts of both allogeneic (BALB/c, n=20) 
and syngeneic (129/SvJ, n=12) recipients after LAD ligation. Hearts were procured at 1, 2, 
4 and 8 weeks after ESC transplantation and analyzed by immunohistochemistry to assess 
immune cell infiltration (CD3, CD4, CD8, B220, CD11c, Mac-1, Gr-1) and ESC differentiation 
(H&E). In a second series (allogeneic n = 5, sham n = 3), ESC transplantation was performed 
similarly, however after 2 weeks, LAD-ligated and ESC-injected hearts were heterotopically 
transplanted into naive BALB/c recipients. After an additional 2 weeks, donor hearts were 
procured and analyzed by immunohistochemistry.
results: In the first series, the size of all ESC grafts remained stable and there was no evidence 
of ESC differentiation 2 weeks post-transplantation; however, after 4 weeks both allogeneic 
and syngeneic ESC grafts showed the presence of teratoma. By 8 weeks, surviving ESCs could 
be detected in the syngeneic but not in the allogeneic group. Mild inflammatory cellular infil-
trates were found in allogeneic recipients at 1 and 2 weeks post-transplantation, progressing 
into vigorous infiltration at 4 and 8 weeks. The second series demonstrated similar vigorous 
infiltration of immune cells as early as 2 weeks after heterotopic transplantation.
conclusion: In vivo differentiated ESCs elicit an accelerated immune response as compared 
to undifferentiated ESCs. These data imply that clinical transplantation of allogeneic ESCs or 
ESC derivatives for treatment of cardiac failure might require immunosuppressive therapy.







Stem cell transplantation has recently emerged as a novel approach for replacement of 
injured myocardium. The potential of both haematopoietic stem cells (HSCs), harvested from 
the adult bone marrow and embryonic stem cells (ESCs), harvested from the inner cell mass 
of embryos at the blastocyst stage, to develop into viable heart muscle cells in the damaged 
heart is now being explored. Despite early encouraging results with HSC transplantation1, the 
ability of these cells to transdifferentiate into cardiomyocytes in vivo and to functionally repair 
ischemic myocardium has recently been seriously questioned2,3. Instead, previous studies 
have reported successful differentiation of ESCs into cardiomyocytes, both in vitro 4,5and in 
vivo6,7. This prompted us to investigate the potential of ESCs as a source of cell transplantation 
for myocardial restoration.
Pluripotent ESCs are capable of spontaneous differentiation into cells of all three different 
germ layers8. Due to their early stage of development, ESCs are considered “immune privi-
leged”, i.e. unrecognizable by the recipient immune defences9. This assumption is bolstered 
by observations in neonatal tolerance. An embryo, consisting of 50% foreign material derived 
from the father, is usually not rejected by the maternal host. However, recent evidence sug-
gests that even in their undifferentiated state, human ESCs express low levels of HLA class 
I antigen, that moderately increase as the cells differentiate10,11. In addition, rat embryonic 
stem cell-like cells (RESCs) also have been shown to express minimal, but detectable, levels 
of MHC class I molecules12. The presence of distinct MHC antigens, suggests that developing 
ESCs can be at risk for immune rejection when introduced in vivo across histocompatibility 
barriers13. However, no progressive studies analyzing the immune fate of ESCs during their 
development in vivo have been reported so far.
In this study, we tested the hypothesis that intramyocardially transplanted ESCs elicit an 
immune response that results in rejection of the transplanted cells. In addition, we investi-
gated whether the state of cell differentiation affects their immunogenicity and the intensity 
of the recipient immune response.
METhOdS
Animals.
Six- to ten-week-old female BALB/c (H-2d) and 129/SvJ (H-2b) mice (20-25 g) were purchased 
from The Jackson Laboratory (Bar Harbor, ME) and housed at no more than five per cage 
in our American Association for Accreditation of Laboratory Animal Care-approved facility 
with 12:12-h light-dark cycles and free access to standard rodent chow and water. All animal 
procedures were approved by the Animal Care and Use Committee of Stanford University.
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cell culture.
ES-D3 embryonic stem cells, a line developed from the 129/SvJ mouse strain, were kindly pro-
vided by Dr. I.L Weissman (Department of Pathology and Developmental Biology, Stanford 
University School of Medicine). Undifferentiated ES-D3 cells were maintained on gelatinized 
tissue culture dishes in Dulbecco modified Eagle medium (Specialty Media, Phillipsburg, NJ) 
supplemented with 15% fetal bovine serum (Hyclone, Logan, UT), 100µg/ml penicillin, 100 
U/ml streptomycin, 1mM sodium pyruvate, 2mM L-glutamine, 1 x non essential amino acids, 
0.1 mM 2-mercaptoethanol (all Gibco, Frankfurt, Germany) and 103 U/ml ESGROTM (Chemicon, 
Temecula, CA). Cells were maintained at 37˚C in a humidified atmosphere of 5% CO2. Monolay-
ers were passaged by trypsinization at confluence of 70-80%. At the day of transplantation, 
ESC were harvested and aliquoted in culture medium.
Left coronary ligation and esc transplantation.
Mice were premedicated with ketamine (100 mg/kg IP) and anesthetized with inhaled isoflu-
rane (2-3%). Mice were intubated and ventilated with a mouse respirator (model 687, Harvard 
Apparatus, Inc., Holliston, MA) and anesthesia was maintained with inhaled isoflurane (1-
2.5%). A left thoracotomy was performed in the 5th intercostal space, the left lung retracted 
and the pericardium opened. The left anterior descending (LAD) artery was permanently 
ligated with a 9-0 Ethilon suture just distal to the level of the left atrium. Infarction was vi-
sually confirmed by blanching of the antero-lateral region of the left ventricle along with 
dyskinesia. After five minutes, 1.0 x 106 ES cells were transplanted by injection into the injured 
myocardium (volume = 25 μL) of a series of allogeneic (BALB/c, n=20) and syngeneic (129/
SvJ, n=12) recipients. Similar surgical procedure, with injection of cell free culture medium, 
was performed on sham control animals (BALB/c, n=8). A thoracostomy tube was placed 
and lungs were re-expanded using positive pressure at end expiration. The chest cavity was 
closed in layers with 5.0 Vicryl suture, and the animal was gradually weaned from the res-
pirator. Once spontaneous respiration resumed, the endotracheal and thoracostomy tubes 
were removed, and the animal was placed in a temperature controlled chamber until they 
resumed full alertness and motility.
heterotopic transplantation of LAD-ligated and esc-injected hearts.
To study the immune response against in vivo matured ESC, a second series of animals (al-
logeneic n=5, sham controls n=3) underwent LAD ligation and ESC transplantation, however 
after 2 weeks, their hearts were explanted and heterotopically transplanted into the abdomen 
of naive syngeneic BALB/c recipients. Heterotopic cardiac transplantation was performed 
according to the method of Corry et al 14 with some modifications. Anaesthesia was induced 
and maintained as described above. Cardiac graft viability was assessed daily by abdominal 
palpitation.






tissue collection, immunofluorenscent and histological analysis.
Subsets of allogeneic, syngeneic and sham operated animals from the first series were sac-
rificed at 1, 2, 4 and 8 weeks after ESC transplantation. Animals from the second series were 
sacrificed at 2 weeks after heterotopic heart transplantation. Hearts were perfused with cold 
saline and rapidly excised. They were fixed in 2% paraformaldehyde for 2 hours at room tem-
perature and cryoprotected in 30% sucrose overnight at 4°C. Tissue was frozen in optimum 
cutting temperature compound (OCT compound, Sakura Finetek USA, Inc. Torrance, CA) and 
sectioned at 5 μm on a cryostat. To evaluate inflammatory cell infiltration, immunostaining 
was performed with a panel of hematolymphoid antibodies. Serial sections were blocked and 
incubated with hamster anti-CD3 (clone G4.18), rat anti-CD4 (H129.19), rat anti-CD8 (53-6.7), rat 
anti-CD45R/B220 (RA3-6B2), hamster anti-CD11c (HL3), rat anti-Mac-1 (M1/70) or rat anti-Gr-1 
(RB6-8C5) antibody (BD Pharmingen, San Jose, CA) for 1 hour at room temperature. Primary 
antibodies were detected by incubation of the slides with goat anti-hamster Texas Red (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA), goat anti-rat Alexa 488 or goat anti-rat Alexa 594 
(Molecular Probes, Eugene, CA) for 45 minutes at room temperature. Sections were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI, Molecular Probes) and analyzed with a Leica 
DMRB fluorescent microscope (Leica Microsystems, Frankfurt, Germany). Images were acquired 
with a SPOT RT Color camera and electronically merged with SPOT RT software (Diagnostic 
Instruments, Sterling Heights, MI). To detect differentiated structures within the ESC grafts 
and to evaluate morphological changes of the left ventricular wall, sections were stained with 
Hematoxylin and Eosin, Masson’s trichrome and Mucin stain (all Sigma-Aldrich Corp., St. Louis, 
MO) according to established protocols and carefully analyzed by a blinded pathologist (H.V.).
histological evaluation.
Shortly after immunofluorescent histology, sections were evaluated and graded a score for 
degree of inflammatory cell infiltration by three independent observers (R.J.S., M.T., F.G.). 
Scores related to the following descriptions: -, absent, no infiltration; +/-, trace, few infiltrat-
ing cells; +, mild, scattered infiltrate or focal accumulation; ++, moderate, modest infiltrate 
progressing into diffuse; +++, severe, intense and diffuse cell infiltration.
RESulTS
transplantation of undifferentiated embryonic stem cells elicits progressive 
inflammatory graft infiltration.
Following successful LAD ligation and ESC injection, ESCs were detected in all transplanted 
animals at 1 week post-injection. (H&E staining, Figure 1) Masson’s trichrome staining con-
firmed location of ESCs within the infarcted left ventricular wall. (Figure 2A) Immunofluores-
cent histological analysis demonstrated that allogeneic ES-D3 cell transplantation elicited 
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progressive graft infiltration of various types of immune cells, involved in both adaptive and 
innate types of immunity. As shown in figure 2B, immune cells strictly infiltrated the area of 
infarction and ESC transplantation. Table 1 summarizes the immunohistology data obtained 
over the 8-weeks time course.
Figure 1
Figure 1. Intramyocardial engraftment of ESCs. H&E staining of the infarcted left ventricular wall revealed ESC grafts in all injected animals at 
1 week post-transplantation. (arrows: borders of the ESC graft) (Original magnification: 200x)   
Table 1. Cellular composition of graft infiltrates over time after intra-myocardial ESC injection. Cell surface markers of  T lymphocytes 
(CD3), T helper cells (CD4), Cytotoxic T cells (CD8), B lymphocytes (B220), Dendritic cells (CD11c), Macrophages (Mac-1) and Granulocytes (Gr-1). 
Degree of infiltration: -, absent; +/-, trace; +, mild; ++, moderate; +++, severe. 
1wk* 2wks* 4wks* 8wks*
2wks
post-htx†
Sham Syn Allo Sham Syn Allo Sham Syn Allo Sham Syn Allo Sham Allo
CD3 +/- + + +/- + ++ +/- + +++ +/- + +++ +/- +++
CD4 +/- + + +/- + ++ +/- + +++ +/- +/- +++ +/- +++
CD8 +/- +/- +/- +/- +/- ++ +/- +/- +++ +/- +/- +++ +/- ++
B220 +/- + + +/- + ++ +/- + ++ - +/- + +/- +++
CD11c +/- +/- +/- - +/- + - + ++ - +/- ++ - +
Mac-1 ++ ++ ++ ++ +++ +++ + ++ +++ + ++ +++ ++ +++
Gr-1 + + + + + ++ + + +++ + + ++ + +++
*Time after LAD ligation and ESC injection
†Time after heterotopic heart transplantation (post-htx) of LAD-ligated and ESC-injected hearts
At 1 week post-injection, allogeneic ESC grafts displayed mild CD3+ T lymphocyte infiltra-
tion within the ESC allograft, which was composed predominantly of CD4+ T helper cells. 
At that time point, sparse CD4+ T cell clusters could be seen at the border of the graft area, 
whereas at weeks 4 and 8 after transplantation massive infiltration of both CD4+ and CD8+ 
T cells was observed throughout ESC graft including the inner area. (Figure 2C) Limited 
numbers of infiltrating T lymphocytes were present in syngeneic ESC grafts (Figure 2D) as 
well as in sham control hearts over the whole tested time period. These results show that 






over time, progressive T lymphocyte graft infiltration occurs following injection of allogeneic 
ESCs. Intensity of T cell infiltration depends on MHC incompatibility between donor ESCs and 
recipient. These data suggest that alloantigens presented by developing ESCs are recognized 










Figure 2. ESC graft infiltration of immune cells after allogeneic transplantation. 
A. Masson’s trichrome staining shows the ESC graft surrounded by infarcted (blue) and healthy myocardium (red). B. Immunofluorescent 
staining of a corresponding section shows infiltration of in this case CD4+ T cells (green) into the area of ESC transplantation. Note that the T 
cells are only found within the ESC graft. Healthy myocardium stains positive for the cardiomyocyte marker α-actinin (red). Counterstaining was 
performed with 4,6-diamidino-2-phenylindole (DAPI, blue) (Original magnification: 200x) C. Representative higher magnification 
images taken from the area of ESC transplantation (as shown in panel B) of progressive ESC graft infiltration of CD3+, CD4+ and CD8+ T cells 
over time. At 4 and 8 weeks after transplantation, severe graft infiltration of T lymphocytes was observed. D. In comparison, limited numbers of 
infiltrating T lymphocytes were present in syngeneic ESC grafts at all time points. (Original magnification: 400x)
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Dendritic cell (DC) infiltration was absent in sham control hearts showing that, at least at 
the time points tested, the performed surgical procedures did not cause non antigen-specific 
DCs activation/migration. Also, no or minimal numbers of infiltrating DCs were found in 
syngeneic hosts demonstrating that MHC disparity is required for DC migration into the area 
of transplanted ESC grafts. Similar to alloreactive T cells, the numbers of graft infiltrating DCs 
increased progressively over time in full-mismatched hosts, and peaked at 4 and 8 weeks 
after ESC transplantation. On the overall, small numbers of ESC graft-infiltrating B cells were 
detected as compared to T cells.
Inflammatory cells mediating innate immunity, including macrophages and granulocytes, 
were also detected in the ESC graft area. Although more profound in the experimental (ESC 
injection) hearts, we found that macrophage and granulocyte cell infiltrates were also pres-
ent in sham control hearts. This indicates that post-transplantation, innate response was not 
exclusively related to ESC antigens but could also be due to surgical trauma after transplanta-
tion (LAD ligation and/or medium injection procedures).
embryonic stem cells differentiate into teratomas in ischemic myocardium.
In both allogeneic and syngeneic ESC grafts, tumor formation was observed. (Figure 3) From 




Figure 3. Transplantation of ESCs causes tumor formation. Tumors were found extending from the left ventricular wall after both syngeneic 
transplantation (A, white arrow), and allogeneic transplantation (B, black arrow). In sham operated hearts (C), as expected, no tumors were 
detected.






walls showed the intramural ESC grafts similarly increasing in size in both allogeneic and 
syngeneic hearts. (Figure 4) H&E staining revealed no evidence of ESC differentiation at 1 
and 2 weeks post-transplantation. However, at 4 weeks, both in the allogeneic and syngeneic 
ESC grafts, differentiated structures originating from all three different germ layers could be 
observed. (Figure 5A-D) At this time point, tumors could be characterized as teratomas. At 8 
weeks, apart from little intramural cartilage, no differentiated or undifferentiated ESCs were 
found in the allogeneic hearts, whereas in the syngeneic hearts both cell types were still pres-
ent. (Figure 4) This finding suggested that at 8 weeks following transplantation the allogeneic 
ESC grafts had been destroyed as a result of the host inflammatory alloimmune response.
Embryonic stem cell immunogenicity increases upon differentiation.
In the present study, progressive host anti-ESC graft immunity associated with ESC differ-
entiation. Thus, differentiated structures could be found within the ESC grafts at 4 weeks 
post-transplantation. At the same time, severe ESC graft infiltration of inflammatory cells 
was observed. Taken together, these findings suggest that once ESCs reach a more differenti-
ated state, they can be more effectively recognized and rejected by the recipient immune 
system.
Sham




Figure 4. Morphological changes of left ventricular wall over time. Masson’s trichrome staining of heart sections at different time points 
after allogeneic (allo) and syngeneic (syn) ESC transplantation revealed intramural tumors over time increasing in size. Note that at 8 weeks 
after allogeneic transplantation, the allogeneic ESC grafts had been destroyed as a result of the host inflammatory alloimmune response. The 
left ventricular walls of the sham control hearts are shown in the lower panels.
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To further investigate this hypothesis, we designed a model to study the immune response 
against in vivo matured ESCs. A group of BALB/c mice underwent similar procedure of myo-
cardial infarction and allogeneic ESC transplantation. However, in this case, after 2 weeks, 
their hearts were explanted and heterotopically transplanted into naive syngeneic BALB/c 
recipients. Daily assessment of heterotopic cardiac grafts by abdominal palpation confirmed 
viability of the grafts throughout the study period. Interestingly, as early as 2 weeks after 
heterotopic transplantation of the isografts containing partly developed allogeneic ESC 
grafts, we found severe graft infiltration of various types of immune cells, including T and 
B-lymphocytes. (Figure 6 and Table 1, right column) Therefore, ESCs that have matured and 
differentiated in vivo for 2 weeks elicit more potent and immediate alloimmune response 
as compared to undifferentiated ESCs. These data indicate that the immunogenicity of ESC 






Figure 5. Intramyocardially transplanted undifferentiated ESCs differentiate into teratomas. Four weeks after ESC transplantation 
structures originating from all three different germ layers were found in both allogenic and syngenic recipient hearts. H&E staining shows 
formation of intramyocardial cartilage (A, mesodermal derivative, arrowheads, 200x), squamous epithelium (B, ectodermal derivative, 400x) 
and glandular epithelium (C, endodermal derivative, 400x). Secretion of mucus (pink) by the intramyocardial glands was confirmed by mucin 
staining (D, 400x).  







This study was designed to investigate whether ESCs elicit an immune response when 
transplanted into genetically identical or full MHC-mismatched ischemic myocardium. These 
data demonstrate, that there is progressive infiltration by various types of inflammatory cells 
within the ESC graft following transplantation across histocompatibility barriers. Severe 
cellulair invasion was observed 4 weeks after intra-myocardial injection, followed by disap-
pearance of the ESC allografts between 4 and 8 weeks after transplantation, presumably due 
to a robust alloimmune response. When transplanted into a naive recipient after 2 weeks 
of in vivo maturation, ESCs triggered an accelerated infiltration of immune cells, indicating 






Figure 6. Graft infiltration of immune cells after transplantation of in vivo differentiated ESCs. Representative images of ESC graft 
infiltration of T- (red) and B-(green) lymphocytes at 2 weeks following undifferentiated ESC transplantation (A) versus 2 weeks following 
in vivo differentiated ESC transplantation through heterotopic transplantation of the LAD-ligated and ESC-injected hearts (B). In vivo 
differentiated ESCs elicited a vigorous and more immediate immune response as compared to undifferentiated ESCs. Counterstaining was 
performed with 4,6-diamidino-2-phenylindole (DAPI, blue) (Original magnification: 400x)
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In contrast to tissue allografts, ESC transplants are devoid of highly immunogenic mature 
dendritic cells, or any other type of professional antigen presenting cells. Thus, the trans-
planted cells do not express MHC class II molecules, required for effective priming of CD4+ 
alloreactive T cells through direct recognition10,15. Therefore, the direct pathway of allore-
sponse is likely to be dominated by MHC class I-reactive CD8+ T cells, whereas the indirect 
alloreactive pathway (presentation of processed allogeneic peptides by host APCs) would 
engage both CD4+ and CD8+ T cells15. In the present study, similar amounts of both CD8+ and 
CD4+ infiltrating T cells were detected within the ESC grafts. Similarly, the numbers of graft 
infiltrating DCs increased progressively over time. Co-localization of antigen presenting DCs 
and T lymphocytes within the ESC graft points at ongoing T cell-APC interaction, and suggest 
that both direct and indirect allorecognition were involved in immune reactions against al-
logeneic ESC antigens. Furthermore, ESC graft infiltration of B cells was observed following 
allogeneic ESC transplantation. CD4+ T cells primed by indirect allorecognition could provide 
contact-dependent help for B cells to produce alloantibody by a classical cognate T cell-B 
cell interaction. Alloantibody might mediate further graft damage by various mechanisms, 
including complement-dependent target-cell injury.13
ESC transplantation is being widely investigated as a potential novel approach to regener-
ate infarcted myocardium. However, a review of the current literature on transplantation of 
ESCs, revealed a surprising lack of concern for potential immunological conflict13. The issue 
of immune recognition by the host is often circumvented by syngeneic transplantation16, 
immunosuppressive therapy17, or transplantation into an immune privileged site18. Moreover, 
previous studies in xenogeneic transplant models provide no evidence for immune rejection 
of engrafted ESCs6,7. This may create an impression that the problem of immune rejection 
does not apply to ESC transplantation. The present study designed to address this question, 
does not support this notion. Thus, we detected potent progressive inflammatory ESC graft 
infiltration, indicating efficient recognition of ESC alloantigens by the host immune system.
One could argue, that ESC immunogenicity could be due to inflammation of the host heart 
tissue caused by LAD-associated ischemia injury. However, histological analysis following 
syngeneic ESC transplantation revealed no progressive infiltration, demonstrating that ob-
served ESC immunogenicity in vivo could not be attributed to ischemia-induced inflamma-
tion of the recipient heart. In addition, it has been reported that transfection of ESCs with a 
genetic marker such as green fluorescent protein (GFP) could alter their immunogenicity.19,20 
Meanwhile, GFP transfection of ESCs is frequently used in quantitative analysis of ESC survival 
and differentiation. To exclude potential immune reactivity towards exogenous proteins, we 
used a non-manipulated ESC line.
It is known that undifferentiated ESCs may form teratomas when transplanted under the 
skin of immunodeficient SCID mice8. In addition, teratoma formation in the host retroperi-
toneum has been observed following ectopic transplantation of allogeneic ESC-derived 
cardiomyocytes21. On the other hand, it has been suggested that the infarcted heart pos-






sesses paracrine signaling pathways that are capable of directing in vivo differentiation of 
transplanted ESCs into functional cardiomyocytes6. In the present study, intramyocardial 
teratomas were observed in both allogeneic and syngeneic hearts at 4 weeks after ESC trans-
plantation. Although, this study was not designed to evaluate cardiomyocyte differentiation 
parameters, detection of ESC derivatives originating from various germ layers demonstrates 
that, at least under current experimental conditions, the host environment could not guide 
differentiation of all transplanted cells into the cardiomyocyte lineage. Careful removal of 
undifferentiated elements from ESC derivatives prior to transplantation may possibly help to 
circumvent formation of intracardiac teratomas.
In conclusion, these data provide a clear demonstration of the induction of an alloimmune 
response against developing ESCs in an experimental animal model. Furthermore, it offers a 
novel experimental approach, in which immunogenicity of partly differentiated ESCs can be 
assessed following heterotopic transplantation of previously LAD-ligated and ESC-injected 
hearts into naïve syngeneic hosts. This model could provide further insight into the charac-
terization of anti-ESC immunity in animal models. In the present study, immunogenicity of 
ESCs was analyzed by immunohistologic evaluation of graft infiltration by host immune cells. 
Intragraft migration and infiltration represents an important step in the sequence of immune 
reactions. It indicates that other systemic immune events, such as peripheral lymphocyte 
activation in the spleen and/or lymph nodes, cytokine release and production of circulating 
alloantibodies, likely are present in this model. Experiments evaluating these parameters are 
in progress in our laboratory.
In summary, we report that ESCs elicit alloimmune response after transplantation into 
MHC-mismatched ischemic myocardium. Upon in vivo differentiation, ESC immunogenic-
ity increases, resulting in efficient recognition of ESC antigens by the host immune system, 
and alloimmune rejection. These results imply that clinical transplantation of ESCs or ESC 
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abSTRaCT
Embryonic stem cell (ESC)-based transplantation is considered a promising novel therapy 
for a variety of diseases. This is bolstered by the suggested immune-privileged properties 
of ESCs. Here we used in vivo bioluminescent imaging (BLI) to non-invasively track the 
fate of transplanted murine ESCs (mESCs) stably transduced with a double fusion reporter 
gene consisting of firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP). 
Following syngeneic intramuscular transplantation of 1x106 mESCs, the cells survived and 
differentiated into teratomas. In contrast, allogeneic mESC transplants were infiltrated by a 
variety of inflammatory cells, leading to rejection within 28 days. Acceleration of rejection 
was observed when mESCs were allotransplanted following prior sensitization of the host. 
Finally, we demonstrate that mESC-derivatives were more rapidly rejected as compared 
to undifferentiated mESCs. These data show that mESCs do not retain immune-privileged 
properties in vivo and are subject to immunological rejection as assessed by novel molecular 
imaging approaches.






Embryonic stem cell (ESC)-based transplantation therapies have significant potential for 
treating a broad spectrum of human diseases through replacement or regeneration of lost or 
damaged tissues (1). ESCs are pluripotent and have the capacity to differentiate into multiple 
adult cell types in vitro, such as cardiomyocytes (2), pancreatic islet cells (3), and neurons 
(4). These ESC-derivatives have demonstrated therapeutic potential in vivo (5). One potential 
benefit of ESC-based transplantation over adult cells is their suggested immune-privileged 
properties (6). Human (h) and murine (m) ESC have been shown to express low levels of major 
histocompatibility (MHC) antigens (7, 8). Previous studies have reported that both mESCs (9) 
and hESCs (10) are capable of inhibiting allogeneic T-cell proliferation in vitro. Furthermore, 
mESCs have been shown to evade immune recognition and survive in immunocompetent 
rats (11) and sheep (12) for many weeks after transplantation. Nevertheless, our group and 
others have found that mESCs transplanted into allogeneic mouse hearts can elicit local graft 
infiltration of inflammatory cells resulting in rejection (13, 14). Similarly, other reports have 
questioned the alleged immune-privilege of mESCs following xenotransplantation into im-
munocompetent baboons (15).
Clearly, the extent to which immunologic rejection of ESCs and/or ESC-derivatives occurs 
following allogeneic transplantation is a crucial question that has yet to be clarified. The 
results of aforementioned studies were primarily based on immunohistological evaluation, 
which provide only a “snapshot” representation rather than a comprehensive picture of cell 
survival over time (16). Such limited techniques may partly contribute to the conflicting ob-
servations of mESC survival in allogeneic or xenogeneic hosts. To address these limitations, 
we have previously validated in vivo bioluminescent imaging (BLI) to be a reliable technique 
for assessing engraftment and survival of mESCs following transplantation in vivo (17). An 
important advantage in using BLI to track cell transplantation is that the expression of the 
firefly luciferase (Fluc) reporter gene, which is integrated into the DNA of the transplanted 
cells, is expressed only by living cells, making it a highly accurate tool for following cell graft 
rejection in the living subject (18). We have previously shown that transduction of mESCs 
with reporter genes that allow in vivo tracking does not alter cellular viability and their ability 
to differentiate into cells of all three germ layers (19, 20). To further delineate the novel field of 
ESC transplantation immunobiology, we used in vivo BLI to visualize patterns of survival and 
rejection of mESCs following transplantation across histocompatibility barriers.
To track the mESCs in vivo by BLI as well as ex vivo by immunohistochemistry, a double 
fusion (DF) reporter gene construct carrying Fluc and enhanced green fluorescent protein 
(eGFP) driven by a constitutive ubiquitin promoter (pUB) was transduced into undifferenti-
ated mESCs (D3 cell line, derived from the 129/Sv mouse strain), using a self-inactivating (SIN) 
lentiviral vector (fig 1A), as previously described (20). After transduction, mESCs robustly 
expressed Fluc (fig 1B) and eGFP (fig 1c). In agreement with previous reports (9, 21), flow 
cytometric analysis showed expression of pluripotency marker SSEA-1 and minimal expres-
sion of H-2kb MHC class I or I-Ab MHC class II antigens on undifferentiated mESCs. By contrast, 
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mESC-derived teratoma cells (mES-TCs) isolated from 6-week-old surgically explanted 
teratomas by a 2-hour enzymatic digestion in Collagenase D (2 mg/mL in RPMI medium) 
clearly expressed both MHC-I and MHC-II antigens (fig 1D). In culture, mES-TCs displayed a 
heterogeneous single cell morphology, as opposed to mESCs, which grow in tight clusters 
(fig 1e).
Transduced mESCs (1x106) were transplanted by direct injection into the gastrocnemius 
muscle of syngeneic (129/Sv, H-2kb, n=8) and allogeneic (BALB/c, H-2kd, n=8) recipient mice 
after which BLI was performed weekly. The BLI protocol involved intra-peritoneal administra-
tion of the D-Luciferin reporter probe at a dose of 375 mg/kg body weight and imaging was 
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Figure 1. Characterization of the double fusion (DF) firefly luciferase (Fluc) and enhanced green fluorescent protein (eGFP) transduced 
D3 murine embryonic stem cells (mESCs). (a) Schema of the DF reporter gene containing Fluc and eGFP driven by an ubiquitin promoter. (b) 
Stably transduced mESCs show a robust correlation between cell number and reporter gene activity. BLI of a 24-well plate containing increasing 
numbers of mESCs are shown above the corresponding graph depicting correlation between cell number and Fluc activity. (c) Flow cytometric 
analysis of transduced mESCs (D3-DF) shows robust expression of eGFP following transduction with the DF reporter gene, as compared to non-
transduced mESCs (D3). (d) Flow cytometric analysis of undifferentiated mESCs shows robust expression of pluripotency marker SSEA-1, but 
minimal expression of MHC-I (H-2kb) or MHC-II (I-Ab) antigens. In contrast, cells isolated from a 6-week old teratoma derived from mESCs (mES-
TCs) express low amounts of SSEA-1 but significant levels of MHC-I and MHC-II antigens. Filled histograms represent isotype control antibodies. 
(e) Phase-contrast images of undifferentiated mESCs and mES-TCs cultured in vitro.






impaired survival of mESCs in the allogeneic recipients was observed as compared to the 
syngeneic animals, reaching statistical significance at day 14 after transplantation (BLI signal: 
129/Sv 9.00±0.57 vs. BALB/c 7.54±0.99 Log[photons/sec]; P<0.01 by T-test). (fig 2A and 2B). By 28 
days, BLI signal in the allogeneic recipients had decreased to background levels, whereas 
signal in the syngeneic recipients continued to increase. These results suggest alloantigen 
specific rejection of the transplanted mESCs. At 28 days following transplantation, gastrocne-
mius muscles were surgically explanted. In syngeneic recipients, intramuscular tumors could 
be observed, whereas the shape of the allogeneic recipient muscles appeared normal (fig 
2c). Differentiated structures originating from all three germ layers could be demonstrated 
by H&E staining in the syngeneic muscles, indicating teratoma formation. Correlating with 
our findings using BLI, no teratoma formation and/or signs of surviving mESCs could be 
found in the allogeneic muscles (fig 2c).
We next investigated the local immune response elicited by mESCs in a second group of al-
logeneic BALB/c and syngeneic 129/Sv mice (n=8 per group). At 10 days following transplan-
tation, the muscles of these mice were explanted and investigated for graft infiltrating cells. 
Immunofluorescent staining of allogeneic muscle sections demonstrated massive infiltration 
of CD45+ inflammatory cells surrounding the eGFP+ mESC grafts (fig 2D). Quantification and 
further characterization of graft infiltrating cells was carried out by enzymatic digestion (2 
hours in 2mg/ml collagenase D in RPMI medium) of the explanted muscles followed by FACS 
analysis. Live cells were gated out from debris and further analyzed for expression of a panel 
of hematopoietic cell surface markers. Comparison of the syngeneic to the allogeneic mESC 
recipient muscles confirmed severe infiltration of various types of immune cells involved in 
both adaptive and innate types of immunity (fig 2e). At this time-point, both the CD3+ cells 
(total T-cell population) and CD8+ cells (cytototoxic T-cells) were present at a significantly 
higher frequency in allogeneic versus syngeneic recipients (P<0.05 by T-test), suggesting a 
prominent role for T-cell mediated immunity in mESC rejection.
To investigate if mESCs could induce immunologic memory, we next performed infusion of 
1x106 non-transduced D3 mESCs or 1x106 irradiated (3000 RAD) 129/Sv splenocytes (as con-
trol) into the tail vein of allogeneic BALB/c recipients (n=4 and 5 per group, respectively). Four 
weeks later, these same mice received intramuscular transplantation with the same number 
of transduced mESCs and cell survival was quantified using longitudinal BLI. Accelerated BLI 
signal loss was observed in both groups, with BLI signal reaching background levels as soon 
as post-transplant day 4 (control group) and 7 (mESC group) (fig 3A and 3B). These find-
ings confirm that a donor (129/Sv)-specific adaptive immune response is generated against 
transplanted mESCs.
Clinical ESC-based transplantation protocols will require differentiation of the donor cells 
into the desired cell type prior to transplantation, due to the risk of teratoma formation 
following transplantation of undifferentiated ESCs (13). Therefore, we thought it relevant to 
study survival of mESC-derivatives following allotransplantation. A group of BALB/c mice 
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Figure 2. In vivo bioluminescent imaging (BLI) of transplanted mESCs. (a) Representative BLI images of animals following intramuscular 
(gastrocnemius muscle) transplantation of mESCs show a decrease in BLI signal in allogeneic animals (BALB/c), as opposed to syngeneic (129/
Sv) mice, reaching background levels between post-transplant day 21 and 28. Color scale bar values are in photons/sec/cm2/steridian (p/s/cm2/
sr). (b) Graphical representation of longitudinal BLI after mESC transplantation into syngeneic (129/Sv, n=8) and allogeneic (BALB/c, n=8) 
mouse strains. Note that in allogeneic recipients, BLI signals decreases to background levels over the course of 28 days, whereas BLI signals in the 
syngeneic recipients increases over time, suggesting mESC proliferation. Data-points represent mean ± s.d.; *P<0.01, **P<0.001 (by T-test). 
Dotted line = background BLI signal (c) Ex vivo images of harvested muscles (left panels) show intramuscular tumors in syngeneic, as opposed 
to allogeneic muscles. Corresponding H&E stained tissue sections (right panels) show presence of teratoma in syngeneic muscles, whereas 
no signs of teratoma formation are observed in allogeneic muscles. Black arrow: Osteoid differentiation (mesoderm); white arrow: glandular 
differentiation (endoderm); black arrow head: neural differentiation (ectoderm). Scale bars: 100μm. (d) Immunofluorescent staining of allogeneic 
transplants reveals severe infiltration of CD45+ cells (red) surrounding eGFP+ mESCs (green). Nuclear staining was performed with 4,6-diamidino-
2-phenylindole (DAPI, blue). Scale bars: 100μm.  (e) To quantify subpopulations of graft infiltrating inflammatory cells, flow cytometry analysis 
of enzymatically digested muscles was performed at day 10 following transplant. Graft infiltration of CD3+ (T-cells), CD4+ (T-helper cells), CD8+ 
(cytotoxic T-cells), Mac-1+Gr-1- (macrophages), and Mac-1+Gr-1+ (neutrophils) was observed. Note that CD3+ and CD8+ cells infiltrated the 
allogeneic grafts at a significantly higher rate than the syngeneic grafts (n=8 per group). Bars represent mean ± s.d.; *P<0.05 (by T-test).






(n=5) was injected with 1x106 mES-TCs and longitudinal BLI was performed. In comparison 
with undifferentiated mESCs, the BLI signal displayed a similar pattern up until 7 days follow-
ing transplantation (fig 4A and 4B). However, BLI signal in the mES-TC animals decreased 
substantially by day 10 (mESC 7.74±0.58 vs. mES-TC 5.46±0.17 Log[photons/sec]; P<0.01 by T-test) 
and reached background levels at day 14. These results show that differentiated mESCs have 
impaired survival capacity as compared to undifferentiated mESCs when transplanted over 
histocompatibility barriers.
In a recent report, higher numbers of transplanted undifferentiated mESCs (5x106 to 20 
x106) were shown capable of survival and formation of teratoma in allogeneic recipients (22). 
Similarly, in this study we found that when 10x106 mESCs were transplanted into allogeneic 






























Figure 3. Accelerated rejection following pre-sensitization and/or pre-differentiation of donor mESCs. (a) Representative BLI images of 
animals following intramuscular allotransplantation of mESCs show an accelerated decrease in BLI signal in animals that were pre-sensitized 
with both non transduced mESCs (mESC pre-sens) or irradiated 129/Sv splenocytes (spleno pre-sens) as compared to naïve allogeneic mESC 
recipients. Color scale bar values are in p/s/cm2/sr. (b) Graphical representation of BLI of mESC survival in the three groups (n=4 to 8 per group). 
Data-points represent mean ± s.e.m.; *P<0.001 mESC vs. spleno pre-sens, ** P<0.001 mESC vs. mESC pre-sens (by ANOVA). Dotted line = 
background BLI signal.
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BALB/c recipient muscles, BLI signal could be followed out beyond 28 days following trans-
plantation in 2 out of 10 animals (20%) and intramuscular teratomas could be observed in 
these two animals. However, when mESCs were allowed to differentiate for 14 days in vitro 
prior to transplantation, 10x106 cells were rejected by 10 out of 10 animals (100%) (data not 
shown).
Undifferentiated mESCs have been reported to possess immune-privileged properties, 
which has been attributed to low expression of MHC molecules (21), expression of perforin-
deactivating Serpin-6 (9) and/or production of lymphocyte-inhibiting TGF-β (22) by the cells. 
However, our study clearly shows that transplantation of mESCs in vivo can result in donor-
specific immune recognition and rejection, which leads to immunologic memory. Impor-
tantly, post-transplant cell death is accelerated when mESCs are allowed to differentiate prior 
to transplantation, a scenario likely to occur in clinical ESC-based transplantation settings 
in the future. Whether the latter phenomenon is truly a result of increased immunogenicity 




























Figure 4. Impaired survival capacity of differentiated mESCs as compared to undifferentiated mESCs following allotransplantation. 
(a) Representative BLI images of animals following intramuscular allotransplantation of mESCs or mES-TCs. Clearly, BLI signal in the mES-TC 
transplanted animals decreased more rapidly as compared to mESC-transplanted animals, reaching background levels at day 14. Color scale 
bar values are in p/s/cm2/sr. (b) Graphical representation of BLI of mESC survival in the two groups (n=5 to 8 per group). Data-points represent 
mean ± s.e.m.; *P<0.01 (by T-test). Dotted line = background BLI signal.






of the cells, as suggested by their increased expression of MHC antigens (fig 1e), or if other 
factors such as a decreased proliferation rate of differentiated cells play part in this process 
remains to be evaluated in detail. Nevertheless, the results of this study emphasize that 
immunologic rejection of ESCs or ESC-derivatives is likely to occur and the need exists for 
solutions that reduce or eliminate immunologic response following ESC-based transplanta-
tion (23). In order to develop and test such strategies, there will also be a need for reliable 
imaging technologies to track and assess behavior of the cells following transplantation. In 
vivo bioluminescent imaging serves these needs and has the potential to play a prominent 
role in future ESC-based transplantation research.
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abSTRaCT
Given their self-renewing and pluripotent capabilities, human embryonic stem cells (hESCs) 
are well-poised as a cellular source for tissue regeneration therapy. However, the host immune 
response against transplanted hESCs is not well characterized. In fact, controversy remains 
as to whether hESCs have immune-privileged properties. To address this issue, we used in 
vivo bioluminescent imaging to track the fate of transplanted hESCs stably transduced with 
a double fusion reporter gene consisting of firefly luciferase (fLuc) and enhanced green fluo-
rescent protein (eGFP). We show that post-transplant survival is significantly limited in immu-
nocompetent as opposed to immunodeficient mice. Repeated transplantation of hESCs into 
immunocompetent hosts results in accelerated hESC death, suggesting an adaptive donor-
specific immune response. Our data demonstrate that transplanted hESCs trigger robust cel-
lular and humoral immune responses, resulting in intra-graft infiltration of inflammatory cells 
and subsequent hESC rejection. Moreover, we have found CD4+ T-cells to be an important 
modulator of hESC immune-mediated rejection. Finally, we show that immunosuppressive 
drug regimens can mitigate the anti-hESC immune response and that a regimen of combined 
tacrolimus (TAC) and sirolimus (SIR) therapy significantly prolongs survival of hESCs for up 
to 28 days. Taken together, these data suggest that hESCs are immunogenic, trigger both 
cellular and humoral-mediated pathways and, as a result, are rapidly rejected in xenogeneic 
hosts. This process can be mitigated by a combined immunosuppressive regimen as assessed 
by novel molecular imaging approaches.







Human embryonic stem cells (hESCs) have generated great interest given their pluripotency 
and capacity to self-renew. Specifically, hESCs can be cultured indefinitely in vitro, and can 
differentiate into virtually any cell type in the adult body 1. Given the limited potential for 
regeneration of most adult tissues following injury and the prevalence of numerous chronic 
diseases involving cell death and dysfunction, hESCs are an attractive source for tissue regen-
eration and repair therapies. Successful in vitro differentiation of hESCs into multiple somatic 
cell types has been reported, including cardiomyocytes 2, hematopoietic cells 3, neurons 4, 
pancreatic islet cells 5 and hepatocytes 6. Furthermore, there is a growing number of reports 
showing the therapeutic benefit of hESC derivatives following transplantation into animal 
models of disease 7, 8. Although such data are encouraging, significant hurdles remain before 
hESC-based treatments can be safely and successfully translated into clinical therapy 9.
An important obstacle facing in vivo engraftment and function of hESCs is the potential im-
munologic barrier 10. hESCs express low levels of Class I Human Leukocyte Antigen (HLA), 
which moderately increases as these cells differentiate 11. The presence of distinct major his-
tocompatibility complex (MHC) antigens suggests that hESCs may elicit an immune response 
and be at risk for immune rejection when introduced in vivo across histocompatibility barriers 
10. At the same time, hESCs theoretically represent an immune-privileged cell population, as 
embryos consisting of 50% foreign paternal material are usually not rejected by the maternal 
host. Recent reports have indeed shown that both mouse embryonic stem cells (mESCs) and 
hESCs seem to have the capability to evade immune recognition in allogeneic as well as in 
xenogeneic hosts. mESCs have been shown to survive in immunocompetent mice 12, as well 
as in rats 13 and sheep 14 for many weeks after transplantation. Similarly, rat ESC-like cells were 
demonstrated to permanently engraft in allogeneic recipients leading to allospecific down-
regulation of the host immune response 15. In addition, not only have hESCs been reported 
to inhibit allogeneic T-cell proliferation in vitro, but also to evade immune recognition in 
xenogeneic immunocompetent mice 16.
Nevertheless, our group and others have found that following transplantation into allo-
geneic murine hearts, mESCs triggered progressive immune cell infiltration and were subse-
quently rejected 17, 18. Others have concluded that hESC grafts are infiltrated by inflammatory 
cells 19 and do not form teratomas in immunocompetent mice 20, suggesting rejection. Clearly, 
questions of whether hESCs have immune-privileged properties and whether immunological 
rejection of transplanted hESCs and hESC derivatives is something that must be addressed 
remains to be clarified 21.
In this study, we used novel, non-invasive molecular imaging techniques to longitudinally 
track hESC fate following transplantation. We present evidence of an adaptive donor-specific 
xenogeneic immune response that is launched against hESCs shortly after transplantation 
into immunocompetent mice, resulting in rejection. We further delineate the role of T-
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lymphocyte subsets in mediation of the murine anti-hESC immune response. Finally, we 
compared the efficacy of various combinations of clinically available immunosuppressive 
regimens for enhancing survival of transplanted hESCs in vivo.
RESulTS
characterization of hescs expressing a double fusion (Df) reporter gene.
To date, most studies on hESC therapy have relied on conventional reporter gene technol-
ogy such as green fluorescent protein (GFP) 16 and β-galactosidase (LacZ) 22 to monitor cell 
survival and behavior following transplantation. These reporter genes are typically identified 
by immunohistochemical staining techniques, which provide only a “snapshot” representa-
tion rather than a comprehensive picture of cell survival over time 23. Such limited techniques 
may, in part, contribute to the conflicting observations of hESC survival in xenogeneic hosts. 
Results from previous studies range from no signs of rejection 16 to complete rejection of 
hESCs 20 following transplantation into mice. To circumvent these issues, a double fusion (DF) 
reporter gene construct carrying firefly luciferase (fLuc) and enhanced green fluorescent 
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Figure 1. Characterization of the double fusion (DF) firefly luciferase (fLuc) and enhanced green fluorescent protein (eGFP) transduced 
hESCs. (a) Schema of the DF reporter gene containing fLuc and eGFP driven by a human ubiquitin promoter. (b) Flow cytometric analysis of H9DF 
hESCs shows robust expression of eGFP. Transduced hESCs are largely positive for SSEA-4, and negative for SSEA-1, confirming their pluripotent 
state. (c) Stably transduced hESCs show robust correlation between cell number and reporter gene activity. BLI of a 24-well plate containing 
increasing numbers of H9DF hESCs are shown above the corresponding graph depicting correlation between cell number and fLuc activity. 






protein (eGFP) driven by a constitutive human ubiquitin promoter (pUB) was successfully 
transduced into undifferentiated hESCs (H9 line), using a self-inactivating (SIN) lentiviral vec-
tor (Fig 1A). This enabled us to track the hESCs in vivo by bioluminescent imaging (fLuc) as 
well as ex vivo by immunohistochemistry (eGFP). After 2 to 3 passages of feeder-free culture 
in mTersh culture medium, FACS analysis of H9DF hESCs revealed robust expression of eGFP 
concomitant with expression of pluripotent hESC markers (SSEA-4+ and SSEA-1-) (Fig 1B). The 
cells exhibited a robust correlation between fLuc expression and hESC number (r2=0.99, Fig 
1C). In vitro analysis showed that H9DF hESCs were able to proliferate and differentiate into 
cells of all three germ layers at a frequency similar to control H9 hESCs (data not shown).
The major system of alloantigens responsible for cell incompatibility is the major histocom-
patibility complex (MHC) 24. In agreement with previous reports 11, 25, we found low expression 
levels of both MHC-I and β2-microglobulin proteins and no expression of MHC-II on both H1 
and H9 hESCs, as compared to a positive control (human lymphocytes). Importantly, these 
profiles were not altered by the introduction of our reporter genes (SI Fig. 6A). Also, lentiviral 
transduction did not result increased autocrine secretion of interferon (IFN)-γ, a cytokine 
known to induce MHC expression 11 (SI Fig 6B and C).
Monitoring of transplanted hescs in immunocompetent and immunodeficient mice.
We investigated longitudinal hESC survival following intramuscular (gastrocnemius muscle) 
transplantation of 1x106 H9DF hESCs into immunodeficient (NOD/SCID, n=5) versus two strains 
of immunocompetent mice (BALB/c and C57Bl/6a, n=5 per group) by in vivo bioluminescent 
imaging (BLI). hESC survival was significantly limited in immunocompetent animals as com-
pared to NOD/SCID mice. (Day 5 BLI signal: NOD/SCID 7.37±0.3; BALB/c 5.91±0.47; C57BL/6a 
6.1±0.19 Log[photons/sec]; P<0.05 immunodeficient vs. immunocompetent). BLI signal completely 
disappeared in immunocompetent animals between 7 and 10 days post-transplant (Fig 2A 
and 2B). Repeated transplantation of H9DF hESCs in the contralateral gastocnemius muscle at 
two weeks following primary injection resulted in accelerated hESC death in immunocom-
petent animals, with BLI signal reaching background levels by post-transplant day 3 (NOD/
SCID 7.95±0.29; BALB/c 4.97±0.10; C57Bl/6a 4.97±0.19 Log[photons/sec]; P<0.001 immunodeficient 
vs. immunocompetent), suggesting an adaptive, donor-specific immune response (Fig 2A 
and 2C). Post-transplant hESC death in immunocompetent mice was confirmed in a control 
experiment, in which 1x106 H1 hESC were transplanted into an additional group of BALB/c 
animals (n=5). Consistent with BLI data, histological evaluation of the graft site at 10 days 
following hESC injection revealed no evidence of hESC survival (SI Fig 7A). By contrast, H9DF 
hESC survived well in NOD/SCID animals with progressively increasing BLI signal intensity 
starting at post-transplant day 10, suggesting hESC proliferation (Fig 2B). At 42 days follow-
ing primary transplantation, intramuscular teratomas were found in transplanted NOD/SCID 
animals (SI Fig 7B), whereas neither teratomas nor persistent hESCs were seen in immuno-
competent animals (data not shown).
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To exclude the possibility that the adaptive immune reaction was launched against xeno-
antigens produced by the reporter genes introduced into the cells, rather than against hESC 
xenoantigens, we next transplanted 1x106 non-transduced H9 hESCs into a second group of 
BALB/c mice (n=3), followed by re-transplantation of 1x106 H9DF hESCs into the contralateral 
A
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Figure 2. In vivo visualization of hESC survival. (a) Representative BLI images of H9DF hESC transplanted animals show a rapid decrease in BLI 
signal in immunocompetent animals (BALB/c), as opposed to immunodeficient (NOD/SCID) mice, reaching background levels at post-transplant 
day 7. Accelerated BLI signal loss in BALB/c animals was seen following repeated hESC transplantation into the contralateral gastrocnemius 
muscle. Color scale bar values are in photons/s/cm2/sr. Graphical representation of longitudinal BLI after (b) primary and (c) secondary hESC 
transplantation into immunodeficient (NOD/SCID, n=5) and two immunocompetent (BALB/c and C57Bl/6a, n=5 per group) mouse strains. Note 
that in NOD/SCID animals, starting at post-transplant day 10, BLI intensity increases progressively, suggesting hESC proliferation. *P<0.05, 
**P<0.01 






leg at two weeks following primary injection. BLI following re-transplantation showed a simi-
lar loss of signal as compared to animals that were primarily stimulated with H9DF hESCs (SI 
Fig. 8A and B), indicating that the adaptive immune response was in fact directed towards 
the hESCs.
In order to determine whether hESC differentiation would influence their capacity to 
escape immunological rejection, we next injected 1x106 H9DF hESC-derivatives following 
spontaneous in vitro differentiation during 14 days prior to transplantation into BALB/c mice 
(n=5). Overall, our results did not show a significant difference in their survival compared to 
undifferentiated hESC (SI Fig 8C)
transplantation of hescs triggers severe graft infiltration by a variety of immune cells.
Five days following transplantation of either 1x106 H9DF or H1 hESCs (n=6) or PBS (n=3) as a 
control, gastrocnemius muscles of BALB/c animals were analyzed for graft infiltrating cells. 
Histological analysis demonstrated severe intra-muscular infiltration of inflammatory cells 
(Fig 3A and B). Immunofluorescent staining showed that a large percentage of infiltrating 
cells stained positive for the T-lymphocyte surface marker CD3 (Fig 3C and D). Quantification 
and further characterization of graft infiltrating cells was carried out by enzymatic digestion 
of the explanted muscles followed by FACS analysis. Comparison of the control PBS to the 
hESC injected muscles confirmed that both H9DF and H1 hESC transplantation elicited severe 
infiltration of various types of immune cells involved in both adaptive and innate types of im-
munity (Fig 3E). Interestingly, both CD3+ T-cells (H9DF: 4.5±0.3%; H1: 4.3±0.5% vs. PBS control: 
0.5±0.1%, P<0.01) and B220+ B-cells (H9DF: 3.4±0.5%; H1: 4.9±0.7% vs. PBS control: 1.0±0.1%, 
P<0.01) were present at a high frequency, suggesting a prominent role for adaptive immunity 
in hESC rejection. Furthermore, CD4+ T-cells, CD8+ T-cells and Mac-1+Gr-1+ neutrophils, and 
Mac-1+Gr-1- macrophages (the latter only in the H1 group) infiltrated into the hESC graft at a 
significantly higher frequency as compared to PBS controls (Fig 3E).
hesc transplantation triggers systemic cellular and humoral murine immune 
responses.
To investigate the cellular immune response, we next performed ELISPOT assays using 
splenocytes of both H9DF and H1 hESC recipient animals. Cytokine release was abundant in 
these animals. At 5 days following transplantation, splenocytes from hESC recipients secreted 
significant amounts of both IFN-γ and Interleukin-4 (IL-4), compared to wild type animals 
(H9DF: IFN-γ: 488±91, IL-4:529±57; H1: IFN-γ: 495±106, IL-4: 563±87 vs. WT group: IFN-γ: 0.5±0.3, 
IL-4: 8.5±2, P<0.001) (Fig 4A). IFN-γ is produced by T-helper (Th)-1 cells and induces cellular 
immune activity, whereas IL-4 produced by Th-2 cells activates humoral immune pathways. 
Thus, our data suggests the involvement of an antibody-mediated B-cell response. Indeed, 
FACS analysis showed a significantly higher presence of circulating xeno-reactive antibodies 
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in hESC recipient sera, as compared to wild type animals (mean fluorescent intensity (MFI): 
H9DF: 7.0±1.2; H1: 6.8±1.5 vs. WT group: 3.8±0.6, P<0.05) (Fig 4B).
Prominent role for cD4+ t-cells in mouse anti-hesc rejection.
The phylogenetic disparity between mice and humans may lead to a lower affinity of mouse 
T-cell receptors (TCR) for human MHC molecules 26. Therefore, the indirect pathway of immune 
recognition, whereby the recipient’s antigen presenting cells (APC) process and present xe-




































Figure 3. Robust inflammatory cell infiltration following intramuscular hESC transplantation. Histopathological evaluation by H&E 
staining of muscle sections of BALB/c animals, obtained at 5 days following H9DF hESC transplantation, demonstrates robust intramuscular 
inflammatory cell infiltration at (a) low power and (b) high power view. (c and d) Immunofluorescent staining on corresponding sections reveals 
abundant presence of CD3+ T-cells (red) surrounding eGFP+ hESCs (green). Counterstaining was performed with 4,6-diamidino-2-phenylindole 
(DAPI, blue). Scale bars: 50μm. (e) FACS analysis of  enzymatically digested muscles revealed intra- H9DF and H1 hESC graft infiltration of CD3+ 
T-cells, CD4+ T-helper cells, CD8+ Cytotoxic T-cells, B220+ B-cells, and Mac-1+Gr-1+ neutrophils at significantly higher intensities, compared to 
PBS injections. Mac-1+Gr-1+ (macrophages) cells were had a significantly higher presence only in the H1 group. *P<0.05 






For these reasons, combined with the fact that hESCs lack expression of MHC-II antigens (Fig 
1D) necessary for direct xenograft recognition by recipient CD4+ T cells, we hypothesized that 
indirect immune recognition by CD4+ T cells could play an important role in mouse anti-hESC 
rejection. To further delineate the role of T-cell subsets in hESC rejection, we transplanted 
1x106 H9DF hESCs into T-cell deficient BALB/c Nude, CD4+ T-cell knockout (CD4-KO), and CD8+ 
T-cell knockout (CD8-KO) animals (n=4 or 5 per group) and followed cell survival by BLI. In 
agreement with prior data 20, hESCs survived in Nude mice over the 42 day study course 
(Fig 5 A and B), and were able to form teratomas. Interestingly, hESCs survived significantly 
longer in CD4-KO compared to CD8-KO animals (BLI signal at post-transplant day 5: CD4-KO: 
6.5±0.6 vs. CD8-KO: 5.0±0.3 Log[photons/sec]; P<0.05). However in both groups, hESC xenografts 
were eventually rejected (SI Fig 9 A and B).
immunosuppressive therapy prolongs survival of hescs following transplantation.
Since post-transplant hESC death appears largely due to T-cell mediated donor-specific 
immune response, we next investigated the efficacy of single and combined immunosup-
pressive drug regimens for preventing post-transplant hESC rejection. Clinically available 
immunosuppressants were chosen based on different mechanism of action: (1) calcineurin 








































Figure 4. hESC transplantation triggers cellular and humoral murine immune responses. (a) ELISPOT assay revealed significantly higher 
production of both INF-γ and IL-4 by both H1 and H9DF hESC recipient BALB/c splenocytes (n=6), compared to wild type (WT) animals (n=3). 
Representative images of ELISPOT wells are shown above the corresponding bars. †P<0.001 (b) Representative flow cytometry histograms (left 
panels) and graphical representation of hESC-specific xeno-reactive IgM antibodies detected at significantly higher rate in H1 and H9DF hESC 
recipient BALB/c sera (n=6), as compared to WT animals (n=3). *P<0.05 
SI Table 1. Immunosuppressive treatment dosages and serum drug through levels.  TAC = Tacrolimus, SIR = Sirolimus, MMF = 
mycophenolate mofetil (n=5 per group).
Dosage (mg/kg/d) trough levels±seM (ng/ml) target values (ng/ml)
tAc 4 11.4±3.6 10 – 15
sir 3 11.6±3.8 10 – 15
MMf 30 3.8±1.2 3.5 – 5.5
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(3) anti-proliferatives (mycophenolate mofetil = MMF) 27. A group of BALB/c mice (n=30) were 
randomized to receive daily TAC, SIR, MMF, TAC+MMF, SIR+MMF or TAC+SIR (n=5 per group) 
treatment following transplantation of 1x106 H9DF hESCs into the gastrocnemius muscle. The 
therapeutic dose range was confirmed by serum drug trough level measurements (SI Table 1).
As monotherapy, SIR extended hESC survival to the greatest degree. Significantly higher 
BLI signals from the SIR treated animals were seen up to 7 days after transplantation, as 
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compared to the no treatment (NT) group (BLI signal at day 7: SIR: 6.4±0.29 vs. NT: 4.98±0.04 
Log[photons/sec]; P<0.05). However, the signal in all single drug treatment groups (TAC, SIR, MMF) 
had decreased to background levels by post-transplant day 10 (Fig 5A and C), emphasizing 
the strong anti-hESC immune response despite high dose immunosuppressive treatment. 
In our model, addition of MMF did not result in significant improvement of hESC survival 
over single TAC and/or SIR treatment (Fig 5B and D). Combined TAC+SIR treatment, however, 























































































Figure 5. Immunosuppressive drug treatment prolongs survival of transplanted hESCs and mitigates adaptive immune response. 
Representative BLI images of H9DF hESCs transplanted mice receiving no treatment compared to those receiving (a) immunosuppressive 
monotherapy (MMF, TAC or SIR) or (b) combined therapy (TAC+MMF, SIR+MMF, TAC+SIR). Although SIR as monotherapy extended hESC 
survival significantly, TAC+SIR combination therapy proved to be optimal and extended survival of the cells up to post-transplant day 28. Color 
scale bar values are in photons/s/cm2/sr. Graphical representation of (c) single or (d) combined drug treatment efficacy on post-transplant hESC 
survival (n=5 per group). *P<0.05, **P<0.01. Combined TAC+SIR treatment effectively suppressed (e) INF-γ and IL-4 production by hESC 
recipient splenocytes (**P<0.01) and (f) reduced production of donor-specific xeno-reactive antibodies (P=0.14; n.s. = not significant). 
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markedly improved survival of hESCs. BLI signals from the TAC+SIR treated animals were 
significantly higher starting at 7 days following transplantation and could be followed out 
to post-transplant day 28 (Fig 5B and D). Finally, the efficacy of combined TAC+SIR treatment 



















































SI Figure 6. Immunological characterization of H9df hESCs compared to non-transduced controls. (a) Compared to human lymphocytes 
as a positive control, both H1 and H9 hESCs as well as transduced H9DF hESCs express low amounts of MHC-I and β2-microglobulin, and remain 
negative for MHC-II. Mean fluorescent intensity (MFI) is shown in the upper right corner of each panel. Results are representative of three 
independent experiments. (b) Representative images and (c) graphical representation of the cytokine antibody array show no difference in 
IFN-γ secretion by H9 or H9DF hESC. (neg = negative control, hESC medium; pos = positive control, medium containing recombinant human 
IFN-γ at 25 ng/ml)






for effective suppression of the recipient anti-hESC immune response was confirmed by in 
vitro analysis. ELISPOT assay showed a significant inhibition of effector cytokine production 
(TAC+SIR: INF-γ: 113±32; IL-4: 45±12 vs. NT: INF-γ: 488±91, IL-4: 529±57, P<0.01) (Fig 5E) and 
FACS analysis revealed a strong trend in reduction of circulating xeno-reactive antibodies 
(TAC+SIR: 4.8±0.5 vs. NT: 7.0±1.2, P=0.14) (Fig 5F).
dISCuSSION
The field of hESC-based therapy is advancing rapidly. Although federal regulations still restrict 
the generation of new hESC lines in the United States, regional funding institutions such as 
the California Institute of Regenerative Medicine foresee hESC-based therapies to go into 
phase I clinical trails within the next 10 years 28. To accomplish such goals, several significant 
hurdles that preclude clinical translation of such therapy need to be overcome, of which hESC 
immunogenicity is a major concern 29.
This study was designed to characterize hESC immunogenicity in a human-to-mouse trans-





SI Figure 7. Histopathological evaluation of hESC survival. (a) Tissue sections of BALB/c recipient muscles show endomysial mixed 
inflammatory infiltrated, sometimes involving the perimysium and adjacent soft tissue, representing the injection track (black arrow). (b) 
On higher magnication, infiltrates consisting of mixed mononuclear and granulocyte infiltrates can be observed.  No hESCs or cells with 
morphology that would suggest anything other then inflammatory could be detected. (c) Explanted muscles of NOD/SCID animals at 42 
days after transplantation demonstrates formation of intramuscular hESC-derived teratomas, composed out of tissue representing the three 
germ layers. (d) On higher magnification endodermal derivatived glandular epithelium (black arrows) surrounded by mesodermal derived 
mesenchyme can be detected. Scale bars: 50μm.
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to improve transplanted hESC survival. Specifically, we have demonstrated that: (1) molecular 
imaging can be used to quantify hESC survival and non-invasively follow donor cell fate; (2) 
hESCs can trigger potent cellular and humoral immune responses following transplantation 
into immunocompetent mice, resulting in intra-graft infiltration of a variety of inflammatory 
cells, leading to rejection; (3) CD4+ T-lymphocytes play an important role in mouse anti-hESC 
rejection; and (4) an immunosuppressive drug regimen consisting of tacrolimus (TAC) and 
sirolimus (SIR) significantly mitigates the host immune response to prolong hESC survival.
Specific studies evaluating immunogenicity of hESCs in vivo are few and have yielded 
mixed conclusions regarding hESC’s potential to induce immune response and/or survive 
in xenogeneic hosts 16, 20, 21. In these studies, results were based on histological techniques to 
evaluate hESC survival and potential immunological rejection. Histological analysis is suscep-
tible to sampling error, as each tissue section represents only one layer of the hESC graft and 
surrounding tissue at one time-point. To address these shortcomings, our group has been 
developing and validating reporter gene-based molecular imaging techniques. In particular, 
fLuc-based optical bioluminescent imaging has proven to be a reliable technique for assess-
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Supplemental Figure 8
SI figure 8. Similar hESC death after re-transplantation following primary stimulation with either transduced hESCs or non-transduced 
hESCs. (a) Representative BLI images (color scale bar values are in photons/s/cm2/sr) and (b) graphical representation shows a similar trend 
in BLI signal loss in the 3 days following secondary transplantation of H9DF hESCs in BALB/c animals, after primary stimulation with either 
non-transduced H9 hESCs (n=3) or transduced hESCs (n=6) two weeks earlier. (c) Graphical representation of BLI signals comparing survival of 
undifferentiated H9DF hESC (H9DF undiff) versus 14 day differentiated H9DF hESC (H9DF diff) following transplantation. No significant difference in 
cell survival was found.






ing engraftment and survival of stem cells following transplantation in vivo 30. An important 
advantage in using bioluminescent imaging to track cell transplantation is that the expres-
sion of the fLuc reporter gene, which is integrated into the DNA of the transplanted cells, is 
expressed only by living cells, making it a highly accurate tool for following cell graft rejection 
in the living subject 31. Using this approach in this report, we have clearly showed impaired 
survival of hESCs in immunocompetent versus immunodeficient mice, a phenomenon which 
was even more pronounced after repeated transplantation of the hESCs.
Xenotransplantation of cells or organs is usually complicated by severe immunological re-
sponses 26. Previous studies have addressed murine xenogeneic immune responses to adult 
human cells or tissues following transplantation. For example, human-to-mouse pancreatic 
islet transplants trigger progressive infiltration of lymphocytes leading to rejection within 
5-6 days 32. Human skin transplants are rejected by immunocompetent mice within 10 days, 
and a delay of rejection is seen when skin is transplanted onto mice lacking CD4+ T-cells, but 
not on those lacking CD8+ T cells 33. A comparison of these data to the results of our study, 
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SI Figure 9. Role of T-cell subsets in mouse anti-hESC immune rejection. (a) Representative BLI images of H9DF hESCs transplanted into 
different immunodeficient mouse strains show survival of the donor cells in Nude mice up to 42 days following transplantation, suggesting 
an important role for T-cells in mouse anti-hESC rejection. Although hESCs are eventually rejected in both CD4 knockout (CD4-KO) and CD8 
knockout (CD8-KO) mice, there is significantly longer survival of hESC in CD4-KO animals. Color scale bar values are in photons/s/cm2/sr. (b) 
Graphical representation of BLI of hESC survival in the three groups (n=4 or 5 per group). *P<0.05
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in which we show a similar time course of rejection of hESCs (7-10 days) that seems largely 
mediated by CD4+ T cells, suggests that hESCs are recognized by the murine immune system 
in a comparable way as adult human cells. This leads us to conclude that, in a discordant 
xenotransplant model, hESCs do not retain immune-privileged and/or immunosuppressive 
properties. During the first 10 days after transplantation, spontaneous non-immune related 
hESC death also occured in immunodeficient mice (Figure 2). In immunocompetent mice, 
spontaneous hESC death could have lead to activation of the adaptive immune system 
through the indirect pathway, in which intracellular antigens shed by hESC debris are phago-
cytosed by host APCs and presented to CD4+ T lymphocytes. This would explain the major 
role of CD4+ cells that we found in our study.
Studies addressing the character and intensity of immune responses towards hESCs in 
a human allogeneic setting in vivo raises ethical considerations and thus are currently not 
feasible. However, the results of this study emphasize that solutions which can reduce or 
eliminate potential immune responses need to be evaluated. Strategies that could prevent 
hESC immune recognition include: (1) forming MHC isotyped hES cell-line banks; (2) creat-
ing a universal donor cell by genetic modification; (3) inducing tolerance by hematopoietic 
chimerism; (4) generating isogeneic hESC lines by somatic nuclear transfer; (5) and/or using 
immunosuppressive medication 34, 35. In the near future, successful clinical application of 
hESC-based transplantation will most likely rely on immunosuppressive therapy based in part 
on the experience learned from organ transplantation. Thus, the significance of evaluating 
the effects of immunosuppressive drugs upon hESC survival in our animal model is two-fold: 
(1) to investigate the efficacy of various compounds that may be used in conjunction with 
clinical hESC-based therapies in the future, and (2) to develop an immunosuppressive drug 
regimen that optimizes transplanted hESC survival in animal models. Our results show that, 
in a xenogeneic murine setting, a combined immunosuppressive drug regimen consisting of 
TAC and SIR optimally suppressed anti-hESC immune response and prolonged their survival 
to 28 days following transplantation. TAC and SIR are a potential combination for an im-
munosuppressive strategy because of their different side mechanisms of action, side-effect 
profiles, and apparent synergism when used together36. TAC and SIR are structurally similar 
macrolide immunosuppressants. Both drugs bind to a common family of immunophilins 
called FK506 binding proteins (FKBPs). SIR binds to FKBP, thereby blocking signal transduc-
tion by inhibiting two kinases late in the G1 cell cycle progression. These kinases have been 
designated TOR-1 and -2, targets of Rapamycin. TAC exerts its effect through the inhibition 
of calcineurin, by the FK506/FKBP complex. Calcineurin plays a critical role in interleukin-2 
promoter induction after T-cell activation27. Although this combination is used with caution 
in clinical transplantation because of potential adverse drug effects, we recommend apply-
ing this treatment protocol to studies in pre-clinical animal models that address the biology 
and therapeutic efficacy of hESC-derivatives.






In summary, our data show that hESC xenografts are effectively recognized and rejected by 
the adaptive murine immune system following transplantation. We also show that standard 
immunosuppressive drugs have the potency to prolong survival of the transplanted cells but 
cannot completely prevent rejection. Finally, the integration of molecular imaging techniques 
for development and validation of different strategies to improve post-transplant survival of 
hESC-derivatives should accelerate progress in this field.
METhOdS
Lentiviral production and generation of stable hesc line.
SIN lentivirus (LV) was prepared by transient transfection of 293T cells 37. H9 hESCs (Wicell) 
were transduced with LV-pUB-fLuc-eGFP double fusion (DF) reporter gene at a multiplicity 
of infection (MOI) of 10. The infectivity was determined by eGFP expression as analyzed on 
FACScan (BD Bioscience, San Jose, CA). The eGFP positive cell populations (~20%) were iso-
lated by fluorescence activated cell sorting (FACS) Vantage SE cell sorter (Becton Dickinson 
Immunocytometry Systems) followed by plating on the feeder layer cells for culturing.
Culture and transplantation of hESCs.
H1, H9 and H9DF hESCs were initially maintained on top of murine embryonic fibroblasts 
feeder (MEF) layers as detailed in SI Methods. To prevent contamination of the transplanted 
hESC population with MEF, hESC colonies were separated from MEF by incubation with 
dispase (Invitrogen) and subcultured on feeder-free matrigel (hESC qualified, BD Biosci-
ences) coated 6-well plates in mTeSR™1 maintenance medium (Stem Cell Technologies) for 
2 to 5 passages. MHC expression on hESCs was evaluated by flow cytometry as detailed in SI 
Methods. Shortly prior to transplantation, hESCs were trypsinated, and resuspended in sterile 
PBS at 1x106 cells per 20μl. hESC viability was >95% as determined by flow cytometry using 
7-amino-actinomycin D (7-AAD) cell viability solution (eBioscience). hESC transplantation 
was performed by direct injection into gastrocnemius muscles of recipient mice (using a 29.5 
gauge insulin syringe.
Animal experiments.
All animal procedures were approved by the Animal Care and Use Committee of Stanford 
University. Mouse stains are detailed in SI Methods.
optical bioluminescent imaging of hesc transplanted animals.
BLI was performed using the Xenogen In Vivo Imaging System as previously described 38. 
Briefly, mice were anesthetized with isoflurane and D-luciferin was administered intraperito-
neally at a dose of 375 mg/kg body weight. At the time of imaging, animals were placed in a 
light-tight chamber, and photons emitted from luciferase expressing hESCs transplanted into 
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the animals were collected with integration times of 5 sec - 5 min, depending on the intensity 
of the bioluminescence emission. The same mice were scanned repetitively as per the study 
design. BLI signal was quantified in units of photons per second (Total flux) and presented as 
Log[photons/sec].
Quantification of graft infiltrating cells.
Intra-hESC graft infiltrating cells were measured by FACS analysis of enzymatically digested 
gastrocnemius muscles as detailed in SI Methods.
Quantification of cellular immune response.
During animal sacrifice on day 5, the spleens were harvested and splenocytes were isolated. 
Enzyme-linked immunosorbent spot (ELISPOT) assays using 1×105 γ-irradiated hESCs (1500 
RAD) as stimulator cells and 1×106 recipient splenocytes as responder cells were performed 
according to the manufacturer’s protocol (BD Bioscience) using IFN-γ and IL-4-coated plates. 
Spots were automatically enumerated using an ELISPOT plate reader (CTL) for scanning and 
analyzing.
Quantification of humoral immune response.
Donor-specific xenoreactive antibodies were detected by FACS analysis of target hESCs fol-
lowing incubation with recipient mouse serum as detailed in SI Methods.
Immunosuppressive therapy.
Tacrolimus (TAC, 4 mg/kg/d; Sigma-Aldrich), sirolimus (SIR, 3 mg/kg/d; Rapamune oral solu-
tion; Sigma-Aldrich) and mycophenolat mofetil (MMF, 30 mg/kg/d; Roche) were administered 
once daily as detailed in SI Methods.
statistical analysis.
Data are presented as mean ± SEM. Comparisons between groups were done by independent 
sample t-tests or analysis of variance (ANOVA) with LSD post hoc tests, where appropriate. 
Differences were considered significant for P-values<0.05. Statistical analysis was performed 
using SPSS statistical software for Windows (SPSS).
SI METhOdS
culture and transplantation of hescs.
H1, H9 and H9DF hESCs were initially maintained on top of murine embryonic fibroblasts feeder 
(MEF) layers seeded onto 0.1% gelatin coated plastic dishes and inactivated by γ-irradiation 
(6000 RAD). hESCs were maintained in hESC medium containing 80% Dulbecco’s modified 
Eagle’s medium/F12 (DMEM/F12, Invitrogen), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 






0.1 mM non-essential amino acids (Invitrogen), 20% Knockout Serum Replacement (Invit-
rogen) and 8 ng/ml human basic fibroblast growth factor (bFGF; Invitrogen) 39. MEF were 
derived from CF-1 E12.5 embryos as previously described1. The hESC culture medium was 
changed daily and hESCs were passaged every 4-5 days. hESC differentiation was induced 
by embryoid body (EB) formation. hESC colonies were dispersed into cell aggregates using 
1mg/ml Collagenase IV. These aggregates were then cultured in suspension in ultra-low at-
tachment plates (Corning) in hESC differentiation medium, consisting of DMEM high glucose 
supplemented with 20% FBS (Hyclone), 1 mM L-glutamine, 0.1 mM β-mercaptoethanol and 
0.1 mM non-essential amino acids for 7 days. Then, EBs were transferred to 10 cm culture 
dishes coated with 0.1% gelatin and cultured for an additional 7 days. hESC differentiation 
medium was changed every two days.
fAcs analysis of hesc surface marker expression.
H1, H9 and H9DF hESCs were trypsinated, washed and incubated with PE-conjugated mouse 
anti-human HLA-ABC (G46-2.6), β2-microglobulin (Tü99), HLA-DR, DP, DQ (Tü39) or their 
respective isotype control antibodies (all BD Biosciences) in FACS buffer (PBS 2% FCS) for 45 
min at 4˚C. Cells were washed, incubated with 7-amino-actinomycin D (7-AAD) cell viability 
solution (eBiosciences), and analyzed on a FACSCalibur system (BD Biosciences). For analysis 
of pluripotency markers, a similar protocol was followed, using PE-conjugated anti-human 
SSEA-1 (MC-480) and purified anti-human SSEA-4 (MC-813-70) antibodies (R&D Systems). The 
latter followed by incubation with PE-conjugated anti-IgG secondary antibody (eBioscience) 
for 30 min at 4˚C.
Quantification of ifN-γ secretion by hesc.
Cytokine Antibody Array (Raybiotech) were used to identify the H9 and H9DF hESC secretion 
profiles of IFN-γ. Membranes were covered with 24-hour supernatant of H9 hESC, H9DF hESC, 
medium alone as well as medium containing 25 ng/ml recombinant IFN-γ (Peprotech) as 
positive control. Membranes were developed according to the manufacturer’s protocol. 
Integrated densities were calculated using National Institutes of Health imageJ 1.38. Values 
were normalized to the integrated positive control on each membrane.
Animal experiments.
Six- to ten-week-old female BALB/c (wild type), C57BL/6J-Tyrc-2J/J (C57Bl/6 albino or C67Bl/6a), 
NOD.CB17-Prkdcscid/J (NOD/SCID), B6.129S2-Cd4tm1Mak/J (CD4 knockout), B6.129S2-Cd8atm1Mak/J 
(CD8 knockout) mice (The Jackson Laboratory), and BALB/c Nude (T-cell deficient, Charles 
River laboratories) mice were housed at no more than five per cage in our American Asso-
ciation for Accreditation of Laboratory Animal Care-approved facility with 12:12-h light-dark 
cycles and free access to standard rodent chow and water. All animal procedures were ap-
proved by the Animal Care and Use Committee of Stanford University.
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tissue collection, immunofluorenscent and histological analysis .
Explanted muscles were fixed in 2% paraformaldehyde for 2 hours at room temperature 
and cryoprotected in 30% sucrose overnight at 4°C. Tissue was frozen in optimum cutting 
temperature compound (OCT compound, Sakura Finetek) and sectioned at 5 μm on a cry-
ostat. Serial sections were blocked and incubated with hamster anti-CD3 (clone G4.18) (BD 
Biosciences) for 1 hour at room temperature, followed by goat anti-hamster Texas Red (Santa 
Cruz Biotechnology) Sections were counterstained with 4,6-diamidino-2-phenylindole (DAPI, 
Molecular Probes) and analyzed with a Leica DMRB fluorescent microscope (Leica Microsys-
tems, Frankfurt, Germany). Hematoxylin and Eosin staining (Sigma) was performed according 
to established protocols. For histopathogical evaluation of hESC survival 6 sections of each 
explanted muscle were stained with H&E and carefully analyzed by a blinded pathologist 
(H.V.).
Quantification of graft infiltrating cells.
Gastrocnemius muscles were surgically explanted, minced and digested for 2 hours in 
Collagenase D (2 mg/mL; Worthington Biochemical) at room temperature in RPMI 1640 
media (Sigma Chemical Co.) with 10% fetal calf serum (FCS; Life Technologies). Muscle cell 
suspensions were ran through a 70 μm cell strainer, washed in FACS buffer (PBS 2% FCS) and 
incubated with PE-conjugated CD3e (145-2C11), CD8a (53-6.7), Mac-1/CD11b (M1/70) and al-
lophycocyanin (APC)-conjugated CD4 (GK1.5), B220 (RA3-6B2) and Gr-1 (RB6-8C5) antibodies 
(CD4 and CD8: eBiosciences, all others: BD Bioscience) for 45 min at 4˚C. Cells were washed, 
incubated with 7-amino-actinomycin D (7-AAD) cell viability solution (eBiosciences), and 
analyzed on a FACSCalibur system (BD Biosciences).
Quantification of humoral immune response.
Sera from recipient mice were decomplemented by heating to 56°C for 30 minutes and 
subsequently diluted by 33% in PBS containing 3% fetal calf serum and 0.1% NaN3. Equal 
amounts of sera and hESC (1×106 cells/ml) suspensions were incubated for 30 minutes at 
4°C and washed with PBS through a calf-serum cushion. IgM xeno-reactive antibodies were 
stained by incubation of the cells with PE–conjugated goat antibodies specific for the Fc por-
tion of mouse IgM (BD Bioscience) at 4°C for 45 minutes. Cells from all groups were washed 
twice with PBS containing 2% FCS and then analyzed on a FACSCalibur system (BD Biosci-
ences). Fluorescence data were collected by use of logarithmic amplification and expressed 
as mean fluorescent intensity.
immunosuppressive therapy protocol.
Adult female BALB/c mice (n=30) were randomized to receive Tacrolimus (TAC; Sigma-Aldrich), 
sirolimus (SIR; Rapamune oral solution; Sigma-Aldrich) and mycophenolat mofetil (MMF; 
Roche). All drugs were administered once daily by oral gavage, using the following doses 






for TAC, SIR and MMF: 4 mg/kg/d, 3 mg/kg/d, and 30 mg/kg/d respectively to achieve drug 
serum levels comparable to clinical trough levels of 10-15 ng/ml for TAC and SIR and 3.5-5.5 
ng/ml for MMF. Blood was drawn during animal sacrifice and 12 or 24-hour drug trough levels 
were quantified by high-performance liquid chromatography (HPLC) as described earlier 40.
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ESCs are showing promise to serve as a cellular source for tissue regeneration therapy. 
However, the host immune response against transplanted ESCs is not well characterized. In 
fact, controversy remains as to whether ESCs have immune-privileged properties. The aim 
of this thesis was to characterize the immunobiology of ESC transplantation with the help 
of non-invasive molecular imaging techniques. Specifically, this thesis presents evidence 
that: (1) molecular imaging can be used to quantify organ, BMC and ESC survival following 
transplantation and non-invasively follow donor graft fate; (2) mESCs and hESCs express 
MHC and co-signaling molecules that are upregulated upon differentiation; (3) mESCs and 
hESCs can trigger potent cellular and humoral immune responses following allogeneic and/
or xenogeneic transplantation, resulting in intra-graft infiltration of a variety of inflammatory 
cells, leading to rejection; and (4) immunosuppressive drugs can significantly mitigate the 
host immune response to prolong hESC survival in immunocompetent mice.
In vIvo bIOluMINESCENCE IMagINg: a ValuablE TOOl TO MONITOR 
TRaNSPlaNTaTION REjECTION
In chapter 2, molecular imaging was used to non-invasively follow cardiac allograft rejection. 
We have shown that BLI signal emitted from Fluc/GFP transgenic cardiac allografts decreases 
after 4 days in the course of acute rejection. In addition, the light intensity emitted from 
donor-derived passenger CD5+ cells diminished within 1 day after allotransplantation. In vivo 
BLI of different promoter Fluc transgenic donor heart recipients allowed us not only to longi-
tudinally quantify the kinetics of cardiac allograft viability, but also the location and distribu-
tion of donor-derived passenger CD5+ cells. In a subsequent study, the value of non-invasive 
imaging was demonstrated in a different and upcoming field of research in cardiovascular 
medicine: BMC therapy for ischemic heart disease. By using in vivo BLI, the study in chapter 3 
confirmed the therapeutic effect of BMC transplantation in the setting of acute MI. However, 
it also clearly showed that delivery of the cells in the time-window following the hostile acute 
inflammatory phase–7 days after MI–does not result in extended long-term survival of donor 
BMCs as compared to BMCs delivered acutely after MI. Again, molecular imaging allowed us 
to obtain these data longitudinally, without the necessity for animal sacrifice.
Clearly, in vivo BLI proved to be a valuable tool for monitoring graft survival and/or rejec-
tion following transplantation. These advantages are a result of the stable genetic integration 
of the Fluc reporter gene into the donor cells, which are also equally transferred to progeny 
cells. As long as the cells are viable, transcription and translation will lead to reporter protein, 
which can be detected by a CCD camera following administration of the D-luciferin reporter 
probe. However, because of the use of low-energy photons (2 to 3 eV), BLI is limited by pho-
ton attenuation and scattering within deep tissues. Therefore, the limitation of this technique 
is that it is not suitable for pre-clinical large animal or human studies. As explained in detail 
Chapter 9138
in chapter 4 and 5, the HSV-tk reporter gene constructs have been applied to large animal1 
and human trials2. The basis behind this approach is injecting the subject with a radiolabeled 
thymidine analog (e.g., [18F]fluoro-3-hydroxymethylbutyl)guanine or [18F]-FHBG) that can be 
detected by PET when it is phosphorylated by HSV-tk and subsequently trapped inside the 
cell. The HSV-tk allows emits high-energy photons (511 keV) and allows for deep-tissue PET 
imaging of gene expression. The development of multi-fusion reporter gene constructs en-
abling PET imaging and iron labeling for MRI, should lead to further application of molecular 
imaging in the clinical setting.
immunogenicity of embryonic stem cells
The study described in chapter 6 was designed to investigate whether ESCs elicit an immune 
response when transplanted into genetically identical or full MHC-mismatched ischemic 
myocardium. The data demonstrate that there is progressive infiltration by various types of 
inflammatory cells within the ESC graft following transplantation across histocompatibility 
barriers. Severe cellular invasion was observed 4 weeks after intra-myocardial injection, fol-
lowed by disappearance of the ESC allografts between 4 and 8 weeks after transplantation, 
presumably due to a robust alloimmune response. However, since non-labeled mESCs are 
used and the cells are transplanted into an infarcted area, questions regarding quantification 
of mESC survival and the potentially pro-inflammatory influence of the ischemic myocardium 
remained. These questions were addressed in chapter 7, in which we describe the success-
ful transfection of mESCs with a double fusion (DF) reporter gene carrying Fluc and eGFP. 
Transduced mESCs were transplanted by direct injection into the gastrocnemius muscle of 
syngeneic and allogeneic recipient mice after which in vivo BLI was performed weekly. By 
28 days, BLI signal in the allogeneic recipients had decreased to background levels, whereas 
signal in the syngeneic recipients continued to increase. Moreover, ESC-derived teratomas 
could be detected in syngeneic, but not in allogeneic muscles. Further investigations showed 
that differentiated mESCs have a higher MHC-expression and impaired survival capacity as 
compared to undifferentiated mESCs when transplanted over histocompatibility barriers, 
suggesting increased immunogenicity.
Clinical ESC-based transplantation protocols will require the use of hESCs. Because of hESCs’ 
potential to differentiate into teratomas, safety considerations prevent clinical research using 
hESC. Since both mESCs3, 4 and hESCs5 had been reported capable of escaping xenogeneic im-
mune recognition, we thought it proper to test hESC immunogenicity in a mouse-to-human 
xenogeneic model, which resulted in the study described in chapter 8. Similarly, a double 
fusion reporter gene construct carrying Fluc and eGFP driven by a constitutive human ubiq-
uitin promoter (pUB) was successfully transduced into undifferentiated hESCs (H9 line), using 
a self-inactivating (SIN) lentiviral vector. Using in vivo BLI, we found that hESC survival was 
significantly limited in immunocompetent animals as compared to immunodeficient NOD/







disappeared completely within 10 days in immunocompetent hosts. Subsequent transplan-
tation of additional hESCs 2 weeks after the original exposure led to accelerated rejection. In 
contrast, transplants into immunodeficient hosts expanded in number after only 10 days, and 
teratoma formation was evident at 42 days. Controls showed that the hESCs did not sensitize 
the hosts to the xenoantigens produced by the reporter genes; transplantation of unma-
nipulated hESCs elicited similar rejection of retransplanted transfected hESCs. Rejection was 
demonstrated to be mediated predominantly by CD4+ T cells, arguing for a predominantly 
indirect pathway of immune rejection.
In summary, by using a multimodality approach of cell surface marker analysis, in vivo 
mouse-to-mouse allogeneic and human-to-mouse xenogeneic ESC transplantation, this 
thesis unequivocally demonstrates the immunogenicity of ESC and their derivatives.
fuTuRE PERSPECTIVES
how do we deal with the immunological challenges?
Before successful clinical application can be accomplished, immunological rejection of ESC 
following transplantation is something that must be overcome. Therefore, specific strategies 
to induce tolerance to an ESC-based transplant will be required. There are quite a few options 
available for the prevention of graft rejection.
Decades of experience in solid organ transplantation has learned that immunosuppres-
sive medication can aid to long-term allograft acceptance by the recipient. In the context of 
ESC-derived transplants, it is possible to imagine that cocktails of immunosuppressive drugs 
could be used to control unwanted immune responses. In chapter 8, we investigated the 
efficacy of single and combined immunosuppressive drug regimens for preventing post-
transplant hESC rejection. Our results show that, in a xenogeneic murine setting, a combined 
immunosuppressive drug regimen consisting of high dose Tacrolimus and Sirolimus optimally 
suppressed anti-hESC immune response and prolonged their survival to 28 days following 
transplantation. These experiments confirm the efficacy of immunosuppressive drugs in 
the context of ESC transplantation. One can imagine that in an allogeneic clinical setting, in 
which a less robust immune response is expected, a less aggressive form or combination of 
immunosuppressive drugs could be successful.
 It has been proposed that a hESC bank containing up to 150 hESC lines9 would suffice to 
match the HLA haplotypes of most of the population. While the extent of genetic disparity in 
hESC or their derivatives that may be accommodated between donor and recipient is unclear, 
mouse models have shown that even single differences between donor ESC and recipient 
minor histocompatibility antigens may facilitate graft rejection10. Therefore, investigating 
strategies to induce donor graft tolerance becomes a crucial component for the clinical ap-
plication and long-term survival of hESC-derived therapeutics.
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Manipulating central tolerance such that the recipient immune system becomes “donor 
tolerant” would be ideal and circumvent the need for long-term, nonspecific immunosup-
pressive therapies11. Transplantation of hematopoietic stem cells derived from hESCs into 
the patient would create mixed hematopoietic chimerism, enabling subsequent therapeutic 
cells derived from the same hESC to escape rejection. In this process, donor APCs repopulate 
the thymus, contributing to negative selection of T-cells, allowing transplantation of hESC-
derived cells from the same donor with limited risk of rejection.
Alternative strategies designed to produce patient-specific stem cells are being investi-
gated to avoid immune tolerance issues. These approaches include production of patient-
specific hESC lines by somatic cell nuclear transfer (SCNT) of a patient cell’s nucleus into an 
enucleated oocyte. This process, referred to as therapeutic cloning, has allowed successful 
creation of ESC lines from sheep and mice, but has been proven difficult for the creation of 
hESC lines12. An infamous study by Hwang et al13, published in Science in 2005, in which he 
claimed to have succesfully created hESCs lines by therapeutic cloning, was later editorially 
retracted after it was found to contain a large amount of fabricated data.
An interesting development has occurred recently in field of ESC research that could 
potentially circumvent immunological problems: the derivation of induced pluripotent 
stem (iPS) cells from human somatic cells. This study demonstrated reprogramming of 
adult fibroblasts14. A cocktail of four retrovirally encoded transcription factors—either Oct4, 
Sox2, c-myc and Klf-4 or Oct4, Sox2, Nanog, and Lin28— was used to reprogram human 
fibroblasts to cells that closely resemble hESCs. These iPS cells had gene-expression profiles 
and DNA-methylation patterns closely resembling hESCs, grew vigorously while expressing 
telomerase, maintained a normal karyotype, and formed teratomas after transplantation into 
immunocompromised mice. The ability to generate pluripotent cells from readily available 
fibroblasts offers the potential to generate patient-specific cells that would be recognized as 
“self” by the immune system, thus preventing rejection15.
fINal REMaRkS
ethical considerations of embryonic stem cell research
In a thesis on a subject that has been the topic of such furious political debate in the past 
several years; we feel that the ethical aspects of ESC research can not be left undiscussed.
ESC are isolated from the inner cell mass of a preimplantation embryo at the blastocyste stage 
around 5-8 days after conception, a procedure that destructs the remainder of the fertilized 
egg. As a consequence, two radically opposed groups have emerged in society: those who 
advocate absolute respect for human life beginning at conception, and those who do not16. 
In the USA, controversy on this subject resulted in contrasting political action. On August 9, 







no new hESC lines would be made using government dollars. In contrast, in 2004, the Cali-
fornia Institute of Regenerative Medicine (CIRM) was established, a granting agency charged 
with distributing $3 billion for stem cell research. Only very recently, President Obama lifted 
the ban on federal funding for hESC research allowing the field to move forward in the years 
to come.
At the core of this whole debate is how we define human life. The key question is whether 
it is permissible to prevent the death or severe suffering of a child or adult by using cells 
derived from fertilized eggs. But do adults and embryos have equal moral status or does 
this increase with advancing development? How else to explain our legal approach to abor-
tion and our readiness to remove ectopic pregnancies? Moreover, human preimplantation 
embryos have only a limited potential to become humans. Most are lost before a menstrual 
period. Contraceptive methods that destroy embryos are used widely and there is general 
public approval of in vitro fertilization (IVF): only around 10% of transferred IVF embryos 
produce a baby, other generated embryos cannot be transferred and perish17.
A frequent argument used by opponents of ESC research is that scientist should focus on 
the use of adult stem cells to treat human disease. However, as stated in the introduction 
of this thesis, there is increasing evidence that there are no pluripotent ASCs in the human 
body, meaning that these cells do not have the ability to transdifferentiate into other cell 
lineages then their own.18 For example, in chapter 3, we concluded that intramyocardially 
transplanted BMCs continue develop along the hematopoietic lineage and no new cardio-
myocytes or endothelial cells were formed. 
The development of iPS cells is exciting and could circumvent both ethical and immuno-
logical issues of ESC transplantation. There are, however, drawbacks to the clinical use of iPS 
cells. The first is the current need to use integrating retroviruses to deliver the reprogram-
ming factors. These viruses may still face immune barriers. The second is that iPS cells are not 
an “off-the-shelf” product and would likely only be produced after the patient becomes ill, 
precluding their use in the acute phase of the disease15.
CONCludINg REMaRkS
The field of hESC-based therapy has been advancing rapidly. The CIRM foresees hESC-based 
therapies to go into phase I clinical trails within the next 10 years19. To accomplish such 
goals, several significant hurdles that preclude clinical translation of such therapy need to be 
overcome. These include the development of animal product-free culture protocols, repro-
ducible differentiation methods for specific cell types, purification of cell populations to be 
transplanted to preclude teratoma formation in vivo, and optimizing cell survival following 
transplantation. The results presented in thesis clearly indicate that the latter issue seems to 
be greatly influenced by the immunological response towards allogeneic ESC-derived cells.
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Clearly, more in depth research on the use of ESC to treat human disease is essential. How-
ever, if one thinks about the enormous progress that has been made in the decade since 
Thompson’s first successful creation of a human embryonic stem cell line in 199820, one can 
only imagine where this field of research leads us to in the years to come. Or to quote Chris-
topher Scott, Executive Director of the Stem Cells in Society Program at Stanford University; 
“It is difficult to find a biologist who will say that stem cells alone hold the key to solving our 
most intractable diseases. But it is safe to say that no single area of biomedicine holds such great 
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Stamcellen hebben twee unieke eigenschappen. Allereerst zijn ze in staat zichzelf te ver-
menigvuldigen en zijn daardoor een onuitputbare bron van cellen te gebruiken voor cel-
vervangende of weefselreparatie therapie. Ten tweede kunnen stamcellen zich ontwikkelen 
tot meer gespecialiseerde dochtercellen. Zij kunnen differentiëren tot zowel voorlopercellen 
als volledig gespecialiseerde cellen van het menselijk lichaam. Gezien deze eigenschappen 
wordt het gebruik van stamcellen als bron voor regeneratieve celtransplantatie therapie als 
veelbelovend beschouwd. Er zijn twee typen stamcellen, volwassen (adult) stamcellen (ASC) 
en embryonale stamcellen (ESC).
Volwassen stamcellen bevinden zich op vele plekken in het menselijk lichaam. Een vol-
wassen stamcel is een nog niet gedifferentieerde of een niet-gespecialiseerde cel die na de 
geboorte voorkomt in een gedifferentieerd en gespecialiseerd weefsel van een organisme. 
Deze cellen zijn multipotent, hun differentiatie en proliferatiemogelijkheden zijn beperkt, 
omdat zij zich enkel tot cellen van één embryonale kiemlaag (endoderm, ectoderm of meso-
derm) kunnen differentiëren. Ze zijn nodig in het lichaam om bepaalde cellen met een korte 
levensduur te verversen. Voorbeelden van ASC zijn de hematopoietische (bloedvormende) 
stamcellen, neurale stamcellen uit hersenweefsel en stamcellen in huid- en vetweefsel. 
Embryonale stamcellen daarentegen worden gewonnen door het isoleren van een aantal 
cellen uit de binnenste celmassa van een blastocyst, ongeveer 4 to 5 dagen na bevruchting 
van de eicel. Deze cellen zijn pluripotent, dat willen zeggen dat zij zich kunnen ontwikkelen 
tot elke cel van het menselijk lichaam. Sinds ontwikkeling van de eerste humane ESC (hESC) 
lijn in 1998 zijn er in de literatuur onder andere hartspiercellen, levercellen, alvleeskliercellen 
en neuronen beschreven die in vitro zijn gekweekt uit ESC. Transplantatie van deze cellen zou 
een regeneratieve therapie kunnen betekenen voor ziekten als het hartinfarct, leverziekten, 
diabetes mellitus en de ziekte van Parkinson. Alvorens regeneratieve celtherapie met ESC kan 
worden toegepast is zal een aantal hordes moeten worden genomen. 
Een van de obstakels is de potentiele immunologische afweerreactie die teweeg wordt 
gebracht na het transplanteren van ESC. Uit de transplantatiegeneeskunde is bekend dat er 
een afstotingsreactie op gang wordt gebracht door het immuunsysteem als men organen of 
cellen transplanteert tussen twee genetisch niet-identieke individuen. Deze immuunreactie 
richt zich tegen Major Histocompatibility Complex (MHC) antigenen op het celmembraan, 
die door het immuunsysteem als ‘niet eigen’ worden herkend. Echter, een embryo, die voor 
50% genetisch materiaal van de vader bezit, wordt over het algemeen niet afgestoten door 
de moeder. Bovendien zijn er uit de vroege ESC literatuur studies bekend waarin langdurige 
overleving van ESC wordt beschreven na allogene (tussen genetisch niet-identieke indivi-
duen) transplantatie en zelfs xenogene (interspecies) transplantatie.
Het onderzoek in dit proefschrift richt zich op de vraag in hoeverre embryonale stamcel-
len na transplantatie een afweerreactie van het immuunsysteem opwekken. Hierbij wordt 
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gebruik gemaakt van molecular imaging om de getransplanteerde ESC in beeld te brengen 
en overleving van de cellen non-invasief te kunnen volgen. 
IN VIVO bIOluMINESCENT IMagINg: EEN gEVOElIgE METhOdE OM 
gETRaNSPlaNTEERdE CEllEN IN bEEld TE bRENgEN
Het eerste deel van dit proefschrift bestaat uit een introductie op het gebruik van een 
nieuwe vorm van molecular imaging: ‘in vivo bioluminescent imaging (BLI)’, voor het in beeld 
brengen van getransplanteerde cellen en/of organen. BLI kan cellen in beeld brengen die 
getransfecteerd zijn met het enzym ‘firefly luciferase (Fluc)’. Cellen die Fluc tot expressie 
brengen produceren na interactie met de lichtproducerende stof luciferine, een vorm van 
biologisch licht (bioluminiscentie, zoals de vuurvlieg) dat kan worden opgevangen door 
ultra-sensitieve ‘charged coupled device (CCD)’ camera’s. In hoofdstuk 2 wordt het gebruik 
van BLI bij experimentele harttransplantatie beschreven. Na heterotope transplantatie van 
harten van transgene Fluc donormuizen in allogene non-transgene ontvangers kan de acute 
afstoting van de organen non-invasief in beeld worden gebracht. In een volgend experiment 
worden harten getransplanteerd van transgene muizen waarin een CD5-promotor het Fluc 
gen aandrijft. Met behulp van BLI kunnen vervolgens CD5-positieve donor leukocyten in 
beeld worden gebracht, die vanuit het donorhart in de circulatie van de ontvanger worden 
opgenomen; zogenaamde ‘passenger leukocytes’, die een belangrijke rol spelen bij acute 
rejectie. Een volgende toepassing van BLI wordt beschreven in hoofdstuk 3. In deze studie 
wordt gekeken naar het injecteren van autologe mononucleaire beenmergcellen in harten 
van muizen na hartinfarct. Deze experimentele therapie heeft zowel in basaal als klinisch 
onderzoek verbetering van de hartfunctie laten zien. In de eerste dagen na hartinfarct vindt 
er een heftige ontstekingsreactie plaats in het geïnfarceerde hartspierweefsel. Deze vijandige 
omgeving zou de overleving van getransplanteerde cellen in dit gebied negatief kunnen 
beïnvloeden. In deze studie wordt onderzocht wat de invloed is van timing van cel injectie na 
hartinfarct op overleving van de getransplanteerde cellen en verbetering van de hartfunctie. 
Mononucleaire beenmergcellen van Fluc transgene muizen werden direct of 7 dagen na 
hartinfarct geinjecteerd in harten van syngene (genetisch identieke) muizen. BLI liet geen 
verschil in overleving van de cellen zien; in beide groepen was het signaal na zes weken 
tot achtergrondwaarden gereduceerd. Ook verbetering van de hartfunctie verschilde niet 
significant. Daarbij viel op dat er geen nieuwe hart- en/of endotheelcellen werden gevormd 









IMMuNOgENICITEIT VaN EMbRyONalE STaMCEllEN
In het tweede deel van het proefschrift wordt specifiek gekeken naar de immunogeniciteit 
van ESC en de waarde van molecular imaging bij het volgen van de overleving van deze 
cellen na transplantatie. hoofdstuk 4 geeft een inleiding op het potentieel van hESC in de 
regeneratieve geneeskunde. Het geeft een overzicht van gespecialiseerde cellen die tot nu 
toe uit ESC zijn gekweekt. Daarbij geeft het een beschrijving van molecular imaging en de 
waarde daarvan voor het non-invasief in beeld brengen van de hESC na transplantatie. In 
hoofdstuk 5 wordt vervolgens meer specifiek ingegaan op hartspiercellen die uit hESC kun-
nen worden gekweekt. Het belang van generatie van cardiomyocyten is groot; de hartspier 
bezit niet de capaciteit zich te regenereren na een hartinfarct, hetgeen in de loop van de 
tijd kan leiden tot hartfalen. In dit hoofdstuk wordt derhalve uitgelegd welke vooruitgang 
er is geboekt in het kweken van cardiomyocyten en er wordt een overzicht gegeven van de 
hordes die nog genomen moeten worden om transplantatie van uit hESC gekweekte cardio-
myocyten in de kliniek te kunnen toepassen. Om dit laatste mogelijk te kunnen maken, zou 
molecular imaging een belangrijke rol kunnen spelen.
hoofdstuk 6 is, voor zover bekend in de literatuur, de eerste studie waarin wordt gekeken 
naar de immunogeniciteit van ESC. In een muis-myocardinfarct-model wordt de mate van 
infiltratie van immuuncellen in de hartspier onderzocht na allogene transplantatie van ESC 
van muizen (mESC). In vergelijking met syngene controle muizen, vindt robuuste infiltratie 
van immuuncellen plaats, hetgeen leidt tot afstoting van de cellen. Een tweede bevinding 
is dat er in de syngene groep, waarbij de cellen niet worden afgestoten, intramyocardiale 
teratomen worden gevormd. Deze tumorvorming laat zien dat ongedifferentieerde ESC na 
transplantatie in hartspierweefsel zich niet per definitie ontwikkelen tot cardiomyocyten, 
maar zich ontwikkelen tot cellen van alle embryologische kiemlagen. 
In de voorgaande studie, wordt overleving van getransplanteerde cellen geanalyseerd door 
middel van histologische technieken, hetgeen vereist dat de muizen moeten worden geof-
ferd om deze informatie te vergaren. Om dit laatste te voorkomen, en bovendien de tijd van 
overleving tot in groter detail te kwantificeren wordt in hoofdstuk 7 molecular imaging van 
ESC toegepast. mESC worden succesvol getransfecteerd met een reporter gen, bestaande uit 
onder meer Fluc. Vervolgens kunnen de cellen na transplantatie met behulp van BLI worden 
gevisualiseerd. Na allogene transplantatie in de kuitspier van muizen worden de cellen in een 
tijdsbestek van ongeveer 28 dagen afgestoten. Intramusculaire teratomen worden wederom 
aangetroffen na syngene, maar niet na allogene ESC transplantatie. Verdere analyse laat zien 
dat gedifferentieerde ESC een sterkere expressie van MHC antigenen hebben in vergelijking 
met ongedifferentieerde moedercellen. Ook worden gedifferentieerde ESC sneller afgesto-
ten. Dit suggereert dat de immunogeniciteit van ESC versterkt wordt naarmate de cellen 
differentiëren. Vervolgens wordt in hoofdstuk 8 de stap gemaakt naar het analyseren van 
transplantatieimmunologie van hESC. Ook nu worden de cellen getransfecteerd met het 
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Fluc reporter gen. Deze studie laat zien dat de overleving van hESC significant beperkt is na 
intramusculaire transplantatie in xenogene immunocompetente muizen in vergelijking met 
immunodeficiente muizen. Herhaalde transplantatie van hESC in de contralaterale kuitspier 
van dezelfde muis leidt tot versnelde afstoting, hetgeen bewijzend is voor een adaptieve 
immuunreactie tegen hESC. Naast een lokale immuuncelinfiltratie in de kuitspier wordt ook 
aangetoond dat deze afstotingsreactie zowel een systemische cellulaire (door T-cellen) als 
een humorale (door B-cellen) component heeft. Tot slot wordt met behulp van BLI gekeken 
naar de meest potente combinatie van immunosuppressieve medicatie om de afstoting 
van hESC na xenotransplantatie te vertragen. hoofdstuk 9 bestaat uit een samenvatting en 
discussie van de studies in dit proefschrift en wordt een aantal mogelijke oplossingen en 
ontwikkelingen beschreven dat zou kunnen bijdragen aan onderdrukking of voorkoming 
van afstoting van ESC na transplantatie.
CONCluSIES
BLI lijkt een betrouwbare en accurate techniek voor het non-invasief en longitudinaal in beeld 
brengen van getransplanteerde ESC. Deze ESC brengen MHC antigenen tot expressie. Deze 
expressie wordt versterkt naarmate de cel differentieert. Bovendien blijkt dat ESC worden 
herkend en afgestoten door het adaptieve allogene en xenogene immuunsysteem na trans-
plantatie. Het gebruik van immunosuppressiva kan deze afstotingsreactie onderdrukken, 
hetgeen leidt tot een significant langere overleving van de cellen, doch niet tot het voorko-
men van afstoting. 
Voordat regeneratieve ESC therapie veilig en succesvol zal kunnen worden toegepast in de 
kliniek, zal de immunogeniciteit en afstoting van de cellen na transplantatie moeten worden 
overwonnen. Bij de ontwikkeling van strategieën ter voorkoming van afstoting van ESC zal 
molecular imaging een belangrijke rol kunnen spelen.
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